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    The central dogma in Nature regarding the translation of genetic information from DNA 
through RNA to proteins could be suggestive of the fact that storage and passing of 
information in living systems relies entirely on nucleotides and proteins. Indeed, these 
biomolecules are essential cellular constituents, but nevertheless cannot entirely explain the 
enormous complexity of a living organism with the relatively small number of genes 
available. Instead, carbohydrates increase biological complexity necessary for living 
organisms, and should therefore be included in the central dogma of molecular biology.
1
 
    It is estimated that approximately 50% of all naturally occurring proteins are 
glycosylated.
2
 Glycosylation takes place during or after synthesis of the protein on the 
rough endoplasmatic reticulum (ER), and is followed by processing of the carbohydrates in 
the ER and Golgi. Glycosylation serves numerous functions, such as proper protein folding, 
trafficking, targeting, thermal and proteolytic stability and assembly of protein complexes. 
Furthermore, cell surface or membrane-bound glycoproteins play an essential role in cell-
cell adhesion, intercellular communication and recognition events (Figure 1.1).
3
  
 
 
Figure 1.1. Schematic representation of functions and interactions of cell surface glycans with viruses, cells, 
antibodies, bacteria and toxins. Reprinted with permission from Macmillan Publishers Ltd: Immunol. Cell Biol. 
2005, 83, 694-708.7 
1.1 General introduction: glycobiology  
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Glycosylation is not template-driven, therefore a glycoprotein can have many different 
glycoforms. The composition and size of glycans on proteins is strongly dependent on the 
competition between various enzymes, the specific target protein, the cell-specific 
expression and organization of the biosynthetic factory, and is also species-specific.
4
 
Nevertheless, some general principles regarding human glycosylation pathways can be 
given.  
    Human glycans are composed of only ten monosaccharide building blocks, i.e. D-glucose 
(Glc), D-galactose (Gal), D-xylose (Xyl), D-mannose (Man), L-fucose (Fuc), D-N-
acetylglucosamine (GlcNAc), D-N-acetylgalactosamine (GalNAc), D-N-acetylneuraminic 
acid (NeuAc), D-glucuronic acid (GlcA) and L-iduronic acid (L-IdoA). The majority of the 
carbohydrate chains are attached to proteins via an amide bond to the nitrogen of 
asparagine or via an ether linkage to the hydroxyl group in serine or threonine, referred to 
as N-linked and O-linked oligosaccharides, respectively (Figure 1.2).
5
 Less common are N-
glycans attached to arginine side chains and O-glycosidic linkages to hydroxylysine, 
hydroxyproline or tyrosine. Additionally, carbon- and phosphor-linked glycans, i.e. C- and 
P-glycans, have also been reported.
6
  
    By far the most abundant glycoproteins in Nature are the N-linked glycoproteins. N-
glycosylation can occur only at Asn residues in the tripeptide sequence Asn-Xxx-Ser/Thr, 
where Xxx is any amino acid but proline.
8
 During synthesis of the protein in the ER, the 
enzyme oligosaccharyltransferase transfers a preformed oligosaccharide precursor from 
dolichol phosphate to the nascent protein. Various glycosidases then trim the 
oligosaccharide to a core pentasaccharide on which all further glycosylations occur. Several 
glycosidases and glycosyltransferases can compete for the same substrate, which yields a 
range of N-glycan structures.
9
 These structures can be subdivided in three groups, depicted 
in Figure 1.2. They share the common pentasaccharide Man3GlcNAc2 core, but additional 
Man residues may be present to different extents, categorized as high-mannose type N-
glycans, complex-type N-glycans and hybrid-type N-glycans.
10
  
    O-linked glycoproteins are the second most abundant glycoprotein in Nature, and 
synthesis of this type of glycoconjugate does not follow a common pathway. Instead, 
monosaccharides are added one at a time with a diverse range of anomeric linkages. A type 
of O-glycosylation that is found on a wide variety of glycoproteins is mucin-type O- 
glycosylation. For this type of O-glycosylation, the monosaccharide GalNAc is 
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Figure 1.2. General and core structures of natural N- and O- linked glycoproteins. Symbols adopted from the 
consortium for functional glycomics.11 
 
transferred from GalNAc-UDP to the protein by GalNAc transferase. After formation of the 
GalNAc-α-Ser/Thr bond, the next sugar is added to form a disaccharide (or a trisaccharide 
after a third addition) to get one of the eight core structures depicted in Figure 1.2.
12
 These 
structures can be extended by subsequent addition of any of the four sugars Gal, GlcNAc, 
Fuc or NeuAc to generate linear or branched chains.
9
 
    Both N- and O-glycosylation are not under direct genetic control and the composition 
and size of glycans is strongly dependent on the presence and activity of various enzymes, 
which leads to microheterogeneity in the structures of N- and O-glycans. Additionally, not 
all N-glycan sequons or Ser/Thr residues are occupied by a glycan, the so-called 
macroheterogeneity.
12
 As a consequence to this heterogeneity, it is difficult to obtain 
substantial amounts of homogeneous glycoprotein in order to study structural and 
functional properties.
13
 As a result, glycosylation research is progressing slowly compared 
to genomics and proteomics.  
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    A relatively new approach for the elucidation and manipulation of the functional roles of 
glycans in biological processes lies in the field of chemical biology. In this context, the 
terms ‘biocompatible chemistry’ and ‘bioorthogonal chemistry’ play a decisive role. 
Reactions of these types of chemistry can be employed in various ways to facilitate 
glycobiology research. First of all, the chemical reporter strategy (see section 1.2.2) enables 
non-invasive imaging of glycan distribution on the exterior of cells and even in live 
organisms. Additionally, this strategy can be employed for isolation and subsequent 
characterization of glycans in healthy or diseased individuals (section 1.2.3). Thirdly, 
immobilization of glycans on arrays enables the high-throughput evaluation of interactions 
between carbohydrates and proteins, antibodies, cells or viruses (section 1.2.4). Lastly, 
substantial amounts of homogeneous glycopeptides or -proteins can be prepared with the 
aid of bioorthogonal click reactions, in order to study structural and functional properties 
(section 1.2.5). These glycobiology approaches utilizing chemical biology tools will be 
discussed later in this chapter, first an introduction concerning biocompatible and 
bioorthogonal reactions will be given.  
 
1.2.1 Biocompatible and bioorthogonal chemistry 
        The terms ‘biocompatible’ and ‘bioorthogonal’ are often used interchangeably, 
especially in the field of biomaterials, meaning that the material can be applied to or in 
living organisms. However, in the field of bioconjugation, these terms have a slightly 
different meaning. Biocompatible reactions are chemical reactions, inert for functional 
groups present in biomolecules such as proteins, nucleotides and glycans, and are suitable 
for bioconjugation. Bioorthogonal reactions go a step further: they can even be used in live 
cells or entire organisms. These reactions do not cross-react with any of the functional 
groups present inside living cells and must proceed rapidly and selectively under 
physiological conditions and be inert towards the plethora of other functional groups 
present in cells.
14
  
 
Oxime and hydrazone ligation 
    A classic example of biocompatible reaction partners involves the aldehyde/ketone and 
hydrazide/alkoxyamine pairs. At pH 5-6 aminooxy or hydrazide groups can attack carbonyl 
1.2 Chemical tools to study glycosylation   
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functionalities to form stable oxime or hydrazone adducts (Scheme 1.1A).
15
 In order to 
increase the reaction rate at physiological pH, Dawson et al. reported that aniline or p-
anisidine as a nucleophilic catalyst for both hydrazone
16
 and oxime ligation
17
 significantly 
accelerated the ligation by means of the transient formation of a protonated, highly reactive 
Schiff base intermediate (Scheme 1.1B).  
 
 
Scheme 1.1. Condensation of an aldehyde or ketone and a substituted hydrazine or hydroxylamine group. (A) 
Uncatalyzed reaction; (B) aniline-catalyzed reaction. 
 
Staudinger ligation 
    Aldehydes and ketones are not completely absent inside living cells, for example they are 
abundantly present in the form of sugars or pyruvate. A functional group that is fully 
abiotic is the azide group, which can therefore be used as a bioorthogonal reaction partner. 
Additional advantages of the azide group include its small size, the easy introduction into 
organic molecules and its inertness towards the cellular constituents.  
    A reaction that elegantly employs the benefits of the azide functional group for 
bioconjugation purposes is the Staudinger ligation, a modification of the long-known 
Staudinger reduction of azides with triphenylphosphine
18
 first reported by the group of 
Bertozzi in 2000.
19
 As depicted in Scheme 1.2A, intramolecular trapping of a nucleophilic 
aza-ylide by an electrophilic ester leads to formation of a stable amide bond after hydrolysis 
of a pentacoordinate phosphine intermediate. Kinetic analysis of the Staudinger ligation 
estimated a second order rate constant of 2.5 × 10
-3
 M
-1
s
-1
 for the reaction of 
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triphenylphosphine with benzyl azide in CD3CN containing 5% D2O.
20
 Soon after the 
discovery of the Staudinger ligation, a modified approach was reported to make the reaction 
suitable for applications in which the phosphine oxide motif is not desired in the final 
product. This so-called traceless Staudinger ligation involved release of 
hydroxyphenyldiphenylphosphine oxide in the last step to give a stable amide bond without 
inclusion of the phosphine oxide moiety (Scheme 1.2B).
21
 The disadvantage of both 
approaches is, however, the sensitivity of phosphines towards oxidation by air and 
metabolic enzymes, leading to limited shelf-life and the necessity to use a large excess of 
phosphine reagents to achieve effective labeling.
22,23
 
 
Scheme 1.2. The Staudinger ligation of azides with triarylphosphines. (A) First generation Staudinger ligation; (B) 
traceless Staudinger ligation. 
 
Copper(I)-catalyzed azide–alkyne cycloaddition 
    Another reaction that fully exploits the benefits of the azide functional group is the 
Huisgen 1,3-dipolar cycloaddition of alkynes and azides to yield 1,2,3-triazoles (Scheme 
1.3A).
24
 The easy synthetic accessibility of the azide and alkyne functionalities, stability, 
orthogonality towards other functional groups, and water compatibility make these reaction 
partners an ideal couple. However, the rate of this reaction is extremely slow, normally 
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requiring prolonged heating for unactivated alkynes. To solve this problem, both Sharpless 
et al.
25
 and Meldal et al.
26
 reported in 2002 the dramatic improvement of rate and 
regioselectivity of alkyne–azide reaction through the use of a copper(I) catalyst (Scheme 
1.3B). Since the discovery of the so-called copper-catalyzed azide–alkyne cycloaddition 
(CuAAC), many studies have been performed to optimize reaction conditions, such as 
addition of a copper chelate to enhance the reaction rate and stabilize the metal.
27-32
  
    Because of the fast and modular reaction, this reaction became the prototypical example 
of a click reaction. The term ‘click chemistry’ was formulated by Sharpless et al. in 2001,33 
and was meant to illustrate the readiness with which two molecular pieces are connected, in 
accordance with ‘clicking’ together the two pieces of a buckle.34 Sharpless defined a set of 
criteria that a reaction must meet in order to be termed ‘click reaction’: “the reaction must 
be modular, wide in scope, give very high yields, generate only inoffensive byproducts that 
can be removed by nonchromatographic methods, and be stereospecific.” 
 
 
Scheme 1.3. (3+2) Cycloadditions of alkynes with azides form the corresponding triazoles. (A) Cycloaddition of 
azides with alkynes requires heat or pressure to give a mixture of 1,4- and 1,5-substituted triazole products; (B) 
terminal alkynes are activitated by Cu(I) to undergo cycloaddition with azides under physiological conditions to 
give specifically 1,4-disubstituted triazoles.  
 
    Despite the power and versatility of CuAAC, the requirement for copper, which is toxic 
to cells,
35
 limits its application in cellular systems or living organisms. E. coli cells 
overexpressing azide-functionalized membrane proteins have been labeled with 100 μM 
CuSO4 for 16 h and survived these conditions, but were unable to divide afterwards. 
Similarly, zebrafish embryos died within 15 min after treatment with 1 mM CuSO4, 1.5 
mM sodium ascorbate and 0.1 mM tris(benzyltriazolylmethyl)amine ligand.
14
 The copper-
induced cytotoxicity may be related to altered cell division, disruption of lipid 
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metabolism,
36
 or copper-catalyzed production of reactive oxygen species from atmospheric 
oxygen.
37
 Although Wu et al. have shown that living zebrafish embryos can be labeled with 
CuAAC in the presence of the copper-binding ligand BTTES,
32
 catalyst-free conjugation 
would simplify the reaction conditions (in accordance with the criteria for click reactions) 
and make modification of metal-chelators or metal-binding proteins possible.  
 
Strain-promoted azide–alkyne cycloaddition 
    In 1953, Blomquist and Liu published the explosive reaction of cyclooctyne with phenyl 
azide.
38
 The product of this reaction, 1-phenyl-4,5,6,7,8,9-hexahydro-1H-
cycloocta[d][1,2,3]triazole, was identified in 1961 by Wittig and Krebs as the product of a 
cycloaddition between cyclooctyne and phenyl azide (Scheme 1.4).
39
 The significant bond 
  
 
Scheme 1.4. 1,3-Dipolar cycloaddition of cyclooctyne with phenyl azide.  
 
angle deformation of the acetylene in cyclooctyne to 163° gives enormous ring strain, and 
this destabilization of the ground state compared to the transition state of the reaction gives 
a dramatic increase in reaction rate in comparison with unstrained alkynes. Smaller 
cycloalkynes were too unstable for isolation, but the presence of cycloheptyne and 
cyclohexyne could be established by trapping with phenyl azide and subsequent isolation of 
the triazole products. The finding that cyclooctyne reacts with phenyl azide 
‘explosionsartig’ inspired Bertozzi et al. to investigate this type of reaction for catalyst-free 
azide–alkyne cycloaddition.40 Hereto, cyclooctyne OCT 1 (Table 1.1, entry 1) was 
synthesized and the second order rate constant of the reaction with benzyl azide was 
determined to be 2.4 × 10
-3
 M
-1
s
-1
, comparable to that of a typical Staudinger ligation (2.0-
2.5 × 10
-3
 M
-1
s
-1
).
41,20
 Despite the slow reaction kinetics, this first generation cyclooctyne 
was successfully employed to label glycans on the exterior of cells.
40
 
     Since the development of the first strained cyclooctyne for strain-promoted azide–alkyne 
cycloaddition (SPAAC), many alternative cycloalkynes have been developed. The first 
step, omission of the phenyl ring to increase water solubility and decrease of steric 
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hindrance near the reactive site to give OCT 2 (entry 2), led to a somewhat lower rate 
constant (1.3 × 10
-3
 M
-1
s
-1
). Omission of the ether linkage to increase the stability of the 
cyclyooctyne derivatives and simultaneous introduction of a fluorine atom adjacent to the 
triple bond (MOFO, entry 3) to lower the energy of its LUMO resulted in an increase in the 
rate constant (4.3 × 10
-3
 M
-1
s
-1
).
41
 This inspired Bertozzi et al. to develop a strained 
cyclooctyne that contained two electron-withdrawing fluorine atoms adjacent to the triple 
bond, DIFO (entry 4). Kinetic analysis with benzyl azide gave a second order rate constant 
of 76 × 10
-3
 M
-1
s
-1
, 17-32 times greater than existing cyclooctynes or Staudinger ligation.
42
 
Unfortunately, synthesis of this cyclooctyne with improved kinetics required up to 10 steps 
and proceeded in low overall yield (1%). As a solution, Bertozzi et al. published an 
alternative difluorinated cyclooctyne (DIFO 2, entry 5). Synthesis of this compound 
required only 6 steps and proceeded in 38% overall yield. Kinetic analysis gave 42 × 10
-3
 
M
-1
s
-1
 as the second order rate constant. DIFO 3 (entry 6), lacking the phenyl ring to 
increase water solubility, was synthesized in 28% yield (7 steps) and had a slightly higher 
rate constant: 52 × 10
-3
 M
-1
s
-1
.
43
 At the same time, efforts to increase water solubility in 
order to decrease nonspecific binding to hydrophobic cell contents resulted in the 
development of DIMAC (entry 7). Synthesis of this compound required 11 steps in an 
overall yield of 5% and gave a rate constant of 3.0 × 10
-3
 M
-1
s
-1
, but improved the 
sensitivity of azide detection.
44
 
    As an alternative for enhancement of the rate constant of SPAAC, Boons et al. 
envisioned that addition of benzene rings to the cyclooctyne would increase ring strain, 
thereby enhancing the reactivity of the alkyne towards azides. Synthesis of DIBO (entry 8) 
was accomplished in 5 steps with an overall yield of 10%, and the second order rate 
constant turned out to be 57 × 10
-3
 M
-1
s
-1
 in methanol.
45,46
 Efforts to increase the polarity of 
DIBO by the introduction of sulfate groups resulted in S-DIBO (entry 9), synthesized by 
the group of Boons in 6 steps in 18% overall yield. Determination of the second order rate 
constant gave 116 × 10
-3
 M
-1
s
-1
.
47
 Inspired by the development of aza-
dimethoxycyclooctyne DIMAC with its increased water solubility and the 
dibenzocyclooctyne DIBO with its improved reaction kinetics, the hybrid structure DIBAC 
(entry 10) was developed by us. As an additional advantage, functionalization via an amide 
bond gives more stable products compared to the ester linkage in for example DIBO.  
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 Table 1.1. Properties of cycloalkynes for SPAAC with azides. 
 
Entry Cyclooctyne Name 
Yield in 
% (nr of 
steps) 
k (× 10-3 M-1 
s-1)a 
k′ Solvent CLogPb Ref 
1 
 
OCT 1 52 (4) 2.4 1 CD3CN 4.23 
40
 
2 
 
OCT 2 36 (5) 1.3 0.5 CD3CN 2.30 
41
 
3 
 
MOFO 15 (5) 4.3 1.8 CD3CN 4.79 
41
 
4 
 
DIFO 1 (10) 76 32 CD3CN 1.93 
42
 
5 
 
DIFO 2 38 (6) 42 18 CD3CN 5.17 
43
 
6 
 
DIFO 3 28 (7) 52 22 CD3CN 2.59 
43
 
7 
 
DIMAC 5 (11) 3 1.3 CD3CN 1.12 
44
 
8 
 
DIBO 10 (5) 57 24 CH3OH 3.90 
45,46
 
9 
 
S-DIBO 18 (6) 116 48 CH3OH 0.83 
47
 
10 
 
DIBAC 41 (9) 310 129 CD3OD 4.07 
48
 
11 
 
BARAC 18 (6) 960 400 CD3CN 3.70 
49
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Table 1.1. Continued 
Entry Cyclooctyne Name 
Yield in 
% (nr 
of steps) 
k (× 10-3   
M-1 s-1) 
k′ Solvent CLogP Ref 
12 
 
endo-BCN 35 (4) 140 58 
CD3CN: 
D2O (3:1) 
0.57 
50
 
13 
 
COMBO (12) 5 240 100 CD3CN 3.22 
51
 
14 
 
TMTH 1 (6) 4000 1667 CD3CN 3.98 
52
 
a  2nd order rate constants were determined in a reaction with benzyl azide. 
b CLogP values were calculated with ChemBioDraw Ultra 12.0.  
 
DIBAC was synthesized in 9 steps in 41% overall yield and gave a rate constant of 310 
×10
-3
 M
-1
s
-1
, approximately 5 times (DIBO) and 100 times (DIMAC) greater than its 
parent compounds.
48
 Additional rate enhancement of dibenzoazacyclooctye was achieved 
by Bertozzi et al. by the introduction of an amide bond in the cyclooctyne ring to give 
BARAC (entry 11). BARAC was synthesized in 18% overall yield (6 steps) and has a 
second order rate constant of 960 × 10
-3
 M
-1
s
-1
, 400 times greater than unactivated 
cyclooctyne OCT 1.
49
 
    As an alternative to increase the ring strain by benzoannulation, a cyclopropane ring was 
fused to the cyclooctyne instead, to give bicyclo[6.1.0]nonyne (BCN, entry 12). Endo-BCN 
was synthesized in only 4 steps in 35% overall yield, and displayed a rate constant of 140 × 
10
-3
 M
-1
s
-1
 in CD3CN:H2O mixture (3:1). As an additional advantage, BCN does not contain 
the lipophilic phenyl rings such as in other fast cyclooctynes.
50
 Similar enhancement of the 
reaction rate was accomplished by Kele et al. by fusion of a benzene group at the 5-6 
position of the cyclooctyne. The resulting carboxymethylmonobenzocyclooctyne 
(COMBO) was synthesized in 12% overall yield (5 steps) and gave a rate constant of 240 × 
10
-3
 M
-1
s
-1
, almost 2 times greater than its cyclopropane relative BCN.
51
  
    Decreasing ring size provides an alternative for the enhancement of the reaction rate of 
cycloalkynes with azides. Because cycloheptynes are unisolable at room temperature due to 
rapid oligomerization, Bertozzi et al. sought to reduce the ring strain in cycloheptyne by 
replacing a carbon atom with a larger sulfur atom, thus giving TMTH (entry 14, 3,3,6,6-
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tetramethylthiacycloheptyne). The rate constant of TMTH with benzyl azide was indeed 
very high (4000 × 10
-3
 M
-1
s
-1
), but introduction of a functional group to TMTH was not 
reported, presumably due to stability problems.
52
 
 
1.2.2 Chemical reporter strategy for glycan imaging    
    As delineated previously, the reported bioorthogonal and biocompatible reactions can be 
employed for glycobiology research. First of all, non-invasive imaging of glycan 
distribution on the exterior of cells and even live organisms is enabled by the chemical 
reporter strategy, which in turn depends on bioorthogonal chemistry. The chemical reporter 
strategy involves incorporation of one of the envisaged reaction partners (the ‘chemical 
reporter’) into a target of interest, followed by covalent linkage of the reporter to an 
exogenous probe through bioorthogonal conjugation, which enables detection of the target 
(Figure 1.3).
53
 The biosynthetic machinery for oligosaccharides has been shown to be 
 
 
Figure 1.3. Schematic representation of the chemical reporter strategy. The chemical reporter (blue circle) is 
incorporated into a target molecule, which can be detected after chemical labeling. Reprinted with permission 
from Macmillan Publishers Ltd: Nat. Chem. Biol. 2005, 1, 13-21.53 
 
tolerant of structural modifications to the natural substrates, thereby enabling incorporation 
of bioorthogonal functional groups into newly synthesized glycans.
54
 After reaction with 
the complementary reaction partner, glycans can be visualized (Figure 1.4).The first 
bioorthogonal functional group that was incorporated into sialylated glycans was ketone-
containing ManNAc derivative ManLev (1) by the group of Bertozzi. The ketone groups 
were then treated with biotin hydrazide and detected by Western blot or flow cytometry.
55
 
Similarly, the same group reported the incorporation of azide-containing ManNAc  
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Figure 1.4. Metabolic oligosaccharide labeling with azido or keto sugars enables visualization of extracellular 
glycans. Different types of unnatural carbohydrate metabolites can be incorporated into glycoconjugates through 
the cell’s own biosynthetic machinery.  
 
derivative ManNAz (2), followed by Staudinger ligation with biotinylated phosphine,
19
 
CuAAC with biotinylated terminal alkyne
37
 or SPAAC with a biotinylated cyclooctyne.
40
 In 
contrast to the levulinoyl derivatives, the azido derivatives could be extended to the 
GalNAc, GlcNAc and Fuc salvage pathways by incorporation of GalNAz 3,
56
  GlcNAz 4
57
 
or peracetylated 6AzFuc 5,
11
 thus enabling visualization of mucin-type O-glycans, O-
GlcNAcylated proteins and fucosylated glycans, respectively. The method can even be  
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extended to living animals such as mice,
58,59
 zebrafishes
60-62
 and C. Elegans,
63
 providing 
more information regarding glycan functions during development. More detailed 
information about metabolic oligosaccharide engineering can be found in a recently 
published review.
64
 
    As an alternative for visualization of sialic acid-containing glycans, vicinal diols of sialic 
acids on the cell surface can be oxidatively cleaved by periodate to generate C7 aldehydes, 
thereby enabling hydrazide or oxime ligation with a biotinylated hydrazide or 
hydroxylamine functionality.
65
 
 
1.2.3 Metabolic labeling for glycan enrichment and analysis 
    Metabolic labeling of glycans can also be used for enrichment of glycans from a complex 
mixture such as a cell lysate, after which glycosylation sites and glycan composition can be 
established. This approach was first applied in 2005 by the group of Zhao for the isolation 
and characterization of O-GlcNAc-modified proteins. To this end, cells were metabolically 
labeled with peracetylated GlcNAz, followed by Staudinger ligation with a biotinylated 
phosphine capture reagent. In the last step, the biotinylated proteins could be affinity-
purified using streptavidin-conjugated beads and analyzed by LC-MS/MS. This analysis led 
to identification of 41 new O-GlcNAc modified proteins.
66
 In a similar way, the group of 
Wong analyzed sialylated glycoproteins after incubation of the cells with alkynyl ManNAc, 
CuAAC with an azido-biotin probe and capture of the tagged proteins on streptavidin-
conjugated beads. This way, over 200 N-glycosylated sites of prostate cancer cells were 
identified, of which 69% had not been reported earlier.
67
  
    To increase the elution yield of labeled target from the streptavidin-conjugated beads, 
Wong et al. designed a trifunctional probe (6, Figure 1.5) containing a fluorogenic group 
(i.e. it becomes fluorescent after CuAAC) for visualization of glycan distribution, biotin for 
capture with streptavidin-conjugated beads and a cleavable linker (cystamine) in between 
for recovery of the target glycan. They incubated prostate cancer cells with alkyne-
functionalized ManNAc, lysed the cells and observed fluorescence signal after treatment of 
the cell lysate with the trifunctional probe. Capture with streptavidin-loaded beads and 
release under reductive conditions gave specific enrichment and efficient elution of 
sialylated proteins.
68
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Figure 1.5. Structure of trifunctional probe containing a fluorogenic azidocoumarin, biotin and a cleavable 
cystamine linker.  
 
1.2.4 Glycan arrays for evaluation of glycan interaction partners 
   The third area of glycobiology research where biocompatible chemistry is employed is in 
the construction of glycan arrays for evaluation of glycan interaction partners. Interactions 
between glycans and proteins, antibodies, cells or viruses are usually quite weak, which is 
the reason why in Nature carbohydrate-mediated responses are often involving multivalent 
interactions on the cell surface in order to achieve high specificity and affinity.
69
 
Traditionally, glycan interactions were measured with isothermal calorimetry, surface 
plasmon resonance and enzyme-linked lectin assays, both labor- and material-intensive 
methods. In order to perform high-throughput screening and to reduce the sample amount, 
glycan array technology was developed,
70
 thereby providing a direct mimicry of the 
multivalent display of carbohydrates on cells.
71
 The key challenge in developing glycan 
microarrays is immobilization of the carbohydrates on the solid surface of the array, 
because interactions between glycans and glycan binding elements are strongly dependent 
on linker length and immobilization concentration.
72
 To establish the connection between 
the solid surface and the glycan, biocompatible reactions are highly suitable because of 
their covalent character and inertness towards other functionalities present in glycans. The 
group of Wong explored in 2002 the use of CuAAC for the immobilization of 
oligosaccharides on microtiter plates in a two-step procedure. First, a C14 hydrocarbon 
chain containing a terminal alkyne was absorbed on polystyrene microtiter plates by 
hydrophobic interactions, followed by CuAAC with azide-functionalized sugars (Scheme 
1.5A).
73
 The inverse strategy in which glass slides are equipped with azide groups and the 
carbohydrate is synthesized with a terminal alkyne has also been reported (Scheme 1.5B).
74
 
Alternatively, the group of Waldmann covalently functionalized glass slides with 
phosphane groups for Staudinger ligation with azide-functionalized Man (Scheme 1.5C).
75
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Scheme 1.5. Click chemistry approaches for covalent immobilization of glycans to form glycan arrays. (A) 
Attachment of azide-modified sugars to alkyne-coated surface by CuAAC; (B) attachment of alkyne-modified 
sugars to azide-coated surface by CuAAC; (C) attachment of azide-modified sugars to phosphane-coated surface 
by Staudinger ligation; (D) attachment of hydroxylamine-modified sugars to aldehyde-coated surface by oxime 
ligation; (E) attachment of unmodified sugars to hydrazide- or aminooxy-coated surface by hydrazone or oxime 
ligation.  
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In a similar fashion, synthetic chondroitin oligosaccharides containing an aminooxy group 
were conjugated to an aldehyde-containing microarray (Scheme 1.5D).
76
 Introduction of the 
azide or aminooxy group to the sugars was in all three cases established during labor and 
time-consuming syntheses of the oligosaccharides, thereby limiting these strategies to 
synthetically accessible glycans.  
    To overcome these issues, Shin et al. reported a strategy for site-specific and covalent 
immobilization of free carbohydrates irrespective of their size. The strategy involved 
functionalization of glass slides with aminooxy or hydrazide groups and subsequent oxime 
or hydrazone ligation with the open aldehyde form of native mono- di- and 
oligosaccharides to give stable conjugates (Scheme 1.5E). Interestingly, higher 
fluorescence signals were observed for glycans immobilized on hydrazide-coated slides 
than those immobilized on aminooxy-coated slides, most probably because oxime ligation 
on the reducing sugar produces preferentially acyclic products, whereas cyclic adducts are 
produced predominantly in reactions of carbohydrates with hydrazide-containing 
compounds.
77
  
 
1.2.5 De novo synthesis of glycoconjugates 
    The last area of glycobiology research where biocompatible chemistry is employed is in 
de novo synthesis of glycoconjugates. As mentioned previously, both N- and O-
glycosylation are not under direct genetic control and the composition and size of glycans is 
strongly dependent on the presence and activity of various enzymes, which leads to 
microheterogeneity in the structures of N- and O-glycans. As a consequence of this 
heterogeneity, it is difficult to obtain substantial amounts of homogeneous glycoprotein in 
order to study structural and functional properties.
13
 Biocompatible reactions are highly 
suitable to establish a non-natural glycosidic linkage between prefabricated unprotected 
protein and carbohydrate units, thereby creating substantial amounts of homogeneous 
glycoprotein for investigation of structural and functional properties. As an additional 
advantage, the resulting glycosidic linkage is stable towards acidic and basic conditions, as 
opposed to the sensitive natural linkage.     
    Oxime ligation was the first biocompatible reaction to be exploited for the conjugation of 
glycans to peptides or proteins. In 1996, the group of Mutter reported the uncatalyzed 
reaction of an aminooxy-functionalized peptide with several native sugars such as 
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maltotriose.
78
 Catalysis of oxime ligation between hydroxylamine-containing peptides and 
saccharides was not reported until 2010, when Jensen et al. reported that addition of 
100 mM aniline led to a 20-fold increase in reaction rate for formation of the 
glycoconjugate. Similar to oxime ligation between an aminooxy-functionalized peptide and 
native glycans, peptides were also equipped with a hydrazide group for hydrazone ligation 
with native glycans.
79
 The inverse reaction, hydrazide- or oxime-functionalized 
carbohydrates with ketone-functionalized peptides, was also reported.
80
 
    As an alternative for oxime and hydrazone ligation, CuAAC was used for the synthesis 
of highly robust isosteres of natural glycoconjugates. To this end, various azide- or 
acetylene-functionalized amino acids were synthesized, incorporated in peptides, and 
subsequently reacted with various acetylene- or azide-containing saccharides, 
respectively.
81
 This way, a glycosylated triazole-RGD derivative was synthesized, which 
showed no significant difference in binding affinity to αvβ3 integrins compared to the 
‘natural’ glycosylated amide-RGD derivative but had improved pharmacological 
properties.
82
 Azide- and acetylene-functionalized amino acids can also be incorporated into 
proteins via biochemical and enzymatic strategies, such as by protein expression in 
methionine auxotrophic E. coli for introduction of azidohomoalanine
83,84
 or 
homopropargylglycine,
84
 or by genetic encoding of azide- or alkyne-containing amino acids 
in the presence of a heterologous suppressor tRNA/aminoacyl tRNA synthetase pair with 
altered specificity.
85,86
 Although CuAAC was only demonstrated with model compounds 
such as biotin or a fluorophore, it should in principle also be possible to use these methods 
for the synthesis of neoglycoproteins.  
 
    Protein glycosylation is of tremendous importance for a plethora of functions and it is 
estimated that at least 50% of human proteins are O- and/or N-glycosylated. Additionally, 
only minor mistakes in the DNA encoding the glycosylation machinery may have a 
dramatic effect on functioning of the entire organism. Research focused at understanding 
the biosynthetic pathways and the biological functions of carbohydrates benefits greatly of 
biocompatible and bioorthogonal chemistry. Nevertheless, the current chemical biology 
toolbox is only poorly filled and relies on only a handful of chemical reactions, mainly 
based on the azide functional group. Therefore, the aim of this thesis is the development of 
1.3 Purpose and outline of this thesis  
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new biocompatible and/or bioorthogonal conjugation tools in order to support research 
towards glycosylation biosynthetic pathways and functions.  
    To this end, the development of a new biocompatible reaction pair is described in 
Chapter 2, namely the reaction between a nitrone and a strained alkyne. It was envisioned 
that this 1,3-dipolar cycloaddition would not only yield stable isoxazoline conjugates of 
peptides and proteins with fast reaction kinetics, but would also enable the introduction of 
two functional groups in a one-pot reaction, which is demonstrated in Chapter 3. In Chapter 
4 the development of a strained alkyne-containing, hydrazine-cleavable linker is described, 
which enables the enrichment of azide-containing biomolecules from a complex mixture. 
For application in enrichment of ester-containing molecules, two different reagent-free 
cleavable linkers were developed, cleavable by 350 nm light. Synthesis and evaluation of 
these linkers is described in Chapter 5. The application of a method to introduce azides to 
the reducing sugar of oligosaccharides for the immobilization of these oligosaccharides on 
a solid support is described in Chapter 6. Finally, new perspectives and an outlook into 
future research are given in Chapter 7.  
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    An azide (R-N3) is a multipurpose functional group that can be readily introduced into an 
organic molecule. Historically, azides have been frequently employed in total synthesis as 
non-nucleophilic, non-protic and relatively stable precursor of primary amines. In more 
recent years, however, azides have also been used as a versatile anchor points for 
conjugation purposes by means of Staudinger ligation with modified phosphines,
1
 
copper(I)-catalyzed cycloaddition with terminal alkynes  (CuAAC)
2,3
 or strain-promoted 
alkyne–azide cycloaddition (SPAAC).4,5 The last type of reaction6-9  is attractive because it 
does not require a cytotoxic metal catalyst (like copper) and therefore provides unique 
opportunities for the labeling of cell-surface glycans
10,4
 and proteins
11,12
 of living cells, the 
decoration of polymeric nanostructures,
13,14
 the labeling of lipids,
15,16
 proteomics,
17
 and 
tissue reengineering.
18
 The first generation of cyclooctynes, originated in 2004, suffered 
from relatively low reaction rates; however, it has been found that the rate of strain-
promoted cycloaddition can be significantly increased by appending electron-withdrawing 
groups adjacent to the triple bond. For example, reaction of a difluorinated cyclooctyne, 
such as 1 (Figure 2.1), with azides proceeds approximately 60 times faster than the 
corresponding reaction of unsubstituted derivatives.
6
 In 2008, it was described that 
derivatives of 4-dibenzocyclooctynol 2 show an additional increase in reaction rate and can 
be employed for the visualization of metabolically azide-labeled glycans of living cells.
19
 
Attractive features of  the dibenzocyclooctynol include easy synthetic access, nontoxicity, 
and the straightforward attachment of a variety of probes. Recently, we reported that 
azacyclooctyne 3
20
 exhibits a further improved reaction rate and is furthermore suitable for 
bioconjugation in aqueous systems due to its slightly higher polarity. Despite these 
 
 
Figure 2.1. Ring-strained cyclooctynes for bioorthogonal cycloaddition reactions with azides.  
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advances in the field of strain-promoted cycloaddition reactions with azides (SPAAC), an 
urgent need remains for new and faster bioorthogonal reactions for labeling at low 
concentration.
21
 In this chapter a novel biocompatible reaction pair is described based on 
strain-promoted alkyne–nitrone cycloaddition (SPANC) to give N-alkylated isoxazolines 
with exceptionally fast reaction kinetics. The new methodology was used in a one-pot 
three-step protocol for site-specific modification of peptides and proteins.  
 
    In order to explore the potential cycloaddition of a cyclooctyne with a nitrone, an 
alternative 1,3-dipole for an azide, a range of nitrones 4a–f (Table 2.1) was first prepared 
 
Table 2.1. Rate constants for the cycloaddition of dibenzocyclooctynol 2 with nitrones 4a-f.a 
 
Entry 4 R1 R2 R3 k
b
 (M
-1
s
-1
) kʹ Yield (%) 
1 a H Ph Me 1.3 × 10
-2 
1 95 
2 b H CH2CH2Ph Me 3.2 × 10
-2
 3 80 
3 c H Ph Ph >0.2
c 
>17 89 
4 d Me CH2CH2CO2Et Me <1 × 10
-3 
<0.1 33 
5 e H CO2Et Me 3.9 330 92 
6 f H C(O)NHBn Me 2.2 180 93 
a The nitrone substrates (except 4d) were formed as pure Z-isomers. Isoxazoline 5 was formed as a mixture of 
regio- and diastereoisomers.  
b Method A: the rate constant was determined by 1H NMR spectroscopy in CD3CN/D2O (3:1); [2] = 18 mM, [4a-f] = 
16.4 mM. Method B: the rate constant was determined by UV spectroscopy22 in CH3CN:H2O (3:1); [2] = 0.33 mM, 
[4a-f] = 0.30 mM. These reactions were too fast for monitoring by NMR spectroscopy.  
c The reaction was too fast for accurate determination of the rate constant by NMR spectroscopy. Determination 
by UV spectroscopy was not possible owing to overlapping absorptions. 
 
2.2 Kinetics 
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by condensation of an aldehyde with an N-alkyl or N-arylhydroxylamine, based on reported 
literature procedures followed by silica gel column purification. Next, each of the nitrones 
4a–f was individually mixed with cyclooctynol 2 in a mixture of acetonitrile and water in 
order to explore the 1,3-dipolar cycloaddition. Much to our satisfaction, it was found that 
the expected corresponding stable
23
 isoxazolines were readily formed, in most cases in high 
yield (Table 2.1). To calculate the rate constants of the cycloaddition reactions, 
1
H NMR or 
UV spectra were measured at 25 °C at preset time intervals and conversion of the reaction 
was determined. From the conversion plots thus obtained, the second order rate plots were 
calculated according to equation (1). 
 
    
 
([ ]  [ ] )
    
[ ] ([ ]  [ ])
([ ]  [ ])[ ] 
                                                   (1) 
 
    Herein, k = second order rate constant (in M
-1
s
-1
), t = reaction time (in seconds), [A]0 = 
the initial concentration of substrate A (in mmol/mL), [B]0 = the initial concentration of 
substrate B (in mmol/mL) and [P] = the concentration of product (in mmol/mL).    
Subsequently, rate constants were obtained by determining the slope of the graph. Using 
this method, we found that the substituents on the nitrone greatly influenced reaction 
kinetics (Table 2.1). For example, an N-phenyl group (as in 4c) instead of an N-methyl 
group gave a faster reaction,
24,25
 whereas nitrone 4d, derived from a ketone, exhibited 
reaction kinetics that were too slow for accurate determination of the rate constant. 
Exceptionally high reaction rates were measured for cycloaddition of 2 with α- 
 
 
Figure 2.2. Logarithmic plot of the reaction of nitrone 4f with dibenzocyclooctyne 2b in different solvent 
mixtures. kt was calculated using equation (1).  
CH3CN:H2O 1:5 
k = 8.8 M-1s-1 
CH3CN:H2O 1:9 
k = 12.8 M-1s-1 CH3CN:H2O 1:3 
k = 5.5 M-1s-
1 
CH3CN:H2O 1:1 
k = 2.2 M-1s-1 
  
  
  
  
  
  
  
  
  
  
  
  
 k
t 
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carboxynitrones 4e and 4f. These reactions proceeded 18 and 32 times as fast, respectively, 
as cycloaddition of 2 with benzyl azide (0.12 M
-1
s
-1
).
26
 Also, we found that a high water 
content increased the reaction rate constants (e.g. 12.8 M
-1
s
-1
 for 2b in acetonitrile/water 
(1:9), Figure 2.2 and Table 2.2).
27,28
 When the reaction was performed at a different 
concentration and with a different ratio between the two reactants (Table 2.2, entries 2 and 
3), identical logarithmic plots were obtained. Finally, we determined a rate constant for the 
cycloaddition of dibenzoazacyclooctyne (DIBAC) 3 with 4f. As expected,
20
 a further 
enhancement of the reaction rate (39 M
-1
s
-1 
in CH3CN:H2O 1:3) was observed when 3 was 
used in place of carbon analogue 2 (Table 2.3).  
 
Table 2.2. Rate constants for the reaction of dibenzocyclooctyne 2 or 2b with nitrone 4f in different solvent 
mixtures.   
entry cyclooctyne [cyclooctyne]       
(mM) 
[4f] (mM) CH3CN:H2O k (M
-1
s
-1
) 
1 2 1.00 1 1:1 2.7 
2 2b 1.00 1.20 1:1 2.2 
3 2b 0.33 0.30 1:1 2.3 
4 2b 0.33 0.30 1:3 5.5 
5 2b 0.33 0.30 1:5 8.8 
6 2b 0.33 0.30 1:9 12.8 
 
Table 2.3. Rate constants for the reaction of azadibenzocyclooctyne 3 with nitrone 4f.a  
 
Entry cyclooctyne [cyclooctyne] 
(mM) 
[4f] (mM) ratio 
CH3CN:H2O 
k (M
-1
s
-1
) 
1 3 0.33 0.30 3:1 8.5 
2 3 0.33 0.30 1:3 39 
a Isoxazoline 6 was formed as a mixture of regioisomers. 
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    Next, the challenge was to find a strategy for incorporation of nitrones into biomolecules. 
Thus, the N-terminal serine residue of model peptide 7 was oxidatively cleaved with 
sodium periodate
29
 (1.1 eq) to rapidly generate aldehyde 8. Subsequent treatment with p-
methoxybenzenethiol (6.6 eq, 30 min), then with N-methylhydroxylamine (2.2 eq), p-
anisidine (5 eq), and finally 2 (2.2 eq) gave the desired isoxazoline 10 via intermediate 
nitrone 9 (Scheme 2.1 and Figure 2.3). We found that treatment with p-
methoxybenzenethiol was essential to avoid oxidative conversion of N-
methylhydroxylamine into nitrosomethane dimer ((MeNO)2) by reaction with residual 
periodate (IO4
−
) or iodate (IO3
−
) formed in the previous step.
30
 Furthermore, the rate of 
nitrone formation was greatly enhanced by addition of p-anisidine, probably by a similar 
mechanism to that described for formation of oximes from aldehydes and 
hydroxylamines.
31
  
 
Scheme 2.1. One-pot N-terminal conjugation of a hexapeptide by SPANC. Reagents and conditions: a) 1. NaIO4, 
NH4OAc buffer, pH 6.8, rt, 1 h; 2. p-MeOC6H4SH, rt, 1 h; then p-anisidine, MeNHOH·HCl, rt, 20 min; b) 2, rt, 1 h. 
 
    To examine whether the one-pot three-step protocol was suitable for protein 
modification, we selected the chemokine interleukin-8 (IL-8)
32
 as a prototypical protein, 
because IL-8 has an N-terminal serine residue and a relatively low molecular weight (72 
amino acids, MW = 8382 Da), which facilitates direct analysis of chemical modification by  
2.3 Peptide modification by SPANC   
2.4 Protein modification by SPANC 
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Figure 2.3. Mass spectra of N-terminal SKYRAG conjugation by direct aliquoting from the reaction mixture into 
MeOH. (A) Native SKYRAG (MW = 681.4 Da). (B) Hydrate and methoxy form of aldehyde-KYRAG 8 after NaIO4 
oxidation of 7 (MW hydrate = 668.7 Da; MW methoxy adduct = 682.7 Da). (C) Isoxazoline-KYRAG conjugate 10 
after quench with p-MeOC6H4SH, then N-methylhydroxylamine and 2 (MW = 900.0 Da). 
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mass spectrometry. Furthermore, IL-8 is a chemotactic cytokine that binds with high 
affinity to receptors present in sites of infection and inflammation.
32
 Current labeling 
methods of IL-8, for example for the installment of a radiolabel for scintigraphic imaging of 
infections,
33
 are based on random reactions of side-chain lysine amino groups. This gives 
no control over the number of reactions that take place or the sites of reaction, which may 
compromise binding affinity and strongly influence pharmacokinetics. Thus, IL-8 in 
NH4OAc buffer pH 6.9 was subjected to oxidation with NaIO4 (1.1 eq, 1 h), followed by 
treatment with p-methoxybenzenethiol (6.6 eq, 2 h), then N-methylhydroxylamine (10 eq) 
and p-anisidine (10 eq), and finally cyclooctynol 2 (25 eq, Scheme 2.2). After 24 h, mass 
spectrometric analysis showed the presence of a single protein with a mass corresponding 
to isoxazoline conjugate 12 (MW = 8600 Da; Figure 2.4). 
 
Scheme 2.2. One-pot N-terminal functionalization of IL-8 by SPANC. Reagents and conditions: (a) 1. NaIO4, 
NH4OAc buffer pH 6.9, rt, 1 h; (b). p-MeOC6H4SH, N-methylhydroxylamine·HCl, rt, 20 min; (c) cyclooctynol 2 or 
PEG-cyclooctyne 14, rt, 20 h.  
Figure 2.4.  Mass spectra (bottom) and deconvoluted massa spectra (top) after oxidation and SPANC of IL-8. (A) 
Native IL-8 (MW = 8382 Da); (B) IL-8 after conjugation with 2 (MW = 8600 Da). 
 
A. B. 
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The one-pot three-step SPANC protocol was also successfully employed to PEGylate
34,35
 
IL-8 by using the PEG2000-modified dibenzocyclooctyne 14. Quantitative formation of 
PEG-modified IL-8 13 was observed by HPLC analysis (Figure 2.5).  
 
Figure 2.5. HPLC traces of Il-8 (11) and crude PEGylated IL-8 (13).  
 
    Shortly after introduction of SPANC, a new cyclooctyne was developed in our group 
based on bicyclo[6.1.0]nonyne (BCN, compound 15, Figure 2.6).
36
 This novel ring-strained 
alkyne is readily accessible in only four synthetic steps from 1,5-cyclooctadiene in 61% 
overall yield. Additionally, it has a reaction rate constant with benzyl azide (k = 0.14 M
-1
s
-1
 
in CD3CN:D2O 3:1 and 0.29 M
-1
s
-1
 in CD3CN:D2O 1:2) similar to or better than most other 
cyclooctyne systems (but slightly below that of DIBAC 3).
10,20
 In addition, BCN may be 
advantageous for bioconjugation due to its slightly lower lipophilicity than the 
dibenzofused cyclooctynes.  
 
 
Figure 2.6. Structures of BCN-CH2OH (15) and BCN-biotin conjugate 16.  
2.5 SPANC with bicyclono[6.1.0]nonyne  
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    The suitability of BCN for reaction with nitrones was therefore also investigated. As 
expected, the rate constant for the reaction between 15 and nitrone 4f appeared almost 10-
fold higher, measuring 1.66 M
-1
s
-1
 in CD3CN:D2O 3:1 mixture, than that for reaction with 
an azide, but somewhat slower than for SPANC with DIBAC and 4f in the same solvent 
mixture (8.5 M
-1
s
-1
).  
    We also became interested in whether BCN is suitable for conjugation of biomolecules, 
in particular peptides and proteins, with SPANC. The usefulness was investigated in the 
one-pot functionalization of a model peptide with an N-terminal serine, FRATtide, a GSK-
1 binding peptide that prevents axin binding.
37
 Thus, the N-terminal serine of FRATide was 
oxidatively cleaved with sodium periodate to rapidly generate the corresponding aldehyde, 
which was first treated with p-methoxybenzenethiol and then with N-methylhydroxylamine, 
p-anisidine, and BCN-CH2OH (15) or biotinylated BCN conjugate 16. In both cases, the 
desired isoxazoline was readily formed after 24 h, as was demonstrated by mass 
spectrometric analysis (Figure 2.7). In addition, biotinylation of FRATtide was 
corroborated by spot blot analysis by binding it to rhodamine red-labeled streptavidin 
(Figure 2.8).  
Figure 2.7. Mass spectra (bottom) and deconvoluted mass spectra (top) of native FRATtide and after SPANC. (A) 
Native FRATtide (MW = 4534 Da); (B) FRATtide after SPANC with BCN-CH2OH (15) (MW = 4682 Da); (C) FRATtide 
after SPANC with biotinylated BCN conjugate 16 (MW = 5127 Da).  
A. B. 
C. 
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Figure 2.8. Spot blot analysis of biotinylated FRATtide. (A) Native FRATtide; (B) purified FRATtide-BCN-biotin 
conjugate. Top: ponceau S stain; bottom: stained with TBS-T solution containing 1% BSA and 0.01% rhodamine 
red-labeled streptavidin.  
    Besides serine or threonine oxidation, a variety of alternative methods have been 
described for the installment of carbonyl groups in biomolecules,
38-40
 which could further 
extend the potential of SPANC for bioconjugation. Potentially the most generally 
applicable method for the oxidation of any N-terminal residue to the corresponding 
aldehyde or ketone involves the use of pyridoxal-5-phosphate (PLP), which may be further 
optimized by judicious choice of the N-terminal amino acid sequence.
41,42
 We subjected the 
protein horse heart myoglobin, containing an N-terminal glycine, to the described 
conditions, and obtained the corresponding aldehyde. Although subsequent SPANC 
reaction with BCN-CH2OH 15 succeeded (Figure 2.9), later attempts to oxidize myoglobin 
with PLP resulted in precipitation of the protein, so we were not able to reproduce those 
results.  
 
    In 2009, Goldenberg et al.
43
 developed a method for the efficient 
18
F-labeling of peptides 
and proteins via a chelate for positron emission tomography (PET) imaging. In this new 
approach, 
18
F was first attached to aluminum as Al
18
F
2+
, which was then bound to a chelate 
attached to a peptide (Scheme 2.3A). With 1,4,7-triazacyclononane-N,N′,N″-triacetic acid 
(NOTA, 17, Figure 2.10) as the chelating agent, a stable Al
18
F
2+
-chelate-peptide complex 
was formed  in an efficient one-pot process. In 2011, the same group
44
 developed a new 
 
2.6 Pyridoxal-5-phosphate oxidation 
2.7 Radiolabeling of IL-8  
Ponceau S 
 
 
Streptavidin- 
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Figure 2.9. Mass spectra (bottom) and deconvoluted mass spectra (top) of myoglobin. (A) Native myoglobin (MW 
= 16951 Da). (B) Myoglobin after PLP oxidation (MW hydrate  = 16968 Da). (C) Myoglobin after SPANC with BCN-
CH2OH 15 (MW = 17129 Da). 
 
chelator, containing the 1,4,7-triazacyclononane-1,4-diacetate (NODA) backbone attached 
to methylphenylacetic acid (MPAA) 18. The resulting pentadentate NODA-MPAA chelator 
gave stable Al
18
F
2+
 complexes with higher radiochemical yields compared to NOTA 
derivatives.  
    A limiting factor in this procedure, however, is the requirement of extensive heating (30 
min at 95 °C or 15 min at 110 °C) at low pH (4.5-5.0) for installment of Al
18
F
2+
 in the 
chelator attached to the peptide, which limits its use to heat-stable peptides. We envisioned 
that the SPANC protocol could extend the applicability of the described procedure to heat-
sensitive peptides and proteins such as IL-8. This approach would require the synthetic 
availability of DIBAC-MPAA-NODA conjugate 21 for loading with Al
18
F
2+
 at 95 °C, prior 
to SPANC with a sensitive substrate at room temperature (‘hot conjugation’, Scheme 2.3B). 
In order to make the described SPANC protocol feasible for imaging of infection or 
inflammation, several criteria need to be met. First of all, SPANC needs to give high 
conversion (min. 60%) in the lowest amount of time possible (max. 60 min) to limit decay 
of radioactivity. Secondly, only a small excess of Al
18
F
2+
-NODA-MPAA-DIBAC can be 
used because IL-8 and 
18
F are both costly. 
A. B. 
C. 
C. 
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Scheme 2.3. Different strategies for the synthesis of Al18F2+-chelator-peptide complexes. (A) Al18F2+ labeling on 
the peptide; (B) ‘hot conjugation’.  Reagents and conditions: (a) AlCl3, 
18F−, pH = 4, 15 min, 110 °C; (b) rt, pH = 6.8.  
 
 
Figure 2.10. Metal-chelating agents based on NOTA (17) and NODA (18).  
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    Thus, DIBAC-MPAA-NODA conjugate 21 was synthesized from DIBAC-OSu 
derivative 20 and NODA-MPAA-amine (19) in 87% yield (Scheme 2.4) and used in 
SPANC with IL-8. Unfortunately, with a relatively small excess of 21 (6-9 eq) with respect 
to oxidized IL-8, mass spectrometric analysis indicated formation of only trace amount of 
product (~3%) after 3 h incubation. We did detect, however a compound with a mass 
corresponding to a potential adduct of DIBAC-NODA conjugate 21 and N-
methylhydroxylamine. Although the formation of such an adduct could not readily be 
explained, we were stimulated to explore the potential purification of the IL-8-derived 
nitrone prior to SPANC in order to remove any residual free N-methylhydroxylamine. 
Indeed, purification of the nitrone with a 3 kDa cutoff spin filter before addition of DIBAC-
NODA conjugate 21 (6 eq) gave almost full conversion to the desired product in only 10 
min (Figure 2.11).  
 
 
Scheme 2.4. Synthesis of DIBAC-MPAA-NODA (21). Reagents and conditions: (a) Et3N, CH3CN:H2O 1:1, rt, 2 h.  
 
    Before DIBAC-NODA 21 was subjected to the labeling reaction with Al
18
F
2+
, stability of 
the conjugate under labeling conditions was examined. To this end, saline, sodium acetate 
buffer pH 4, acetonitrile and 2 mM AlCl3 solution were added to DIBAC-NODA in H2O, 
similar to the conditions used for Al
18
F
2+
 labeling. Unfortunately, after heating for 15 
minutes at 95 °C, LC-MS showed that approximately 95% of 21 had disappeared. 
 
Protein modification by strain-promoted alkyne-nitrone cycloaddition 
 
 
- 51 - 
 
 
Figure 2.11. Mass spectra (bottom) and deconvoluted mass spectra (top) of IL-8 after purification after nitrone 
formation and SPANC. (A) Il-8 after purification of the nitrone (MW nitrone = 8380 Da); (B) IL-8 after 10 min 
incubation with 6 equivalents of DIBAC-NODA conjugate 21 (MW product = 9117 Da). 
 
Leaving the reaction mixture at room temperature instead of 95 °C or addition of H2O 
instead of AlCl3 solution resulted in slightly increased recovery (30-40%) of 21, leading to 
the conclusion that disappearance of the DIBAC-NODA conjugate is caused by a 
combination of heating and the presence of AlCl3.  
    From these experiments it can be concluded that DIBAC-NODA conjugate 21 is not 
suitable for hot conjugation, because it does not survive the labeling procedure. 
Nevertheless, it is expected that DIBAC-NODA can be applied for the site-selective N-
terminal F
18
 labeling of heat-stable peptides and proteins. Additionally, we learned from 
these experiments that if the protein-derived nitrone intermediate is purified before 
SPANC, almost quantitative isoxazoline formation can be accomplished with a  small 
excess of cyclooctyne in only 10 minutes.  
 
    We have shown that 1,3-dipolar cycloadditions of cyclooctynes with nitrones containing 
ester or amide substituents exhibit much faster kinetics than similar reactions with azide. 
This finding is in agreement with the results of McKay et al., who independently reported 
the same result at the same time.
45
 The new methodology was successfully employed for 
the site-specific modification of the peptide SKYRAG and the protein IL-8 by 
implementing a one-pot three-step protocol. Additionally, we have shown that purification 
of the nitrone is possible, even at the protein stage, after which only small amounts (≤ 6 eq) 
2.8 Conclusions & outlook     
A. B. 
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of cyclooctyne are sufficient for fast conversion to the corresponding isoxazoline in only 
ten minutes.  
    Besides serine or threonine oxidation, a variety of methods have been described for the 
installment of carbonyl groups in proteins
38-40
 and we succeeded in performing a SPANC 
reaction after PLP oxidation. Therefore, we anticipate that SPANC will offer an attractive 
alternative
46
 to the well-established oxime ligation,
47,48
 because synthesis of nitrones is 
simple
49
 and the isoxazoline products are stable.
23
 Additionally, the combination of a 
functionalized nitrone (R3 is a functional group, Table 2.1) with a cyclooctyne conjugate 
such as 16 will make it possible to introduce two different functionalities in a single 
process, which will further be described in Chapter 3. 
    Finally, it must be mentioned that metal-free click reactions have found entry into 
materials science.
18
 SPANC will provide an additional tool for the preparation of 
increasingly complex materials by simple and flexible chemical modifications.  
 
    Jan Dommerholt is greatly acknowledged for synthesis of nitrones 4a-f and kinetic 
experiments. Dr. Daniel Blanco Ania is gratefully acknowledged for development of the 
one-pot SPANC protocol. Gerben Fransen, dr. Peter Laverman and prof. dr. Otto Boerman 
(Nuclear Medicine, Radboud University Medical Centre) are kindly acknowledged for 
useful discussions regarding IL-8 labeling.  
 
Unless stated otherwise all chemicals were obtained from commercial sources and used without 
further purification. CH2Cl2, acetonitrile and toluene were distilled from calcium hydride; THF from 
sodium; and CH3OH from magnesium and iodine. Aqueous solutions are saturated unless otherwise 
specified. All reactions were performed under anhydrous conditions under argon and monitored by 
analytical thin layer chromatography (TLC) on Kieselgel 60 F254 (Merck). Detection was by 
examination under UV light (254 nm) and by charring with 10% sulfuric acid in methanol. Silica gel 
(Merck, 70-230 mesh) was used for chromatography. SKYRAG was synthesized with standard Fmoc 
solid phase peptide synthesis.  
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Nuclear Magnetic Resonance (NMR) Spectroscopy: 1H NMR spectra were recorded in CDCl3, 
CD3CN, acetone-d6, DMSO-d6, CD3OD or D2O on Bruker DMX300 or Varian Inova-400 
spectrometers equipped with Sun workstations at 300 K. 1H-NMR chemical shifts (δ) are reported in 
parts per million (ppm) relative to TMS (δ = 0.00), CHCl3 (δ = 7.26), CH3CN (δ = 1.94), acetone (δ = 
2.05), DMSO ((δ = 2.50)  CH3OH (δ = 3.31) or H2O (δ = 4.67). 
13C NMR spectra were recorded in 
CDCl3, CD3CN, acetone-d6, DMSO-d6, CD3OD or D2O at 75 MHz on a Bruker DMX300 
spectrometer using the central resonance of CHCl3 (δ = 77.0), CH3CN (δ =118.3), acetone (δ = 29.8), 
DMSO δ = 39.5)  or CH3OH (δ = 49.0) as the internal reference.  
 
Mass spectrometry: High resolution mass spectra and protein spectra were recorded on a JEOL 
AccuTOF (Electrospray Ionization (ESI)) or a JEOL JMS-T100GCv AccTOF (EI and CI). Peptide 
mass measurements were performed on Thermo LCQ Advantage Max (ESI) or a Thermo LCQ Fleet 
(ESI). Deconvoluted mass spectra were obtained with MagTran 1.03b2. 
 
Reversed Phase High Performance Liquid Chromatography (RP-HPLC): Analytical RP-HPLC was 
performed on a Shimadzu LC-2010AHT HPLC using an analytical reversed-phase RPC18 column 
(Varian intersil ODS-3, 100 Å, 5 µm, 150 mm × 4.6 mm) and a Shimadzu UV detector operating at 
254 nm. Elution was effected using a gradient of 10-70% of CH3CN in water (both containing 0.1% 
TFA) over 30 minutes at a flow rate of 1.0 mL/min. Preparative RP-HPLC was performed on a 
Shimadzu LC-20A Prominence system equipped with a C18 column (150 × 20 mm, particle size 10 
µm, 8 mL/min flow) and a CH3CN/H2O gradient containing 0.1% trifluoroacetic acid (5-100%, 70 
min).  
 
Nitrones 4a, b, d-f were prepared according to the method described by Parhi et al.50 Nitrone 4c was 
prepared according to Tian et al.51 
 
Nitrones 4a,52 4b,53 4c51 and 4e52 are known compounds. Analytical data for nitrones 4d and 4f are 
given below.  
 
Ethyl (1-(N-methylimino)ethyl N-oxide)propanoate (4d) 
Mixture of E/Z-isomers. 
1H NMR (CDCl3, 400 MHz): δ 4.12-4.03 (m, 2H), 3.71 (s, 1.2H), 3.62 (s, 2.8H), 
2.71-2.64 (m, 3H), 2.51-2.45 (m, 1H), 2.08 and 2.05 (2 × s, 3H), 1.19 (m, 3H). 13C 
NMR (CDCl3, 75 MHz): δ 172.8, 171.3, 146.0, 146.0, 87.4, 61.0, 60.5, 47.9, 47.3, 
2.10.2 Preparation procedures and analytical data of nitrones 4a-f. 
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44.1, 37.8, 30.8, 29.2, 28.7, 28.4, 19.8, 17.4, 14.1, 14.0. HRMS (ESI+) m/z calcd for C8H16NO3 (M + 
H)+: 174.1130, found: 174.1122. 
 
N-(Methyliminoacetyl N-oxide)benzylamine (4f) 
1H NMR (CDCl3, 400 MHz): δ 10.12 (bs, 1H), 7.32 (bs, 5H), 7.12 (s, 1H), 4.56 (d, 
2H), 3.81 (s, 3H). 13C NMR (CDCl3, 75 MHz): δ 160.3, 137.6, 131.9, 128.6, 127.6, 
127.4, 54.5, 42.8. HRMS (ESI+) m/z calcd for C10H13N2O2 (M + H)
+: 193.0977, 
found: 193.0969. 
 
 
General procedure 
To a solution of 2 (0.1 mmol) in a 1:1 mixture of CH3CN and H2O (2 mL) was added 4a-f (0.1 
mmol). The mixture was stirred at room temperature until TLC analysis indicated complete 
consumption of starting materials. The reaction mixture was concentrated in vacuo, and the residue 
was purified by column chromatography on silica gel. 
 
2-Methyl-3-phenyl-2,3,8,9-tetrahydrodibenzo[3,4:7,8]cycloocta[1,2-d]isoxazol-8-ol (5a) 
Prepared according to the general procedure by stirring for 16 h. RF 0.3 
(EtOAc:heptane, 1:2). Yield 95%, isolated as a mixture of regio- and 
diastereomers. 1H NMR (CDCl3, 400 MHz): δ 7.66-6.84 (m, 13H), 5.26 (m, 0.5H), 
5.14-5.01 (m, 1.5H), 3.67 (m, 0.3H), 3.42-3.33 (m, 0.3H), 3.23-3.06 (m, 4.4H). 13C 
NMR (CDCl3, 75 MHz): δ 146.8, 144.1, 140.6, 140.5, 140.2, 136.9, 136.4, 132.6, 
131.4, 129.7, 128.6, 128.5, 127.2, 127.1, 126.7, 126.3, 111.2, 110.0, 80.7, 80.4, 73.7, 68.7, 47.2, 46.8, 
45.3, 42.8, 41.8, 40.1. HRMS (ESI+) m/z calcd for C24H22NO2 (M + H)
+: 356.1651, found: 356.1637. 
 
2-Methyl-3-phenethyl-2,3,8,9-tetrahydrodibenzo[3,4:7,8]cycloocta[1,2-d]isoxazol-8-ol (5b) 
Prepared according to the general procedure by stirring for 16 h. RF 0.3 
(EtOAc:heptane, 1:3). Yield 80%, isolated as a mixture of regio- and 
diastereomers. 1H NMR (CDCl3, 400 MHz): δ 7.69-7.07 (m, 13H), 5.69 (m, 
0.3H), 5.55-5.47 (m, 0.3H), 5.14 (m, 0.2H), 5.04 (m, 0.3H), 4.14 (m, 0.2H), 
4.04-3.95 (m, 0.8H), 3.81-3.67 (m, 0.6H), 3.62-3.50 (m, 0.6H), 3.36-3.25 (m, 
0.6H), 3.21-3.13 (m, 0.6H), 2.96, 2.95 (2 × s, 3H), 2.94-2.54 (m, 2.3H), 2.39-2.25 (m, 0.5H, OH), 
2.22-1.72 (m, 2.7H), 1.68-1.58 (m, 0.4H, OH). 13C NMR (CDCl3, 75 MHz): δ 148.5, 146.4, 143.9, 
141.8, 141.7, 141.6, 140.3, 140.1, 137.3, 137.2, 136.5, 136.1, 133.1, 131.4, 130.3, 130.0, 129.6, 
128.8, 128.5, 128.4, 128.3, 127.6, 127.3, 127.2, 126.8, 126.4, 125.8, 125.7, 125.4, 112.6, 111.2, 
2.10.3 Cycloaddition of 2 and 4a-f leading to isoxazolines 5a-f. 
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110.9, 109.7, 76.1, 74.3, 71.3, 69.0, 47.2, 47.0, 46.8, 46.7, 45.6, 42.9, 41.5, 35.6, 32.6, 32.4, 32.3, 
32.2. HRMS (ESI+) m/z calcd for C26H26NO2 (M + H)
+: 384.1964, found: 384.1943.  
 
2,3-Diphenyl-2,3,8,9-tetrahydrodibenzo[3,4:7,8]cycloocta[1,2-d]isoxazol-8-ol (5c) 
Prepared according to the general procedure by stirring for 16 h. RF 0.4 (EtOAc: 
heptane, 1:2). Yield 89%, isolated as a mixture of regio- and diastereomers. 1H 
NMR (CDCl3, 400 MHz): δ 7.82-7.74 (m, 1.6H), 7.57-6.56 (m, 20H), 6.30-6.22 
(m, 0.3H), 5.99-5.89 (m, 0.3H), 5.70-5.61 (m, 0.5H), 5.40 (s, 0.3H), 5.27 (s, 0.5H), 
5.17-5.12 (m, 0.4H), 4.57 (s, 0.3H), 4.02-3.90 (m, 0.7H), 3.71-3.66 (0.3H), 3.59-
3.48 (m, 0.4H), 3.42-3.28 (m, 0.5H), 2.96-2.76 (m, 0.6H), 2.15 (bs, 0.3H), 1.92 
(bs, 0.3H), 1.55 (bs, 0.4H). 13C NMR (CDCl3, 75 MHz): δ 147.3, 147.0, 146.4, 143.2, 141.0, 138.9, 
135.5, 133.0, 131.9, 130.2, 129.8, 129.1, 128.9, 128.3, 128.2, 127.9, 127.1, 126.5, 126.2, 123.0, 
121.6, 121.3, 120.8, 118.6, 117.9, 117.7, 115.8, 98.3, 98.2, 93.4, 73.7, 70.0, 49.3, 45.0, 44.3, 41.2, 
41.1, 36.6, 35.5. HRMS (ESI+) m/z calcd for C29H24NO2 (M + H)
+: 418.1807, found: 418.1795. 
 
Ethyl 3-(8-hydroxy-2,3-dimethyl-2,3,8,9-tetrahydrodibenzo[3,4:7,8]cycloocta[1,2-d]isoxazol-3-
yl)propanoate (5d) 
Prepared according to the general procedure by stirring for 72 h. RF 0.3 
(EtOAc:heptane, 1:1). Yield 33%, isolated as a mixture of regio- and 
diastereomers (contaminated with uncharacterized side-products), main peaks 
are given. 1H NMR (CDCl3, 400 MHz): δ 7.73-6.90 (m, 8H), 5.87-5.76 (m, 
0.2H), 5.54 (m, 0.3H), 5.46-5.43 (m, 0.4H), 4.20-4.03 (m, 2H), 3.85 (m, 
0.2H), 3.75-3.70 (m, 0.4H), 3.58 (m, 0.6H), 3.32 (m, 0.8H), 3.14-2.96 (m, 1.4H), 2.86 (s, 1.1H), 2.84 
(s, 0.3H), 2.80-2.71 (m, 0.9H), 2.31-2.03 (m, 2H), 1.43 (s, 0.4H), 1.42-1.18 (m, 3H). 13C NMR 
(CDCl3, 75 MHz): δ 174.1, 154.5, 139.0, 131.5, 131.2, 128.8, 128.6, 127.8, 127.6, 126.9, 126.7, 
126.1, 125.2, 124.7, 120.7, 120.4, 110.1, 109.6, 106.9, 95.3, 93.1, 86.7, 84.7, 83.5, 74.3, 73.1, 60.6, 
60.4, 60.4, 50.2, 44.0, 43.5, 42.2, 40.7, 36.5, 35.9, 29.8, 14.8. HRMS (ESI+) m/z calcd for C24H28NO4 
(M + H)+: 394.2018, found: 394.2001. 
 
Ethyl 8-hydroxy-2-methyl-2,3,8,9-tetrahydrodibenzo[3,4:7,8]cycloocta[1,2-d]isoxazole-3-
carboxylate (5e) 
Prepared according to the general procedure by stirring for 16 h. RF 0.4 
(EtOAc:heptane, 2:1). Yield 92%, isolated as a mixture of regio- and 
diastereomers. 1H NMR (CDCl3, 400 MHz): δ 7.70-7.67 (m, 0.7H), 7.57-7.54 (m, 
0.4H), 7.45-7.41 (m, 1H), 7.37-7.12 (m, 8.6H), 5.82-5.77 (m, 0.4H), 5.57-5.52 
(m, 0.3H), 5.07-4.96 (m, 0.6H), 4.79 (s, 0.2H), 4.73 (s, 0.3H), 4.72 (s, 0.3H), 4.71 
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(s, 0.2H), 4.28-4.08 (m, 2.7H), 3.84-3.79 (m, 0.5H), 3.73-3.55 (m, 0.7H), 3.43 (m, 0.2H), 3.29-3.13 
(m, 1H), 3.09, 3.09, 3.08 (3 × s, 2.4H), 1.25 (m, 0.3H), 1.20 (m, 0.6H), 1.15 (m, 1H), 1.11 (m, 0.9H). 
13C NMR (CDCl3, 75 MHz): δ 169.7, 169.5, 151.2, 149.1, 144.2, 143.0, 140.5, 138.4, 137.4, 136.8, 
133.1, 131.5, 130.2, 129.9, 129.7, 129.6, 129.3, 127.8, 127.7, 127.6, 127.4, 127.2, 126.7, 126.4, 
125.7, 126.6, 105.3, 103.9, 78.4, 71.5, 68.6, 62.3, 61.5, 48.2, 47.5, 47.4, 47.3, 45.4, 42.6, 42.2, 40.2, 
13.4. HRMS (ESI+) m/z calcd for C21H22NO4 (M + H)
+: 352.1549, found: 352.1539. 
 
N-Benzyl-8-hydroxy-2-methyl-2,3,8,9-tetrahydrodibenzo[3,4:7,8]cycloocta[1,2-d]isoxazole-3-
carboxamide (5f) 
Prepared according to the general procedure by stirring for 16 h. RF 0.4 
(EtOAc:heptane, 2:1). Yield 93%, isolated as a mixture of regio- and 
diastereomers. 1H NMR (CDCl3, 400 MHz): δ 7.84 (m, 0.2H), 7.75 (m, 0.2H), 
7.66-7.62 (m, 1H), 7.39-7.23 (m, 8.9H), 7.20-7.08 (m, 3.9H), 5.38 (m, 0.2H), 
5.29-5.23 (m, 0.5H), 5.03-4.98 (m, 0.3H), 4.95-4.86 (m, 0.3H), 4.65, 4.64 (2 × 
s, 0.8H), 4.60 (s, 0.2H), 4.55 (m, 0.3H), 4.48 (m, 0.5H), 4.45-4.33 (m, 1.3H), 3.67 (m, 0.2H), 3.54 (m, 
0.4H), 3.35 (m, 0.2H), 3.27-3.08 (m, 1.3H), 3.05, 3.04, 3.03, 3.03 (4 × s, 3H), 2.20-2.13 (m, 0.3H), 
2.11-2.04 (m, 0.3H), 1.78 (bs, 0.5H). 13C NMR (CDCl3, 75 MHz): δ 169.2, 168.5, 168.3, 147.5, 
146.8, 144.5, 143.0, 140.5, 139.1, 138.4, 138.3, 138.2, 137.7, 137.1, 136.8, 136.4, 133.1, 132.8, 
131.8, 131.1, 129.8, 129.5, 129.4, 129.3, 128.6, 127.7, 127.5, 126.2, 125.6, 125.1, 109.0, 107.7, 
107.6, 105.8, 78.5, 78.1, 77.9, 71.5, 68.4, 46.3, 46.2, 46.0, 45.3, 43.2, 43.0, 42.9, 42.7, 40.4. HRMS 
(ESI+) m/z calcd for C26H25N2O3 (M + H)
+: 413.1865, found: 413.1862. 
 
 
Prepared according to the general procedure by stirring 3 and 4f for 30 min. Purification by column 
chromatography on silica gel (EtOAc:CH2Cl2, 1:1) led to the isolation of 4 isomers of 6. HRMS 
(ESI+) m/z calcd for C29H29N3O5Na [M+Na]
+ 522.1999, found 522.2030. Isomer 1: RF = 0.24 
(EtOAc:CH2Cl2 1 : 1). 
1H NMR (300 MHz, CDCl3): δ 7.63-7.18 (m, 13H), 6.18-6.12 (m, 1H), 5.00 
(bs, 1H), 4.66 (s, 1H), 4.50-4.30 (m, 2H), 3.70 (bs, 2H), 3.37-3.18 (m, 4H), 3.06 (s, 3H), 2.09 (bs, 
1H). MS (LCQ): m/z calcd for C29H29N3O5Na [M+Na]
+ 522.2, found 522.3.7 Isomer 2: RF = 0.17 
(EtOAc:CH2Cl2 1 : 1). 
1H NMR (300 MHz, CDCl3): δ 7.64-7.12 (m, 13H), 6.14-6.06 (m, 1H), 5.13 
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(bs, 1H), 4.67 (s, 1H), 4.41-4.35 (m, 2H), 3.65 (bs, 2H), 3.33-3.13 (m, 4H), 3.04 (s, 3H). MS (LCQ): 
m/z calcd for C29H29N3O5Na [M+Na]
+ 522.2, found 522.5. Isomers 3 + 4. RF = 0.13 and 0.10 
(EtOAc:CH2Cl2 1:1). 
1H NMR (300 MHz, CDCl3): δ 7.72-7.09 (m, 26H). 6.38-6.29 (m, 1H), 6.20-
6.11 (m, 1H), 5.18 (bs, 1H), 5.00 (bs, 1H), 4.67-4.49 (m, 4H), 4.46-4.35 (m, 2H), 3.73 (bs, 2H), 3.56-
3.17 (m, 10H), 3.07 (s, 3H), 3.04 (s, 3H), 2.12 (bs, 1H).MS (LCQ): m/z calcd for C29H29N3O5Na 
[M+Na]+ 522.2, found 522.3. 
 
NMR experiments: Stock solution A: alkyne 2 (79 mg, 0.36 mmol) was dissolved in a mixture of 
CD3CN and D2O (ratio 3:1, 10 mL) to give a 36 mM solution. Stock solution B (32.8 mM): nitrone 
4a-d (0.338 mmol) was dissolved in a mixture of CD3CN and D2O (ratio 3:1, 10 mL) to give a 32.8 
mM solution. 1H-NMR monitoring of cycloaddition of 2 and 4 was performed by rapid mixing (t = 0) 
of stock solutions A and B (0.3 mL each) in an NMR tube and immediate insertion into a 400 MHz 
NMR spectrometer. NMR spectra were measured at preset time intervals. Kinetics of the reaction of 2 
with nitrone 4a (Table 2.1, entry 1) were determined by measuring the decrease of the integral of the 
signal caused by the nitrone methyl groups, with the integral of the acetonitrile solvent peak as 
internal standard. A starting value for the integral of the methyl signals was estimated, due to the fact 
that cycloaddition had already proceeded significantly by time of the first measurement. The 
conversion was determined by dividing the combined integrals of the methyl groups of 5a and 6a by 
the estimated starting value. For the reaction of 2 with nitrone 4b (Table 2.1, entry 2), kinetics were 
determined by integration of the methyl peaks of the nitrone in starting material and product. The sum 
of these two integrals was taken as internal standard, due to the fact that the acetonitrile peak was not 
distinct from other signals. Now, conversion was determined by the relative increase of methyl 
signals of product 5b and 6b, compared to the sum of both signals. The reaction of 2 with nitrone 4c 
was too fast to follow by NMR. By the time of the first measurement, the reaction had already 
reached such a conversion that no reliable kinetic plot could be made. Therefore only a rough 
estimate was made based on the first measurement. From the conversion plots thus obtained, the 
second order rate plots were calculated according to equation (1). 
 
UV experiments: Stock solution A: alkyne 2, 2b or 3 (110 mg, 0.5 mmol) was dissolved in CH3CN 
(50 mL) to give a 10 mM solution. Stock solution B: nitrone 4e or f (0.5 mmol) was dissolved in 
CH3CN (50 mL) to give a 10 mM solution. To achieve the desired CH3CN:H2O ratio, to 1 mL of 
stock solution A or B was added the correct amount of H2O, giving solutions A' and B'. Solutions A' 
and B' were left to adjust to room temperature for at least 30 minutes. UV monitoring of cycloaddition 
of dibenzocyclooctyne (2 or 3) and nitrone 4 was performed by rapid mixing (t = 0) of solutions A' 
2.10.4 General procedure kinetic experiments 
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and B' (1 mL each) and immediate insertion into a 1 mm UV cuvette. Next, UV absorption was 
measured at preset time intervals (in general every five seconds) at 304 nm. The graphs thus obtained 
showed a decrease of the absorption over time, sloping to a final absorption that was subtracted from 
the measured absorptions to obtain a relative absorption. To determine conversion, the relative 
absorption was divided by the difference between the maximal and the minimal absorption. Since the 
reactions already proceeded before measurement of the first absorption, the maximum absorption was 
adjusted to an estimated starting point. From the conversion plots thus obtained, the second order rate 
plots were calculated according to equation (1). 
 
Kinetics of SPANC with BCN: 1H-NMR monitoring of cycloaddition of 15 with nitrone 4f was 
performed by rapid mixing (t = 0) of stock solutions A and B (0.3 mL each) in an NMR tube and 
immediate insertion into a 400 MHz NMR spectrometer. NMR spectra were measured at preset time-
intervals. Each experiment was performed in triplo. Stock solution A: alkyne 15 was dissolved in a 
mixture of CD3CN and D2O (ratio 3:1 or 1:2, 10 mL) to give a 36 mM solution. Stock solution B: N-
(methyliminoacetyl N-oxide)benzylamine (nitrone 4f) was dissolved in a mixture of CD3CN and D2O 
(ratio 3:1 or 1:2, 10 mL) to give a 32.8 mM solution. Kinetics of the reaction of 15 with nitrone 4f 
were determined by measuring the decrease of the integral of the nitrone methyl groups, with the 
integral of the acetonitrile or water solvent peak as internal standard. A starting value for the integral 
of the methyl signals was estimated, due to the fact that cycloaddition had already proceeded 
significantly by the time of the first measurement. From the conversion plots thus obtained, the 
second order rate plots were calculated according to equation (1). 
 
 
SKYRAG isoxazoline 10 
Peptide 7 (SKYRAG, 5.5 mg, 8.08 μmol) was dissolved in 0.1 M NH4OAc buffer (1 mL, pH 6.9) and 
NaIO4 (1.9 mg, 8.89 μmol) was added. The resulting mixture was stirred at room temperature until 
mass spectral analysis (LCQ, 30 min) indicated that oxidative cleavage was complete. Subsequently, 
p-methoxybenzenethiol (7.5 mg, 0.053 mmol) was added to give a white cloudy solution, and the new 
mixture was stirred for 1 h at room temperature, until the reaction mixture turned colorless. p-
Anisidine (5.0 mg, 0.040 mmol) was then added and the solution was stirred until dissolved 
completely (15 min). N-Methylhydroxylamine hydrochloride (1.5 mg, 0.018 mmol) and 2 (3.9 mg, 
0.018 mmol) were added. The resulting reaction mixture was stirred at room temperature for 30 min 
to give isoxazoline 10. HRMS (ESI +) m/z calcd for C45H59N10O10 [M+H]
+ 899.4410, found 
899.4446.  
 
2.10.5 SKYRAG, FRATtide and IL-8 labeling 
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IL-8 isoxazoline 12 
A solution of IL-8 (5 μg, 0.60 nmol) in PBS buffer (10 μL) was diluted with 0.1 M NH4OAc buffer 
pH 6.9 (10 μL). Subsequently, NaIO4 (0.66 nmol, 0.14 μg) was added. The reaction was allowed to 
take place for 1 h at room temperature, and p-methoxybenzenethiol was added (3.9 nmol, 0.55 μg, 0.5 
nL). After shaking for 1 h at room temperature, p-anisidine (5.6 nmol, 0.69 μg) was added. After 
stirring for 15 min at room temperature, N-methylhydroxylamine hydrochloride (5.6 nmol, 0.47 μg) 
and 2 (14.0 nmol, 1.24 μg) were added. The reaction mixture was shaken overnight at 25 °C to give 
conjugate 12. MS (Accu-TOF) measurement gave 8601 Da as the main peak after deconvolution. 
 
IL-8-PEG isoxazoline 13 
A solution of IL-8 (5 μg, 0.60 nmol) in PBS buffer (10 μL) was diluted with 0.1 M NH4OAc buffer 
pH 6.9 (10 μL). Subsequently, NaIO4 (0.66 nmol, 0.14 μg) was added. The reaction was allowed to 
take place for 1h at room temperature, and p-methoxybenzenethiol was added (3.9 nmol, 0.55 μg, 0.5 
nL). After shaking for 1 h at room temperature, p-anisidine (5.6 nmol, 0.69 μg) was added. After 
shaking for 15 min at room temperature, N-methylhydroxylamine hydrochloride (5.6 nmol, 0.47 μg) 
and 1420 (14.0 nmol, 28 μg) were added. The reaction mixture was shaken overnight at 25 °C to give 
conjugate 13. The product was analysed by RP-HPLC. Retention time IL-8 11.54 min; retention time 
PEGylated IL-8 (13) 13.01 min. 
 
SPANC labeling of FRATtide with 15 
FRATtide (15.6 μg, 3.4 nmol, 34 μM) was dissolved in 0.1 M NH4OAc buffer pH 6.9 (100 μL) and 
NaIO4 (1.1μg, 5.5 nmol, 48 μM) was added. The reaction was allowed to take place at room 
temperature for 40 min and p-methoxybenzenethiol (9.2 μg, 66.0 nmol, 565 μM) was added. The 
mixture was shaken for 2 h at 25 °C and p-anisidine (13.5 μg, 109.3 nmol, 845 μM), N-
methylhydroxylamine hydrochloride (18.2 μg, 218.6 nmol, 1.5 mM), and 15 (41.1 μg, 273.3 nmol, 
1.8 mM) were added. Finally, the reaction mixture was shaken at 25 °C for 24 h to give the desired 
conjugate. MS (Accu-TOF) measurement gave 4681.3 Da as the main peak after deconvolution. 
 
SPANC labeling of FRATtide with BCN-biotin conjugate 16 
FRATtide (9.3 μg, 2.1 nmol, 35 μM) was dissolved in 0.1 M NH4OAc buffer pH 6.9 (60 μL) and 
NaIO4 (0.7μg, 3.4 nmol, 52 μM) was added. The reaction was allowed to take place at room 
temperature for 40 min and p-methoxybenzenethiol (5.7 μg, 40.7 nmol, 581 μM) was added. The 
mixture was shaken for 2 h at 25 °C and p-anisidine (8.3 μg, 67.2 nmol, 864 μM), N-
methylhydroxylamine hydrochloride (11.3 μg, 134.8 nmol, 1.6 mM), and 16 (100.3 μg, 168.6 nmol, 
1.7 mM) were added. Finally, the reaction mixture was shaken at 25 °C for 24 h to give the desired 
conjugate. The residue was purified using a YM-3 millipore microcon centrifugal filter device (3 kDa 
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cut off) by centrifuging three times for 30 min at 13,000 × g with 300 μL 0.1 M NH4OAc buffer pH 
6.9. MS (Accu-TOF) measurement gave 5126.8 Da as the main peak after deconvolution. 
 
Spot blot analysis of biotinylated FRATtide 
1 µL of native FRATtide or purified FRATtide-BCN-biotin conjugate was spotted on Whatman 
nitrocellulose membrane. Non-specific sites were blocked using 5% BSA in TBS-T (20 min). 
Proteins were stained with Ponceau S or TBS-T solution containing 1% BSA and 0.01% rhodamine 
red-labeled streptavidin (Invitrogen) for 5 min.  
 
PLP oxidation and SPANC of horse heart myoglobin 
Myoglobin from equine heart (1.31 mg, 77 µmol) was dissolved in 25 mM NaPO4 buffer pH 6.5 (773 
µL) to give a 100 µM solution. Pyridoxal-5-phosphate monohydrate (2.64 mg, 10.0 mmol) was 
dissolved in 498 µL of the same buffer to give a 20 mM solution. The myoglobin solution (210 µL) 
and the PLP solution (105 µL) were combined with 105 µL of the same buffer and the reaction 
mixture was incubated at 37 °C for 16 h, followed by purification using a Millipore Amicon Ultra-0.5 
mL centrifugal filter (10 kDa cut off). To the oxidized myoglobin solution (18.0 nmol in 370 µL 0.1 
M NH4OAc buffer pH 6.8) was added p-anisidine (540 nmol, 67 µg), N-methylhydroxylamine (1.1 
µmol, 90 µg) and BCN-CH2OH 15 (1.4µmol, 216 µg). Incubation overnight at room temperature 
gave approximately 85% conversion to the product based on MS (Accu-TOF) measurement. 
Deconvolution gave 17130 Da as the main peak. 
 
DIBAC-MPAA-NODA (21) 
All glassware was made metal-free before 
use by overnight incubation in 2 M HCl 
followed by washing with metal-free H2O 
(2×). NODA-MPAA-NH2 (36 mg, 0.076 
mmol) and DIBAC-OSu (26 mg, 0.063 
mmol) were dissolved in CH3CN:metal-free H2O 1:1 (2 mL) and triethylamine (45 mg, 61 µL, 0.441 
mmol) was added. The reaction mixture was stirred at room temperature for 2h until mass analysis 
(LCQ) showed complete disappearance of the starting material. The product was purified by 
preparative RP-HPLC and lyophilized to give 21 as an off-white solid (41 mg, 0.056 mmol, 88%). 1H 
NMR (CD3CN, 300 MHz): δ 7.62 (d, 1H, J = 7.4 Hz), 7.44-7.24 (m, 11H), 5.05 ( d, 1H, J = 14.1 Hz), 
4.27 (s, 2H), 3.85 (s, 4H), 3.66 (d, 1H J = 14.0 Hz), 3.44 (s, 2H), 3.35 (bs, 4H), 3.14 (bs, sH), 3.07 (s, 
4H), 2.73 (s, 4H), 2.21-2.11 (m, 1H), 1.84-1.74 (m, 3H), 1.60-1.38 (m, 3H). 13C NMR (CD3CN, 75 
MHz): δ 174.6, 173.8, 173.6, 172.8, 151.5, 148.4, 137.5, 132.4, 130.8, 130.2, 129.6, 129.5, 129.2, 
128.7, 128.5, 128.1, 127.1, 125.6, 122.9, 122.1, 114.4, 107.9, 58.7, 55.5, 55.0, 51.1, 49.5, 46.7, 42.3, 
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39.0, 38.4, 34.8, 33.7, 21.4. HRMS (ESI+) m/z calcd for C41H49N6O7 (M + H)
+: 737.36627, found: 
737.36624. 
 
SPANC reaction of DIBAC-MPAA-NODA (21) with IL-8 
IL-8 (106 µg, 12.6 nmol) was dissolved in 0.1 mM NH4OAc buffer pH 6.8 (124 µL) and NaIO4 (2.4 
µg, 2.6 nmol) was added. After 45 minutes at rt, p-methoxybenzenethiol was added and the reaction 
mixture was allowed to stand for 1 h at rt. p-Anisidine (100 mM final concentration, 12.4 µmol, 1.5 
mg) and N-methylhydroxylamine (1.26 µmol, 105 µg) were added. After 1 h at rt, the nitrone was 
purified with a Millipore Amicon Ultra-0.5 mL centrifugal filter (3 kDa cut off). DIBAC-MPAA-
NODA (21, 50 nmol, 37 µg) was added and reacted for 45 min at rt. MS (Accu-TOF) measurement 
gave 9117 Da as the main peak after deconvolution. 
 
Stability tests of DIBAC-MPAA-NODA (21) 
DIBAC-MPAA-NODA (21, 0.47 mg, 0.64 µmol) was dissolved in H2O (94 µL) to give a final 
concentration of 5 µg/µL. To 6 µL of this solution was added saline (50 µL), NaOAc buffer pH 4.0 or 
H2O (1.5 µL), CH3CN (400 µL) and 2 mM AlCl3 in H2O or H2O (20 µL). The mixture was shaken at 
rt or 95 °C for 15 min, and the reaction mixture was analyzed by LC-MS. 
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3.1 Introduction 
    Chemical conjugation of a functional tag, e.g. a polyethylene glycol (PEG) tail, a small 
molecule toxin, or a reporter molecule, is a well-established technique to modulate behavior 
or study the biological function of proteins. As a further extension of the strategy, interest is 
growing in the dual conjugation of two orthogonal functionalities to a single protein. For 
example, multimodality imaging is offering increased accuracy for diagnosis and surgical 
treatment of human disease. To this end, an antibody (or another targeting protein) with 
high affinity for a site of disease is labeled with two different imaging reporters to enable 
the simultaneous visualization of a single target with two diagnostic techniques, e.g. 
positron emission tomography (PET), computated tomography (CT), fluorescence imaging, 
or magnetic resonance imaging (MRI).
1
 Synthesis of the requisite dual-labeled targeting 
agents, however, is more challenging than attachment of a single reporter molecule, as 
schematically depicted for three different strategies in Figure 3.1. Approach A, involving 
conjugation of a bifunctional linker to the protein, appears most attractive but requires the 
potentially complex synthesis of a branched, bifunctional structure before conjugation. 
Approach B is more straightforward in design and is based on combining two existing tools 
for protein conjugation, involving selective targeting of canonical amino acids such as 
cysteine, lysine, tyrosine or tryptophan.
2
 However, such processes typically proceed with 
low site-specificity and poor control over the number of reactions, thereby potentially 
attenuating protein function in case conjugation takes place in close proximity to a binding 
region or an active site. Some approaches for selective N-terminal labeling have been 
developed in recent years, however these require specific enzymes
3,4
 or elaborate 
 
Figure 3.1. Different approaches for the introduction of two functional labels to a peptide or protein. (A) Via a 
pre-synthetized complex containing the two labels; (B) via two separate functional handles; (C) via the N-
terminal, one-pot SPANC reaction. 
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optimization of reaction conditions to reach full conversion to a singly modified product.
5
 
    To overcome the limitations associated with conjugation to canonical amino acids, 
labeling techniques based on non-native functional handles have been developed, for 
example hydrazone
6
 or oxime ligation
7
 to an aldehyde. An aldehyde can be chemically 
introduced into a protein by oxidation of the N-terminal amino acid upon the action of 
sodium periodate
8
 or pyridoxal-5-phosphate,
9
 or at an internal site by genetically encoding 
a cysteine-containing pentapeptide tag for enzymatic oxidation
10
.  
    Another frequently applied non-natural functional handle is azide,
11
 that may undergo 
reaction with a phosphine probe by Staudinger ligation,
12
 with a terminal acetylene by 
copper-catalyzed click reaction (CuAAC),
13,14
 or with a strained alkyne by strain-promoted 
azide–alkyne cycloaddition (SPAAC).15 Conveniently, several methods have been 
developed for site-selective introduction of an azide into a protein, such as post-
translational diazotransfer,
16,17
 protein expression in auxotrophic  E. coli,
18
 or genetic 
encoding of azide-containing amino acids in the presence of a heterologous suppressor 
tRNA/aminoacyl tRNA synthetase pair with altered specificity.
19
 The latter technique has 
also been found suitable for site-specific incorporation of cyclooctyne-charged lysine into 
proteins,
20,21
 thereby enabling the alternative SPAAC route for protein conjugation by 
reaction with an azide-containing probe.  
    Despite the existence of a multitude of conjugation methods, it requires great effort to 
introduce two functional handles into a protein, and to our knowledge only few successful 
adaptations of this approach have been reported.
22-24
 In summary, there is great need for a 
straightforward and practical method for simultaneous introduction of two imaging 
modalities or other functional labels into a peptide or protein. 
    In Chapter 2 the SPANC procedure was described and it was postulated, but not yet 
demonstrated, that SPANC would also enable dual protein functionalization. In addition, 
our earlier protocol required relatively high concentrations of peptide or protein and large 
excess of reagents. In this chapter, the dual functionalization of peptides and proteins is 
demonstrated using an optimized SPANC procedure (Figure 3.1, approach C). The 
usefulness of the dual labeling protocol is exemplified by the simultaneous introduction of 
two endosomal escape-improving functional groups onto the cell-penetrating peptide hLF 
(human lactoferrin). Additionally, we demonstrate that dual labeling of proteins is feasible 
by combining metal-free and copper-catalyzed click chemistry, enabling the introduction of 
both biotin and a fluorophore into enhanced green fluorescent protein (eGFP). 
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3.2 Optimization of SPANC on S-hLF 
    Optimization of the one-pot three-step protocol for the introduction of two functional 
labels to a biologically relevant system was performed on hLF, a recently established cell-
penetrating peptide (CPP). hLF is a 20-mer peptide derived from the N-terminal domain of 
human lactoferrin and was recently found to transport cargo across cell membranes in a 
concentration-dependent manner.
25
 It was reported that at a concentration of 20 µM nearly 
all cells showed a homogeneous cytoplasmic and nuclear peptide distribution next to 
vesicular staining. However, at lower concentrations (up to 10 µM), the peptide was 
localized predominantly in vesicles, thus hampering cytosolic delivery. In order to facilitate 
escape from the acidic endosomal compartment and enabling cytoplasmic targeting, 
Andaloussi et al.
26
 introduced a trifuoromethyl quinoline derivative and a stearyl moiety 
into the cell-penetrating peptide TP10 by coupling stearic acid to the N-terminus, and a 
quinoline analog to a lysine residue of resin-bound TP10. We envisioned that the SPANC 
procedure could be employed to simultaneously introduce both the quinoline analog and the 
stearyl group post-synthetically to hLF, providing a method for optimization of the cell-
penetrating properties of commercially available CPPs. To this end, screening of SPANC 
conditions was undertaken first, in order to determine the optimized stoichiometry of 
reagents, because relatively high concentrations of peptide or protein (up to 8 mM) and/or 
large excess of reagents (60-80 eq) were previously required.  
    The first round of optimization was performed on the model hexapeptide SKYRAG 
(Table 3.1). Thus, varying amounts of reagents were applied to SKYRAG for N-
methylhydroxylamine (1-10 eq) and BCN-CH2OH (1-20 eq) and the conversion was 
measured after 2 hours and 3 days. From these experiments it was concluded that optimal 
conditions at a peptide concentration of 1 mM involve 10 equivalents of both N-
methylhydroxylamine and BCN-CH2OH. In the next step, an hLF analog containing the 
requisite N-terminal serine residue (S-hLF, Scheme 3.1) was oxidized under carefully 
controlled conditions (0 °C, 1.0 eq NaIO4, 10 min) in order to avoid oxidation of the 
disulfide linkage. Under these conditions, mass spectrometric analysis (Figure 3.2B) 
showed formation of the desired aldehyde along with only a minor amount of a p-
methoxybenzenethiol adduct, presumably by opening of the disulfide linkage. Then, the 
optimized SPANC conditions were applied to the resulting glyoxylyl-hLF derivative by 
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addition of N-methylhydroxylamine and BCN-CH2OH (1), resulting in full conversion to 
desired isoxazoline product 3 (Figure 3.2C).   
 
Table 3.1. SPANC experiments on the model peptide SKYRAG to find optimal conditions for peptide modification 
 
Entry MeNHOH·HCl 
(eq) 
BCN-CH2OH (eq) Conv. after 2h  Conv. after 3d 
1 1 1 -- -- 
2 1 2 -- -- 
3 2 2 -- - 
4 2 4 -- - 
5 3 3 +/- +/- 
6 3 6 - +/- 
7 4 4 +/- + 
8 4 8 +/- + 
9 5 5 + ++ 
10 5 10 +/- ++ 
11 10 10 ++ ++ 
12 10 20 + ++ 
.  
.  
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Scheme 3.1. Procedure for the one-pot N-terminal dual SPANC labeling of the peptide S-hLF. Reagents and 
conditions: (a) NaIO4 (1 eq), 0 °C, 10 min; (b) p-methoxybenzenethiol (10 eq), 0 °C, 1 h; (c) N-
methylhydroxylamine (10 eq), p-anisidine (10 eq), BCN-CH2OH (10 eq), rt, 16 h. 
Figure 3.2. Deconvoluted mass spectra of  S-hLF. (A) Native peptide (MW = 3290 Da); (B) after oxidation with 
NaIO4 (MW hydrate = 3277 Da; MW glyoxylyl = 3259 Da); (C) after dual SPANC labeling with BCN-CH2OH (1) and 
N-methylhydroxylamine (MW = 3438 Da); (D) after dual SPANC labeling with BCN-QN (6) and N-
stearylhydroxylamine (8) (MW = 4015 Da). 
3.3 Dual functionalization of S-hLF 
    Now, the stage was set for the introduction of two functional labels onto hLF via the 
SPANC procedure, i.e. a trifluoromethyl quinolone analog and a stearyl moiety for 
endosomal escape. Thus, we synthesized the required BCN-trifluoromethylquinoline analog 
(BCN-QN, 6, Scheme 3.2) by condensing commercially available BCN succinimidyl 
carbonate and amine-functionalized trifluoromethylquinoline 5.
26
 Similarly straightforward, 
N-stearylhydroxylamine (8) was synthetized by nucleophilic substitution of stearyl bromide 
D. 
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with N,O-di-Boc-protected hydroxylamine
27
 followed by Boc deprotection (TFA in 
CH2Cl2) to give the desired product 8 in 80% overall yield. Both reagents 6 and 8 were then 
applied in the SPANC protocol on glyoxylyl-hLF in the same stoichiometry as applied 
earlier in the optimization studies (10 eq. of N-stearylhydroxylamine (8), 10 eq. of BCN-
QN 6). However, overnight incubation gave low conversion (20%) to the desired 
isoxazoline product, probably caused by the increased steric hindrance of both BCN-QN 
and stearylhydroxylamine compared to their unfunctionalized analogs. Much to our 
satisfaction, by partially increasing the stoichiomety of BCN-QN (40 eq) and by prolonging 
the reaction time (3 days), full conversion to the desired dual functionalized product was 
observed (Figure 3.2D).  
 
Scheme 3.2. Synthesis of BCN-trifluoromethylquinoline 6 and N-stearylhydroxylamine (8). Reagents and 
conditions: (a) neat, 140 °C, 2 h (83%); (b) BCN-succinimidyl carbonate, Et3N, CH2Cl2, rt, 90 min (93%); (c) N-O-di-
Boc-hydroxylamine, K2CO3, DMF, rt, 3 d (80%); (d) TFA:CH2Cl2 1:1, rt, 1 h (quant).  
3.4 Optimization of SPANC on the protein HspB2 
    The next stage of SPANC labeling of a biomolecule involved application to a model 
medium-sized protein (20 kD). To this end, we selected heat shock protein HspB2, a 
protein with an N-terminal serine that was conveniently expressed in-house (along with 
25% of HspB3).
28
 Not unexpectedly, it was found that periodate cleavage of the N-terminal 
aminoalcohol of HspB2 was accompanied by significant concomitant oxidation of the free 
cysteine.  
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    Gratifyingly, alkylation of the free cysteine with iodoacetamide
29
 prior to periodate 
oxidation led to clean conversion of the alkylated HspB2 to the desired glyoxylyl product 
(Figure 3.3B). Given the compromised introduction of the sterically hindered stearyl 
hydroxylamine, we now opted to introduce propargylhydroxylamine instead. 
Propargylhydroxylamine is small, readily synthesized and may serve as a convenient 
handle for the subsequent further introduction of azide-substituted functional handles by 
means of copper-catalyzed click chemistry.
13,14
 Thus, varying amounts of reagents were 
applied to HspB2 for p-anisidine (10 eq-100 mM), BCN-CH2OH (10-100 eq) and N-
propargylhydroxylamine (10-100 eq), while opting to keep the N-propargylhydroxylamine 
and BCN-CH2OH stoichiometry to a minimum (Table 3.2). From these experiments it was 
concluded that optimal conditions involve 50 equivalents of N-propargylhydroxylamine and 
20 equivalents of BCN-CH2OH, leading to efficient formation of the desired propargyl 
isoxazoline derivative, as indicated by mass spectrometric analysis (Figure 3.3D). 
 
Figure 3.3. Mass spectra (bottom) and deconvoluted mass spectra (top) of rHspB2/3. (A) Native protein (MW 
rHspB2 = 20215 Da; MW rHspB3 = 17007 Da); (B) after alkylation with iodoacetamide (MW = 20272 Da); (C) after 
NaIO4 oxidation (MW hydrate form = 20259 Da); (D) after dual SPANC labeling with BCN-CH2OH (1) and N-
propargylhydroxylamine (MW = 20444Da).  
 
A. B.
C. D.
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Table 3.2. SPANC experiments on the model protein HspB2/3 to find optimal conditions for protein modification.  
 
3.5 Dual functionalization of S-eGFP 
    Finally, the 28 kDa protein enhanced green fluorescent protein (eGFP)
30
 was selected to 
explore the generality of the optimized SPANC reaction conditions, as well as to 
investigate the envisioned further functionalization of the protein by a second, copper-
catalyzed derivatization. To this end, eGFP with an N-terminal serine residue was 
expressed in E. coli. The resulting S-eGFP was subjected to oxidation with sodium 
periodate (1.5 eq, Figure 3.4A), followed by quenching with p-methoxybenzenethiol (10 
eq), leading to the near quantitative formation of the aldehyde derivative of eGFP as 
expected. Conveniently, in this particular case no competitive oxidation of the cysteine 
residues in eGFP was observed. Then, p-anisidine (100 mM final concentration), N-
propargylhydroxylamine (50 eq) and BCN-biotin (20 eq) were added. After 2.5 h, mass 
spectrometric analysis showed full conversion of glyoxylyl-eGFP to the dual labeled 
product (Figure 3.4C) in only four hours. The minor peak in the MS spectrum belongs to 
residual (unoxidized) native S-eGFP.  
 
3.6 CuAAC on alkyne-functionalized eGFP 
    To show the full extent of this technology for dual functional labeling, a CuAAC reaction 
was next performed between the N-terminal propargyl function and azido-containing 
fluorescein derivative 11 (Scheme 3.3). To this end, isoxazoline 10 was dissolved in 20 mM 
phosphate buffer (pH 7.6) and subjected to typical CuAAC conditions (CuSO4, 
 
Entry p-anisidine 
(eq) 
N-propargyl 
hydroxylamine (eq) 
BCN-CH2OH 
(eq) 
Conversion 
after 16h 
1 10 10 10 -- 
2 0 10 10 -- 
3 1500 10 10 + 
4 10 10 100 -- 
5 10 100 10 ++ 
6 10 100 100 ++ 
7 1500 50 20 ++ 
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Figure 3.4. Mass spectra (bottom) and deconvoluted mass spectra (top) of S-eGFP. (A) Native protein (MW = 
28326 Da); (B) after NaIO4 oxidation (MW hydrate form = 28313 Da); (C). after dual SPANC labeling with BCN-
biotin and N-propargylhydroxylamine (MW = 28898 Da); (D) after CuAAC reaction with azido-fluorescein 12 (MW 
= 29505 Da).  
 
 
A. 
D.
B.
C.
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tris(benzyltriazolylmethyl)amine (TBTA), sodium ascorbate and azido-fluorescein 9). After 
overnight incubation at room temperature, mass spectrometric analysis showed the near 
complete conversion of the starting alkyne to desired triazole product 11 (Figure 3.4D), 
thereby demonstrating the potential of combined SPANC and CuAAC for the dual 
functionalization of proteins. 
Scheme 3.3. CuAAC of alkyne-functionalized eGFP with azido-fluorescein 9. 
3.7 Conclusions & outlook 
    For the first time, the SPANC protocol was employed for the site-selective one-pot 
introduction of two functional groups to a peptide and a protein. First, a trifluoromethyl 
quinoline analog and a stearyl moiety were introduced to the cell penetrating peptide hLF, 
thus potentially providing a method for the improvement of the cell-penetrating properties 
of commercially available CPPs.  
    Further optimization of the SPANC protocol for proteins led to conditions highly suitable 
for introduction of N-propargylhydroxylamine and BCN-biotin to S-eGFP within a few 
hours. The terminal alkyne served as a convenient anchor point for a CuAAC reaction with 
azido-containing fluorescein, thereby demonstrating the potential of combined SPANC and 
CuAAC for the dual functionalization of proteins. In this respect, it is of relevance to note 
that the applicability of combined SPANC and CuAAC is particularly facilitated by the 
commercial availability of a wide range of functionalized azides and cyclooctynes, in 
contrast to for example N-functionalized hydroxylamines. We anticipate that the SPANC 
protocol will find in particular application in the simultaneous visualization of a single 
target with two diagnostic techniques, i.e. multimodality imaging. However, numerous 
other (combinations of) functional groups can be envisioned, e.g. polyethylene glycol 
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(PEG) chains, imaging modalities, drugs, targeting elements, saccharides, nanoparticles and 
solid surfaces, thereby further enhancing the prospect of SPANC for dual labeling of 
peptides and proteins. 
 
3.8 Acknowledgments 
    Loek van Eggermont is greatly acknowledged for his work on SKYRAG and hLF. Mark 
van Eldijk is gratefully acknowledged for expression of S-eGFP and useful discussions. Dr. 
Marjoke Debets is kindly acknowledged for the synthesis of azido-fluorescein. Dr. Remon 
van Geel is greatly acknowledged for a kind gift of HspB2/3. 
 
3.9 Experimental section 
3.9.1 General methods and procedures 
    See section 2.9. TBTA was synthesized according to a literature procedure.31 Azido fluorescein 9 
was synthesized according to a literature procedure32 with CH2Cl2 as the solvent.  
  
3.9.2 Peptide modification, protein modification and synthesis 
 
SKYRAG as a model peptide for optimization of SPANC 
SKYRAG (1.02 mg, 1.5 µmol) was dissolved in 0.1 M NH4OAc buffer (1.5 mL, pH 6.8) and NaIO4 
(0.35 mg, 1.8 µmol) was added. After incubation for 20 min at rt, p-methoxybenzenethiol (2.1 mg, 
1.8 µL, 15 µmol) was added and the mixture was allowed to react for 1 h. p-Anisidine (1.8 mg, 15 
µmol) and the required amounts of N-methylhydroxylamine (1-10 eq in H2O) and BCN-CH2OH (1) 
(1-20 eq in CH3CN:H2O 1:1) were added. The conversion was measured with mass spectrometry after 
2 h and 3 d. 
 
Dual labeling of S-hLF with BCN-CH2OH (1) and N-methylhydroxylamine 
S-hLF-K-Fluo (EMC microcollections, SKCFQWQRNMRKVRGPPVSCIKRK(ɛ-
carboxyfluorescein)-NH2 2, 1.6 mg, 486 nmol) was dissolved in 0.1 M NH4OAc buffer (1.1 mL, 
adjusted to pH 8.3 using NaOH) and shaken (300 rpm) at 40 °C for 2 h to form the disulfide bridge. 
0.1 M HCl (5.5 µL) and 0.1 M NH4OAc buffer pH 6.8 (1.1 mL) were added to adjust to pH 6.8. The 
reaction mixture was cooled to 0 °C and NaIO4 (93 ng, 486 nmol in H2O) was added. The reaction 
mixture was incubated for 10 min at 0 °C and immediately quenched with p-methoxybenzenethiol 
(0.59 mL, 4.7 µmol dissolved in THF). After incubation at 0 °C for 1 h, the reaction mixture was 
warmed to rt and diluted with THF (2.2 mL) to get a mixture of THF/H2O 1:1. Then, p-anisidine 
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(0.58 mg, 4.7 µmol dissolved in THF), N-methylhydroxylamine (0.39 mg, 4.7 µmol in H2O) and 
BCN-CH2OH 1 (0.72 mg, 4.7 µmol in THF:H2O 1:1) were added. The reaction was incubated at rt for 
16 h, until mass spectrometric analysis showed full conversion to isoxazoline 3. ESI: calculated 
3440.1 Da, found 3438.2 Da. 
 
N1-Methyl-N1-(2-((7-trifluoromethyl)quinolin-4-yl)amino)ethyl)propane-1,3-diamine (QN, 5) 
4-Chloro-7-(trifluoromethyl)quinoline (1.02 g, 4.4 mmol) and 2,2’-
diamino-N-methyldiethylamine (6.6 mL, 50.9 mmol) were heated 
neat to 140 °C for 2 hours to give a red solution. After cooling to rt, 
CH2Cl2 (20 mL) was added and the solution was washed with a 
5% NaHCO3 solution (2 × 20 mL) and H2O (2 × 20 mL). The 
organic phase was dried (Na2SO4), filtered and the solvent was removed under reduced pressure to 
give QN 5 (1.14 g, 83%). RF  = 0.10 (CH3OH:CH2Cl2 1:2). 
1H NMR (300 MHz, CDCl3) δ 8.61 (d, J 
= 5.3 Hz, 1H), 8.25 (s, 1H), 7.97 (d, J = 8.8 Hz, 1H), 7.57 (dd, J = 8.8, 1.9 Hz, 1H), 6.46 (d, J = 5.4 
Hz, 1H), 6.25 (bs, 1H), 3.30-3.36 (m, 2H), 2.90 (t, J = 6.1 Hz, 2H), 2.81 (dd, J = 6.4, 5.1 Hz, 2H), 
2.57 (t, J = 6.1 Hz, 2H), 2.33 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 152.4, 149.9, 147.7, 131.0, 130.6, 
127.5, 125.9, 121.6, 120.0, 100.2, 59.7, 55.1, 41.9, 40.2, 39.5. FT-IR νmax  (cm
-1): 3250-2794, 1584, 
1537, 1324, 1161, 1122, 811. HRMS (ESI+) m/z calcd for C15H20F3N4 (M+H)
+: 313.1640, found: 
313.1631. 
 
(1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-ylmethyl 2-(methyl(2-((7-(trifluoromethyl)quinolin-4-yl) 
amino)ethyl)amino)ethyl)carbamate (BCN-QN, 6) 
BCN succinimidyl carbonate (50.6 mg, 0.17 mmol) was 
dissolved in CH2Cl2 (2 mL), QN 5 (82 mg, 0.26 mmol) 
and Et3N (75 µL, 0.54 mmol) were added and the reaction 
mixture was stirred at rt for 90 min. Saturated NH4Cl 
solution (15 mL) was added and extracted with CH2Cl2 (2 
× 15 mL). The CH2Cl2 layer was dried using Na2SO4, 
filtered and solvents were removed in vacuo. Products 
were separated by silica gel column chromatography (CH2Cl2:CH3OH 19:1) to give BCN-QN 6 (79 
mg, 93%). RF = 0.20 (CH2Cl2:CH3OH 19:1). 
1H NMR (300 MHz, CDCl3) δ 8.56 (d, J = 5.4 Hz, 1H), 
8.26 (s, 1H), 8.07 (d, J = 8.9 Hz, 1H), 7.57 (d, J = 9.2 Hz, 1H), 6.44 (d, J = 5.4 Hz, 1H), 5.13 (bs, 
1H), 4.07 (d, J = 7.9 Hz, 2H), 3.36-3.33 (m, 4H), 3.13 (bs, 1H), 2.83 (t, J = 5.7 Hz, 2H), 2.61 (t, J = 
5.9 Hz, 2H), 2.33 (s, 3H), 2.29-2.08 (m, 6H), 1.55-1.40 (m, 2H), 1.29-1.16 (m, 1H), 0.92-0.81 (m, 
2H). 13C NMR (75 MHz, CDCl3) δ 157.2, 151.5, 150.2, 146.8, 131.4, 131.0, 126.7, 125.8, 121.9, 
120.6, 100.1, 98.8, 63.1, 57.3, 55.1, 42.1, 40.2, 38.7, 29.0, 21.5, 20.2, 17.8. FT-IR νmax (cm
-1): 3334, 
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2924, 2846, 1701, 1588, 1571, 1537, 1372, 1325, 1268, 1156, 1126, 1070. HRMS (ESI+) m/z calcd 
for C26H32N4O2F3 (M+H)
+: 313.1640, found: 313.1631. 
 
N,O-di-Boc-N-stearylhydroxylamine (7) 
Stearyl bromide (1.7 g, 5.1 mmol) was dissolved in DMF (20 mL) before addition 
of N,O-di-Bochydroxylamine (1.2 g, 5.1 mmol) and K2CO3 (861 mg, 6.2 mmol). 
The reaction mixture was stirred for 3 d at room temperature. H2O (40 mL) was 
added and the product was extracted using EtOAc (3 × 30 mL). The organic layer was dried over 
Na2SO4, filtered and the solvent was removed under reduced pressure. The product was purified by 
silica gel column chromatography (heptane:EtOAc 15:1) to give N,O-di-Boc-N-stearylhydroxylamine 
7 (1.98 g, 80%). RF = 0.58 (heptane:EtOAc 9:1). 
1H NMR (400 MHz, CDCl3) δ 3.56 (bs, 2H), 1.62-
1.56 (m, 2H), 1.53 (s, 9H), 1.48 (s, 9H), 1.25 (s, 30H), 0.90-0.86 (m, 3H). 13C NMR (75 MHz, 
CDCl3) δ 155.1, 152.5, 84.7, 82.2, 50.4, 32.1, 29.9, 29.5, 29.4, 28.4, 28.3, 27.9, 27.7, 26.7, 22.8, 14.3. 
FT-IR νmax (cm
-1): 2920, 2855, 1783, 1718, 1476, 1394, 1372, 1247, 1130, 841. HRMS (ESI+) m/z 
calcd for C28H56NO5 (M+H)
+: 486.4159, found: 486.4181. 
 
N-Stearylhydroxylamine TFA salt (8) 
N,O-di-Boc-N-stearylhydroxylamine 7 (84.3 mg, 0.17 mmol) was dissolved in 
CH2Cl2 (1 mL) and TFA (1 mL) was added dropwise. After stirring at rt for 1 
h, solvents were removed in vacuo and the product was co-evaporated with 
toluene (3 × 60 mL) to give the TFA salt of N-stearylhydroxylamine 8 (67 mg, 
quant.). 1H NMR (300 MHz, DMSO-d6) δ 3.10-3.05 (m, 2H), 1.60-1.52 (m, 2H), 1.24 (s, 30H), 0.89-
0.82 (m, 3H) 13C NMR (75 MHz, DMSO-d6) δ 50.2, 31.3, 30.7, 29.0, 28.9, 28.8, 28.7, 28.5, 25.7, 
23.0, 22.1, 13.9. FT-IR νmax (cm
-1): 3386, 2906, 2859, 1653, 1467, 1200, 1018, 616. HRMS (ESI+) 
m/z calcd for C18H40NO (M+H)
+: 286.3110, found: 286.3102. 
 
Dual labeling of S-hLF with BCN-QN 6 and N-stearylhydroxylamine 8 
S-hLF-K-Fluo (SKCFQWQRNMRKVRGPPVSCIKRK(carboxyfluorescein)-NH2, 1.6 mg, 486 nmol) 
was dissolved in 0.1 M NH4OAc buffer (1.1 mL, adjusted to pH 8.34 using NaOH) and shaken (300 
rpm) at 40 °C for 2 h to form the disulfide bridge. 0.1 M HCl (5.5 µL) and 0.1 M NH4OAc buffer pH 
6.8 (1.1 mL) were added to adjust to pH 6.8. The reaction mixture was cooled to 0 °C and NaIO4 
(0.093 µg, 486 nmol in H2O) was added. The reaction mixture was incubated for 10 min at 0 °C and 
immediately quenched with p-methoxybenzenethiol (1.22 mL, 9.8 µmol dissolved in THF). After 
incubation at 0 °C for 1 h, the reaction mixture was warmed to rt and diluted with THF (2.2 mL) to 
THF:H2O ratio of 1:1. Then, p-anisidine (1.20 mg, 9.8 µmol dissolved in THF), N-
stearylhydroxylamine 8 (3.92 mg, 9.8 µmol in H2O) and BCN-QN 6 (4.8 mg, 9.8 µmol in THF:H2O 
N-terminal dual protein modification by SPANC 
- 79 - 
 
1:1) were added. The reaction was incubated at rt for 3 d, until mass spectrometry showed full 
conversion to the product. ESI: calculated 4016.9, found 4015.4 Da 
 
N,O-di-Boc-N-propargylhydroxylamine 
N,O-di-Bochydroxylamine (435 mg, 1.86 mmol) was dissolved in dry DMF (15 
mL) under argon atmosphere and K2CO3 (343 mg, 2.48 mmol) was added. 
Propargyl bromide (80% solution in toluene, 230 µL, 2.07 mmol) was added dropwise, and the 
reaction mixture was stirred at rt for 20 h. H2O (150 mL) was added and extracted with CH2Cl2 (2 × 
200 mL). The organic layer was dried over Na2SO4, filtered and evaporated under reduced pressure. 
The product was purified by silica gel column chromatography (heptane:EtOAc 5:1) to give the title 
compound as a colorless oil (488 mg, 93%). RF = 0.29 (heptane:EtOAc 5:1). 
1H NMR (400 MHz, 
CDCl3) δ 4.31 (bs, 2H), 2.25 (t, J = 2.4 Hz, 1H), 1.51 (s, 9H), 1.47 (s, 9H). 
13C NMR (75 MHz, 
CDCl3) δ 154.7, 152.1, 85.1, 83.5, 77.1, 72.7, 40.6, 28.2, 28.1, 27.7, 27.7. FT-IR νmax (cm
-1): 3296, 
2980, 1792, 1718, 1372, 1230, 1148, 1091, 832. HRMS (CI+) m/z calcd for C13H22NO5 (M+H)
+: 
272.1498, found: 272.1487. 
 
N-propargylhydroxylamine HCl salt 
N,O-di-Boc-N-propargylhydroxylamine (563 mg, 2.075 mmol) was dissolved 
in EtOAc (10 mL) and H2O (5 mL) was added. To this mixture was added 
conc. HCl (5 mL) and the reaction was stirred at rt for 2 h. The solvents were evaporated in vacuo to 
give N-propargylhydroxylamine HCl salt as an off-white solid (223 mg, quant.). 1H NMR (400 MHz, 
D2O) δ 4.14 (d, J = 2.6 Hz, 2H), 2.98 (t, J = 2.6 Hz, 1H). 
13C NMR (75 MHz, MeOD) δ 79.4, 72.8, 
42.1. FT-IR νmax (cm
-1): 3378, 3291, 2915, 2747, 2613, 1632, 664. HRMS (ESI+) m/z calcd for 
C3H6NO (M+H)
+: 72.0449, found: 72.0436. 
 
Dual labeling of HspB2/3 with N-propargylhydroxylamine and BCN-CH2OH 1 
A 245 µM stock solution of rHspB2/3 complex 3:1 in PBS buffer (150 µL) was diluted with 0.1 M 
NH4OAc buffer pH 6.8 (600 µL) to give a 50 µM solution. An equal amount of a 10 mM stock 
solution of iodoacetamide in H2O (750 µL) was added, and the mixture was incubated for 3.5 h at rt. 
The reaction mixture was purified with a Millipore amicon ultra centrifugal filter (10 kDa cut off). 
After each spin cycle the spinfilter was refilled with 0.1 M NH4OAc buffer pH 6.8, finally resulting in 
a 100 µM solution. 1.1 Equivalent NaIO4 was added (40.6 nmol, 7.8 µg in H2O) and the reaction 
mixture was incubated for 1 h at rt. 10 equivalents of p-methoxybenzenethiol (370 nmol, 53 µg in 
CH3CN) was added and allowed to react for 16 h at rt. The reaction mixture was divided in 7 and to 
each tube was added the required amount of p-anisidine (0-1500 eq in CH3CN), N-
propargylhydroxylamine (10-100 eq in H2O) and BCN-CH2OH (1, 10-100 eq in CH3CN:H2O 1:1). 
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After 16 h at rt, the conversion was analyzed with mass spectrometry. ESI-TOF: calculated 20444, 
found 20448.  
 
Expression and purification of S-eGFP 
Cloning of expression vector 
Cloning techniques were performed according to standard molecular biology protocols. Restriction 
enzymes (NdeI and HindIII), ligase (T4 DNA Ligase), Antarctic phosphatase and DNA polymerase 
(Phusion® Hot Start DNA Polymerase) were obtained from New England Biolabs. The eGFP gene 
(Clontech) was modified by PCR using primers (Biolegio) with overhangs. The forward primer was 
used to introduce a NdeI restriction site and a serine codon (5’-GACGAGCATATGAGCGGCGTGA 
GCAAGGGCGAGGAGCTGT-3’) and the reverse primer was used to introduce a HindIII restriction 
site (5’- CTCGTCAAGCTTGTACAGCTCGTCCATGCC -3’). The PCR product and the pET21a(+) 
expression vector (Novagen) were then digested with NdeI and HindIII. After dephosphorylation of 
the vector, the digested PCR product was ligated into the vector to yield pET21a(+)-S-eGFP-H6. This 
plasmid was transformed into E. coli XL1 Blue cells and then the DNA was extracted and the 
sequence was confirmed by DNA sequencing. The pET21a(+)-S-eGFP-H6 plasmid was transformed 
into E. coli BLR(DE3)pLysS cells (Novagen), which were used for the expression of S-eGFP. 
 
Expression and purification of S-eGFP 
For a typical expression, 100 mL 2xYT medium, supplemented with ampicillin (100 mg/L) and 
chloroamphenicol (50 mg/L), was inoculated with a single colony of E. coli BLR(DE3)pLysS 
containing pET21a(+)-S-eGFP-H6 and was incubated at 30 °C overnight. This overnight culture was 
used to inoculate 900 mL of 2xYT medium supplemented with ampicillin (100 mg/L) and 
chloroamphenicol (50 mg/L). The culture was grown at 37 °C and protein expression was induced 
during logarithmic growth (OD600 = 0.4-0.6) by addition of IPTG (Sigma-Aldrich) up to 1 mM. After 
4 h of expression, the cells were harvested by centrifugation (4000 g at 4 °C for 15 min) and the pellet 
was stored at -20 °C overnight.  
After thawing, the cell pellet was resuspended in 20 mL lysis buffer (50 mM NaH2PO4, 10 mM 
imidazole and 300 mM NaCl, pH 8.0) and incubated with lysozyme (1 mg/mL) for 30 min on ice. 
The cells were then further lysed by ultrasonic disruption (6 times 10 s, 100% duty cycle and output 
control 3, Branson Sonifier 250, Marius Instruments Nieuwegein, the Netherlands). The lysate was 
centrifuged (10000 RPM at 4 °C for 15 min, Sorvall HB-4) to remove the cellular debris. The 
supernatant was incubated with 2 mL Ni-NTA agarose beads (Qiagen) for 1 h at 4 °C. Subsequently, 
the suspension was loaded onto a column, the flow-through was collected and the column was washed 
twice with 10 mL wash buffer (50 mM NaH2PO4, 20 mM imidazole and 300 mM NaCl, pH 8.0). 
Finally, the S-eGFP was eluted from the column using 5 mL elution buffer (50 mM NaH2PO4, 250 
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mM imidazole and 300 mM NaCl, pH 8.0). The volume of the protein solution was reduced to 1 mL 
using centrifugal filtration (Amicon Ultra-0.5 mL, 10 kDa). The protein was then further purified and 
the buffer was exchanged to 100 mM ammonium acetate (pH 6.8) via size exclusion chromatography 
(Superdex 75 HR 10/30). 300 µL fractions were collected and were analyzed by SDS-PAGE and 
mass spectrometry. The fractions containing S-eGFP were combined and 1 mg aliquots were stored at 
-20 °C. The protein was produced with a yield of 5 mg/L of culture and the purity was verified by 
SDS-PAGE. ESI-TOF: calculated 28325.9 Da, found 28325.1 Da (Figure 3.4A). The observed mass 
confirmed efficient processing of the N-terminal methionine residue, resulting in eGFP with an N-
terminal serine. Sequence: SGVSK GEELF TGVVP ILVEL DGDVN GHKFS VSGEG EGDAT 
YGKLT LKFIC TTGKL PVPWP TLVTT LTYGV QCFSR YPDHM KQHDF FKSAM PEGYV 
QERTI FFKDD GNYKT RAEVK FEGDT LVNRI ELKGI DFKED GNILG HKLEY NYNSH 
NVYIM ADKQK NGIKV NFKIR HNIED GSVQL ADHYQ QNTPI GDGPV LLPDN HYLST 
QSALS KDPNE KRDHM VLLEF VTAAG ITLGM DELYK LAAAL EHHHH HH. 
 
Dual labeling of S-eGFP with N-propargylhydroxylamine and BCN-biotin 
A 92 µM solution of S-eGFP in 0.1M NH4OAc buffer pH 6.8 (65 µL, 6.0 nmol S-eGFP) was diluted 
with the same buffer (130 µL), to give a 30 µM solution. NaIO4 was added (14.3 nmol, 2.7 µg in 
H2O) and the reaction mixture was incubated for 65 min at rt. p-Methoxybenzenethiol (60 nmol, 8.4 
µg in CH3CN) was added and allowed to react for 16 h at rt. p-Anisidine was added to give a final 
concentration of 100 mM (2.9 µmol, 0.36 mg in CH3CN) and N-propargylhydroxylamine HCl salt 
(285 nmol, 30.6 µg in H2O) and BCN-biotin (114 nmol, 62.8 µg in CH3CN:H2O 1:1) were added. 
After incubation for 4 h at rt, mass spectrometric analysis showed full conversion to isoxazoline 
product 10, along with a minor amount of unoxidized, native S-eGFP. The product was purified using 
a Millipore Amicon Ultra-0.5 mL centrifugal filter (10 kDa cut off). After each spin cycle the 
spinfilter was refilled with 20 mM phosphate buffer (pH 7.6) to finally give 187 µL of a 31 µM 
solution. ESI-TOF: calculated 28898 Da, found 28899 Da. 
 
CuAAC on propargyl-isoxazoline 10 with azido-fluorescein 9 
A 20 mM solution of CuSO4·5H2O in H2O was prepared and mixed in a 1:1 ratio with a 20 mM 
solution of sodium ascorbate in H2O. A 10 mM solution of the Cu(I) ligand Tris-
(benzyltriazolylmethyl)amine (TBTA) in tBuOH:DMSO 4:1 was prepared, and this was mixed in a 
1:1 ratio with the Cu/ascorbate mixture to give a 5 mM solution of all reagents. 20 µL of the 
previously prepared 31 µM solution of 11 in 20 mM phosphate buffer (pH 7.6) was taken (0.6 nmol 
protein) and to this mixture was added 30 equivalents of Cu/ascorbate/ligand and 20 equivalents of 
azido-fluorescein 9 (12 nmol, 7.3 µg in CH3CN:H2O 1:1). After incubation at rt for 19 h, mass 
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spectrometric analysis showed app. 90% conversion to triazole product 11. ESI-TOF: calculated 
29505 Da, found 29507 Da. 
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    An essential aspect in proteomics, metabolomics, glycomics and other analytical life 
sciences is the identification, isolation, and structural characterization of a specific 
biomolecule of interest. Several strategies have been applied in the field of proteomics for 
the global analysis of protein expression and function. Examples include the shotgun 
analysis of protein expression
1
 and modification state
2
 by liquid chromatography-mass 
spectrometry (LC–MS), the large scale mapping of protein-protein interactions by yeast 
two-hybrid assays,
3
 and the proteome-wide analysis of biochemical activities of proteins 
with protein microarrays.
4
 However, proteins and peptides containing post-translational 
modifications like glycans are often difficult to detect in a background of (unmodified) 
biomolecules, due to low ionization efficiencies and/or low abundance. An efficient and 
specific enrichment procedure is therefore required to study detailed structural aspects of a 
biomolecule of interest (peptide, protein, lipid or glycan) from complex mixtures like cell 
lysates. For example, studying proteome dynamics by mass spectrometry requires selective 
analysis of subsets of peptides that may be posttranslationally modified, cross-linked or 
newly synthesized. Similarly, efficient separation of glycan-containing macromolecules 
from proteins and lipids in complex mixtures is required for their efficient analysis. Recent 
advances have shown the possibilities of selective labeling of glycans and proteins with 
azides, via metabolic labeling with azidosugars like ManNAz,
5
 GalNAz
6
 and 6AzFuc
7
 or 
with azidoamino acids like azidohomoalanine (AHA).
8,9
 Such procedures provide a 
selective handle to isolate subsets of a proteome, but obviously, mild and effective methods 
for specific enrichment are still required.
10
  
    Several methodologies for protein enrichment have been developed over the years, such 
as activity-based protein profiling (ABPP)
11,12
 and photoaffinity labeling.
13
 For example, 
ABPP is an efficient method for detection of the activity of proteins, rather than their mere 
expression level. Similarly, photoaffinity labeling is a powerful strategy to study the 
interactions between biologically active compounds (ligands) and their target molecules. In 
both strategies, the reactive probe requires the presence of an analytical handle, typically a 
fluorophore for visualization or an immune epitope tag for binding and characterization. 
With respect to the molecular tag, biotin is a popular choice because a biotinylated 
molecule can easily be detected by immunological methods.
14
 Moreover, the presence of 
biotin offers the possibility of isolation through affinity purification with avidin beads, 
4.1 Introduction  
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although harsh conditions are subsequently required to liberate the biotinylated molecule by 
disruption of the strong biotin-avidin interaction; typically boiling of the beads with 
detergents. Clearly, such conditions may result in degradation of the target molecule(s) as 
well as in contamination of other proteins that bind to the beads in a non-specific manner.   
    To overcome the drawbacks associated with biotin, a variety of linkers have been 
developed that can be cleaved under mild conditions. Examples of such cleavable linkers 
are constructs based on disulfides (reductive cleavage),
15
 on peptide substrates (enzymatic 
cleavage),
16
 on acetals (cleavable with acid),
17,18
 on diazobenzene (cleavable with 
Na2S2O4),
19
 hydrazone-based linkers,
20,21
 and light-sensitive linkers.
22,23
 An ideal cleavable 
linker is stable towards the various conditions to which the biological sample may be 
exposed (acidic, basic, reductive, including generally applied buffer systems), and can 
withstand the reactive (nucleophilic) species that are present in a cell extract. At the same 
time, the linker should be susceptible to mild cleavage conditions that in turn are 
compatible with functional groups inherent to the biological sample. 
    Recently, Nessen et al. disclosed a general method to sequester peptides from complex 
mixtures by means of capture with an azido-reactive cleavable cyclooctyne resin.
24
 Thus, 
metabolic incorporation of azidohomoalanine in the E. coli proteome allowed the 
characterization of numerous newly synthesized peptides via trapping by strain-promoted 
alkyne–azide cycloaddition (SPAAC)25 followed by reductive cleavage of the disulfide 
linker employed. Despite the elegancy of the procedure, broad application is unlikely 
because synthesis of the cyclooctyne probe is rather lengthy and its reactivity in strain-
promoted cycloadditions is modest. Furthermore, the disulfide linker necessitates the strict 
avoidance of reductive conditions during the enrichment process, in order to avoid 
premature cleavage, while native protein disulfides are inevitably also reduced during 
cleavage. The in Chapter 2 applied DIBAC and BCN cyclooctynes display high reaction 
rates with a range of dipoles. While both probes are synthetically readily accessible, BCN 
particularly stands out because it can be prepared from synthetically cheap starting 
materials in a matter of days and its relatively low lipophilicity is beneficial for application 
under aqueous conditions. Based on these features, we considered BCN a promising probe 
for the development of a novel enrichment tool. With respect to the choice of a linker, we 
were drawn towards a report by Geurink et al. on a cleavable linker inspired by the 
levulinoyl (Lev) protective group.
26
 By careful fine tuning of the phenolic leaving group, a 
construct was derived with significant advantages over earlier published strategies. The 
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Lev-based linker appeared robust enough to survive conditions commonly applied to cell 
extracts in biochemical experiments, including aqueous, acidic and basic media. 
Importantly, the linker was found resistant towards disulfide reducing conditions but was 
readily cleaved upon treatment with hydrazine. The versatility of the linker was nicely 
demonstrated in enrichment of proteasome active sites by activity-based profiling. Based on 
these arguments, we set out to prepare a novel, readily accessible and reactive probe for 
enrichment by a capture–release strategy based on a Lev-based linker and BCN. 
 
 
    Our work started from the known levulinoyl-based 2,6-di-iso-propylphenolic ester 1
27,26
 
(Scheme 4.1). We reasoned that the azido moiety of 1 could be readily reduced to an amine 
and therefore serve as a useful functionality for attachment to activated agarose beads. 
However, without taking appropriate precautions, an amino group at that position rapidly 
cyclizes onto the δ-keto function, leading to a non-nucleophilic dihydropyrrole. Based on 
this rationale, we opted to chain-extend 1 with a rigid aromatic moiety to preclude a 
potential ring-closure. Therefore, we performed a copper(I)-catalyzed alkyne–azide 
cycloaddition (CuAAC)
28,29
 of 1 with Fmoc-protected propargylamine, leading to triazole 
adduct 2 in excellent yield. Next, in the reported two-step process, the tert-butyl ester was 
smoothly converted into hydroxysuccinimide-activated ester 4. The latter ester was 
efficiently coupled to BCN-amino derivative 7 via a short hydrophilic spacer. Finally, 
Fmoc-removal was accomplished by treatment of 5 with 20% piperidine in 
dichloromethane, leading to the effective and clean conversion of 5 into the desired amino 
derivative 6. 
 
    Having obtained the desired amino derivative 6, coupling to an insoluble bead was 
investigated. For this purpose, we selected cyanogen bromide-activated Sepharose™ 4B 
from GE Healthcare, a 4% cross-linked spherical agarose known to react rapidly with 
amines without the need for additional reagents. The resulting carbamate bonds are stable 
and resistant to a wide range of conditions, including base and high temperatures. 
4.2 Synthesis of resin-bound BCN 
4.2.1 Attachment of BCN to the cleavable linker 
4.2.2 Immobilization of BCN-Lev linker to agarose beads  
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Therefore, compound 6 was coupled at pH 8.3 to the Sepharose™ beads at 1, 2, and 10 mM 
concentration, thus affording the desired ‘azidotrap’ beads.  
 
 
 
Scheme 4.1.Synthesis of BCN-Lev linker 6. Reagents and conditions: (a) tert-BuOH, FmocNHCH2C≡CH, Cu(OAc)2, 
Na-ascorbate, TBTA (quant), (b) CF3CO2H, CH2Cl2 (1:1), 1 h, then (c) CH2Cl2, EDC, HOSu, 40 h (88%, two steps), (d) 
7, DIPEA, DMF, 16 h (63%), (e) piperidine:CH2Cl2 1:4, 10 min (95%). 
 
    As delineated above, our strategy for protein enrichment involved a selective pull-down 
from a mixture of proteins, or ideally whole cell lysate, followed by filtration and chemical 
release. However, before suitability of the agarose-BCN conjugate for capture-release of 
azido-containing proteins could be performed, it was mandatory to validate the general 
applicability of the beads for such purpose. 
 
4.3 Protein enrichment by capture–release 
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    The rapid and reagent-free reaction of ring-strained alkynes with azides allows a 
straightforward validation of the versatility of the BCN-modified beads with an 
azidocoumarin probe. The unique aspect of specific azidocoumarins is that they are 
fluorogenic, that is, the emission of fluorescent light occurs only upon conversion of the 
azide moiety into a triazole.
30
 Therefore, linker-coupled beads (1, 2 and 10 mM linker 
concentration) were incubated with a 7-azidocoumarin derivative (Compound 8, Scheme 
4.1, 1 mM) and aliquots were taken at specific time intervals for analysis with fluorescence 
microscopy. A time-dependent increase of fluorescence staining of the beads became  
Figure 4.1. Fluorescence pictures of BCN-modified SepharoseTM beads. (A) Treatment of BCN-modified 
SepharoseTM beads with fluorogenic substrate 8. Left to right: 1, 2 and 10 mM linker concentration. Time points 
indicate SPAAC reaction times; (B) cleavage of the linker on the beads using 100 mM hydrazine. 
4.3.1. Evaluation of on-resin SPAAC and cleavage 
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apparent (Figure 4.1A), a strong indication that SPAAC between immobilized BCN and 
azidocoumarin had taken place. Additionally, fluorescence intensities of the beads 
increased with higher loading concentrations of the linker, so the highest signal was 
established with beads charged at 10 mM. For this reason, the latter beads were selected for 
forthcoming experiments.      
    The fluorophore-attached beads also enable a straightforward evaluation of the release 
concept by cleavage of the levulinoyl linker. To this end, the fluorescent beads were 
incubated with 100 mM hydrazine, leading to a rapid and irreversible decrease in 
fluorescence (Figure 4.1B).  
    In order to quantify the loading of BCN, the fluorophore-attached beads were treated 
with 100 mM hydrazine, with the objective to directly correlate fluorescence in the 
resulting supernatant to bead loading. Unfortunately, it was found that the fluorescent 
signal in the supernatant rapidly decreased due to degradation of the fluorophore in 100 
mM hydrazine. Therefore, a BCN derivative lacking the Lev-linker (7) was coupled to 
CNBr-Sepharose beads, followed by SPAAC with base-sensitive azido-ester-coumarin 9 
under the same conditions as described for the levulinoyl linker (10 mM). As expected, 
fluorescence microscopy indicated comparable fluorescence staining of the beads after 
SPAAC reaction. Next, loading of the beads was determined by measuring fluorescence 
emission of the coumarin adduct (ex 325 nm, em 452 nm) after cleavage from a bead 
sample (25 μL), relative to a standard curve of 7-hydroxycoumarin in 10 mM NaOH. Under 
these conditions, coumarin ester 9 showed only minimal degradation. After correction for 
background hydrolysis, it was determined that loading of the beads with BCN is 0.39 
µmol/mL gel (Figure 4.2), which is somewhat lower than the loading capacity indicated by 
the manufacturer (1-2.4 µmol α-chymotrypsinogen/mL). Taken together, these findings 
established the suitability of the BCN-modified ‘azido-trap’ beads for an enrichment 
protocol of azide-containing molecules. 
 
 
A. 
Chapter 4 
 
- 92 - 
 
 
    To test whether the ‘azido-trap’ beads are useful for selective enrichment of a specific 
protein of interest from a mixture of proteins, we selected azide-modified Candida 
antartica lipase B (CalB) as a model protein. This modified CalB, obtained by expression 
in methionine auxotrophic E. coli in the presence of AHA, contains five azides, of which 
typically only one or two are accessible for reaction with an alkyne probe.
31,32
 Thus, AHA-
CalB was mixed with proteins lacking an azido function, a mixture consisting of α-
lactalbumin, trypsin inhibitor, carbonic anhydrase, ovalbumin, albumin, and 
phosphorylase B.  
   The mixture of proteins, including azido-CalB, was incubated with the BCN-derivatized 
beads at three different temperatures and two different reaction times. Of each sample, the 
supernatant of the beads after SPAAC was resolved on SDS-PAGE. As can be seen in 
Figure 4.3A, the amount of CalB was clearly reduced in all experiments, best conditions 
involving a prolonged reaction time (18 h) at 37 °C. Under these conditions, near 
quantitative removal of CalB from the mixture was observed, while no detectable change of 
other proteins became apparent.  
 
Figure 4.2. Determination of the loading of coumarin 9 functionalized beads. Increase in fluorescence intensity in 
the supernatant of a bead sample in 10 mM NaOH in time, corrected for a small amount of degradation of the 
fluorophore. 
 
4.3.2. Selective enrichment of an azide-modified protein from a protein 
mixture 
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Figure 4.3. SDS-PAGE gels after enrichment of azido-modified CalB from a protein mixture. CalB (arrows) in a 
mixture of standard proteins M (from top to bottom phosphorylase B, albumin, ovalbumin, carbonic anhydrase, 
trypsin inhibitor and α-lactalbumin) was used for SPAAC-mediated enrichment. (A) Coomassie-stained SDS-PAGE 
gel. Lanes 1-3: supernatants after SPAAC, lanes 4-6: supernatant after cleavage for 18 h at 4 °C, lane 7: azido-
modified CalB, lane 8: protein mixture M. (B) Silver-stained SDS-PAGE gel. Lanes 1 and 8: CalB in protein mix M 
before capture, lanes 2-4: supernatants after SPAAC, lanes 5-7: supernatants after cleavage for 18 h at 4 °C, lanes 
9-11: supernatant of beads treated with denaturing buffer after specific release. 
 
    Next, cleavage of the linker with hydrazine was performed at 4 and 37 °C for 18 h. At 4 
°C, a protein with a similar mass as AHA-CalB appeared on the gel, although at a slightly 
higher molecular weight (Figure 4.3A). A logical explanation for the latter observation lies 
in the presence of the residual part of the linker, covalently attached to the protein. At 37 
°C, the optimal temperature reported by Geurink et al., we observed some protein 
precipitation. This indicates that, in contrast to the capture conditions, a lower reaction 
temperature (4 °C) is advantageous for isolation of CalB from the mixture. Nevertheless, 
some non-specific binding of phosphorylase B and albumin during SPAAC and subsequent 
release was observed. To reduce the non-specific binding to the beads, we compared 
washing the beads in PBS with washing in 0.5% SDS in PBS, and washing the beads an 
additional three times at 37 °C with larger volumes while shaking for 2 h instead of just 
washing three times with a larger volume. It turned out that the effect of addition of SDS to 
the washing buffer was negligible, while more extensive washing steps seemed to decrease 
the recovery of modified CalB (Figures 4.4B and C). Varying the amount of beads per 
sample indicated that use of 50% of the beads as used in Figure 4.3A resulted in slightly  
 
    A. B. 
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Figure 4.4. SDS-PAGE gels of optimization experiments for enrichment of CalB from a protein mixture. (A) 
Comparison between 10 and 20 µl beads, and SPAAC and cleavage temperatures of 4 and 37 °C for 18 h. Lane 1: 
CalB and protein mixture. Lanes 2, 3 and 4: supernatants after SPAAC with 10 or 20 µl beads, 4 or at 37 °C. Lanes 
5, 6 and 7: cleavage products captured with 10 and 20 µl beads, at 4 and 37 °C. Lanes 8, 9 and 10: beads 
denatured for 5 min at 95 °C. (B) Comparison between washing the beads with or without 0.5% SDS in PBS 
between SPAAC and cleavage. Lanes 1 and 2: cleavage products. (C) Comparison between short (s) and long (l) 
washing of the beads between SPAAC and cleavage with PBS. Short washing: 3 times 200 µl PBS at rt, long 
washing: an additional 3 times with 200 µl PBS at 37 °C, shaking for 2 h. Lanes 1 and 6: CalB and protein mixture. 
Lanes 2 and 3: supernatants after SPAAC with 10 µL beads at 37 °C. Lanes 4 and 5: cleavage products, performed 
at 4 °C. Lanes 7 and 8: beads denatured in SDS-PAGE sample buffer for 5 min at 95 °C.  
A. 
B. C. 
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less non-specific binding, while CalB recovery remained similar (Figure 4.4A). Apparently, 
the lower amount of beads is sufficient to capture CalB specifically, while higher amounts 
lead to more non-specific binding of other proteins. The SDS-PAGE profile (Figure 4.3B) 
of hydrazine-released proteins under optimized conditions showed a single band at the 
position of CalB without the presence of other proteins, indicating highly specific 
enrichment of modified CalB from the protein mixture. Scheme 4.2 schematically shows 
the enrichment procedure with optimized conditions.  
 
 
Scheme 4.2. Schematic representation of the AHA-CalB enrichment procedure with optimized conditions for 
SPAAC and cleavage.  
 
    We have synthesized an effective ‘azido-trap’ bead based on a combination of 
Sepharose™ beads, a hydrazine-sensitive linker, and a strained alkyne (BCN). We 
demonstrated the concept by fluorogenic staining of the beads with azidocoumarin, which 
displayed a clear time and concentration dependence. Next, we succeeded in selective pull-
down of an azide-modified protein (AHA-CalB) from a mixture of proteins by covalent 
attachment to the beads. Finally, both the coumarin derivative and the protein were 
effectively cleaved from the beads by treatment with hydrazine. After optimization of 
4.4 Conclusions & outlook 
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conditions, highly enriched CalB could be recovered from the protein mixture in two 
simple and straightforward steps.  
    Based on these findings, it can be concluded that a versatile construct has been prepared 
for enrichment of azide-containing molecules, including proteins. The strategy presented 
here has several distinct advantages over the earlier reported capture-release approach 
involving strain-promoted cycloadditions. First of all, the cyclic alkyne applied here (BCN) 
is more readily obtained by synthesis (and commercially available) and displays much 
higher reactivity to azides. Secondly, we have exploited a stable, levulinoyl-based cleavable 
linker that does not preclude reductive conditions during the capture step, yet the linker is 
readily cleaved upon treatment with hydrazine. Thirdly, it must be noted that the 
symmetrical nature of BCN (versus all other cyclooctynes employed for SPAAC published 
to date) will facilitate detailed structural analysis of the enriched products after cleavage, 
due to the absence of regioisomeric triazole products.  
    Taken together, the successful capture-release of CalB from the protein mixture 
constitutes a promising general strategy for enrichment of azide-containing (glyco)proteins 
from complex biological samples after metabolic incorporation. 
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    See section 2.9. Additionally, 7-azidocoumarin-4-acetic acid was prepared according to a literature 
procedure.33 Fluorescence microscopy was performed on a Zeiss Axioskop 20, with an HB050 
mercury lamp.  
 
4.5 Acknowledgements 
4.6 Experimental section     
4.6.1 General methods and procedures 
Protein enrichment by capture-release via SPAAC with BCN 
- 97 - 
 
 
4-(3-(tert-Butoxy)-3-oxopropyl)-2,6-diisopropylphenyl 7-(4-(((((9H-fluoren-9-yl)methoxy) 
carbonyl)amino)methyl)-1H-1,2,3-triazol-1-yl)-4-oxoheptanoate (2)  
To a solution of sodium ascorbate (3.5 mg, 17.8 
µmol) in tert-BuOH (1 mL) was added successively 
tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
(TBTA, 4.7 mg, 8.9 µmol), azide 1 (42 mg, 88.6 
µmol) and Fmoc-N-propargylamine34 (27 mg, 97.6 
µmol) and the mixture was gently heated until all reagents were dissolved. Then 250 µL from a stock 
solution of CuSO4 (11 mg in 2.5 mL H2O) was added to the mixture and the reaction was stirred at 
room temperature until TLC analysis (EtOAc:heptane 1:1) after 16 h indicated the complete 
consumption of 1 and the formation of a more polar product (RF 0.1). The reaction was diluted with 
EtOAc (20 mL) and washed successively with H2O (4 mL) and brine (4 mL). The organic layer was 
dried (MgSO4), filtered, concentrated and purified by silica gel column chromatography 
(EtOAc:heptane 1/1→2/1→3/1) to give title compound 2 as a colorless oil. Yield 67 mg (quant). RF = 
0.1 (EtOAc:heptane 1:1). 1H NMR (CDCl3, 400 MHz):  7.75 (d, J = 7.2 Hz, 2H), 7.57 (d, J = 7.6 Hz, 
2H), 7.48 (s, 1H), 7.39 (t, J = 7.6 Hz, 2H), 7.29 (t, J = 7.4 Hz, 2H), 6.95 (s, 2H), 5.50 (bs, 1H), 4.45 
(d, J = 6.0 Hz, 2H), 4.40 (d, J = 6.8 Hz, 2H), 4.34 (t, J = 6.8 Hz, 2H), 4.20 (t, J = 7.0 Hz, 1H), 2.92-
2.84 (m, 6H), 2.84-2.80 (m, 2H), 2.55-2.49 (m, 4H), 2.21-2.14 (m, 2H), 1.42 (s, 9H), 1.16 (d, J = 6.8 
Hz, 12H). 13C NMR (CDCl3, 75 MHz):  207.0, 172.3, 171.6, 156.4, 145.0, 143.8, 143.7, 141.3, 
140.1, 138.8, 127.7, 127.0, 125.0, 123.8, 122.1, 119.9, 80.3, 66.8, 49.1, 47.2, 38.7, 37.0, 36.9, 36.4, 
31.0, 29.7, 28.1, 27.7, 27.4, 24.1.  IR (neat) 2958, 1718, 1524, 1450, 1368, 1256, 1145, 741, 612 cm–
1. HRMS (ESI+) m/z calcd for C44H55N4O7 (M+H)
+: 751.4071, found: 751.4096. 
 
4-(3-((2,5-Dioxopyrrolidin-1-yl)oxy)-3-oxopropyl)-2,6-di-isopropylphenyl 7-(4-(((((9H-fluoren-9-
yl)methoxy)carbonyl)-amino)methyl)-1H-1,2,3-triazol-1-yl)-4-oxoheptanoate (4)  
Trifluoroacetic acid (1 mL) was added to a solution 
of tert-butyl ester 2 (67 mg, 88.6 µmol) in CH2Cl2 (1 
mL) and the mixture was stirred until TLC analysis 
(EtOAc:heptane, v/v, 3:1) showed complete 
consumption of starting material (30 min). Toluene 
(3 mL) was added and the mixture was concentrated under reduced pressure, which was repeated 
twice to give carboxylic acid 3 as an oil (crude). RF 0.25 (EtOAc). Without further purification, 
compound 3 was dissolved in CH2Cl2 (2 mL) and to this solution was added N-hydroxysuccinimide 
(15 mg, 0.133 mmol) and EDC (25 mg, 0.133 mmol). The mixture was stirred overnight after which 
4.6.2 Synthesis of the BCN-cleavable linker conjugate  
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time TLC (EtOAc) indicated the incomplete conversion of 3 into a more lipophilic product (RF 0.35, 
EtOAc). To the mixture was again added N-hydroxysuccinimide (7.5 mg, 66.5 µmol) and EDC (12.5 
mg, 66.5 µmol) and the mixture was stirred overnight again, leading to the complete disappearance of 
starting material. The mixture was diluted with CH2Cl2 (10 mL), and washed with 1 N HCl solution 
(2 × 1 mL) and H2O (1 mL). The organic layer was dried (MgSO4), filtered, concentrated and purified 
by silica gel column chromatography (CH2Cl2:acetone 90:10→85:15) to give title compound 4 as a 
colorless oil. Yield 62 mg (88%, two steps). RF = 0.35 (EtOAc). 
1H NMR (CDCl3, 400 MHz):  7.75 
(d, J = 7.6 Hz, 2H), 7.57 (d, J = 7.2 Hz, 2H), 7.47 (s, 1H), 7.40 (t, J = 7.4 Hz, 2H), 7.30 (t, J = 7.6 Hz, 
2H), 6.98 (s, 2H), 5.40 (bs, 1H), 4.45 (d, J = 6.0 Hz, 2H), 4.40 (d, J = 7.2 Hz, 2H), 4.34 (t, J = 6.6 Hz, 
2H), 4.21 (t, J = 7.0 Hz, 1H), 3.04-3.00 (m, 2H), 2.93-2.77 (m, 11H), 2.51 (t, J = 6.8, 2H), 2.21-2.14 
(m, 3H), 1.17 (d, J = 6.8, 12H). 13C NMR (CDCl3, 75 MHz):  207.0, 171.6, 169.0, 167.9, 156.3, 
145.0, 144.2, 143.8, 141.3, 140.6, 137.2, 127.7, 127.0, 125.0, 123.8, 122.1, 120.0, 66.8, 49.1, 47.2, 
38.8, 37.0, 36.5, 32.7, 30.4, 27.7, 27.5, 25.6, 24.2. IR (neat) 2958, 1735, 1524, 1442, 1364, 1208, 
1161, 1143, 1070, 906, 733, 651, 616 cm–1. HRMS (ESI+) m/z calcd for C44H50N5O9 (M+H)
+: 
792.3609, found: 792.3655. 
 
N-Fmoc-protected levulinoyl-BCN conjugate (5)  
Activated ester 4 (30 mg, 37.9 
µmol) was dissolved in DMF 
(1 mL) before the addition of 
DIPEA (13 µL, 75.8 µmol) and 
BCN-(POE)3-NH2 (7, 15 mg, 
46.2 µmol). The mixture was 
stirred overnight, after which 
time TLC analysis (EtOAc) indicated complete conversion of 4 into a more polar product (RF 0.13). 
The mixture was concentrated, applied onto a column of silica gel and eluted with 4% MeOH in 
CH2Cl2. Title compound 5 was obtained as a colorless oil. Yield 24 mg (63%). RF = 0.13 (EtOAc). 
1H 
NMR (CDCl3, 400 MHz):  7.76 (d, J = 7.2 Hz, 2H), 7.57 (d, J = 7.2 Hz, 2H), 7.47 (s, 1H), 7.40 (t, J 
= 7.4 Hz, 2H), 7.30 (t, J  = 7.2 Hz, 2H), 6.96 (s, 2H), 6.02 (bs, 1H,), 5.49 (bs, 1H), 5.20 (bs, 1H), 
4.45-4.32 (m, 6H), 4.22-4.12 (m, 3H), 3.63-3.49 (m, 8H), 3.47-3.40 (m, 2H), 3.39-3.31 (m, 2H), 2.96-
2.86 (m, 6H) 2.80-2.77 (m, 2H), 2.53-2.46 (m, 4H), 2.27-2.17 (m, 8H), 1.61-1.52 (m, 2H), 1.36-1.31 
(m, 1H), 1.16 (d, J = 6.8 Hz, 12H), 0.96-0.88 (m, 2H). 13C NMR (CDCl3, 75 MHz):  207.0, 172.2, 
171.7, 162.5, 156.4, 145.0, 143.8, 141.3, 140.2, 139.0, 127.7, 127.0, 125.0, 123.8, 122.1, 120.0, 98.8, 
70.2, 70.1, 69.9, 66.8, 62.8, 49.1, 47.1, 40.7, 39.1, 38.7, 38.6, 36.9, 36.5, 31.7, 31.4, 29.7, 29.0, 27.7, 
27.4, 24.1, 21.4, 20.1, 17.7. IR (neat) 3320, 2959, 2923, 1714, 1667, 1533, 1450, 1364, 1257, 1142, 
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1102, 1047, 800, 762, 741, 619 cm–1. HRMS (ESI+) m/z calcd for C57H72N6O10Na (M+Na)
+: 
1023.5208, found: 1023.5207. 
 
Amino-levulinoyl-BCN conjugate (6)  
To a solution of Fmoc-protected 
conjugate 5 (11 mg, 10.8 µmol) in 
CH2Cl2 (800 μL) was added 
piperidine (200 µL) and the 
solution was stirred for 10 minutes. 
The mixture was concentrated and 
purified by silica gel column 
chromatography (CH2Cl2:MeOH:Et3N 94:5:1→89:10:1) to give title compound 6 as a white solid. 
Yield 8 mg (95%). RF = 0.1 (CH2Cl2:MeOH 9:1). 
1H NMR (CDCl3, 400 MHz):  7.76 (d, J = 7.2 Hz, 
2H), 7.57 (d, J  = 7.2 Hz, 2H), 7.47 (s, 1H), 7.40 (t, J = 7.4 Hz, 2H), 7.30 (t, J =  7.2 Hz, 2H), 6.96 (s, 
2H), 6.02 (bs, 1H), 5.49 (bs, 1H), 5.20 (bs, 1H), 4.45-4.32 (m, 6H), 4.22-4.12 (m, 3H), 3.63-3.49 (m, 
8H), 3.47-3.40 (m, 2H), 3.39-3.31 (m, 2H), 2.96-2.86 (m, 6H) 2.80-2.77 (m, 2H), 2.53-2.46 (m, 4H), 
2.27-2.17 (m, 8H), 1.61-1.52 (m, 2H), 1.36-1.31 (m, 1H), 1.16 (d, J = 6.8 Hz, 12H), 0.96-0.88 (m, 
2H). 13C NMR (CDCl3, 75 MHz):  207.0, 172.2, 171.7, 162.5, 156.4, 145.0, 143.8, 141.3, 140.2, 
139.0, 127.7, 127.0, 125.0, 123.8, 122.1, 120.0, 98.8, 70.2, 70.1, 69.9, 66.8, 62.8, 49.1, 47.1, 40.7, 
39.1, 38.7, 38.6, 36.9, 36.5, 31.7, 31.4, 29.7, 29.0, 27.7, 27.4, 24.1, 21.4, 20.1, 17.7. IR (neat) 3320, 
2959, 2923, 1714, 1667, 1533, 1450, 1364, 1257, 1142, 1102, 1047, 800, 762, 741, 619 cm–1. HRMS 
(ESI+) m/z calcd for C42H63N6O8 (M+H)
+: 779.47074, found: 779.47329. 
 
Coupling linker-BCN conjugate 6 to agarose was performed with SepharoseTM beads from GE 
Healthcare (formerly Amersham, cat. no. 17-0430) according to the instructions of the manufacturer. 
The linker-BCN conjugate 6 was coupled to the beads at 1, 2 and 10 mM concentrations, for 16 hours 
by end-over-end rotation. Beads were stored in 20% ethanol at 4 °C. 
 
Bead solutions obtained above were individually incubated with 1 mM azidocoumarin in 50% 
methanol (1:1, v/v) at 20 °C in the dark, by shaking at 400 rpm. After 0.25, 0.5, 1 and 4 hours, 1 µL of 
the mixture was used for fluorescence microscopy. 
 
  
4.6.3 Immobilization of BCN-Lev linker to agarose beads    
4.6.4 SPAAC of linker-coupled beads with 7-azidocoumarin  
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To follow the cleavage in time, samples of 15 µL beads of the 10 mM linker concentration and 15 µL 
1 mM azidocoumarin were incubated for 2 hours. Cleavage was carried out by addition of 30 µL 200 
mM hydrazine and shaking at 400 rpm at either 4 or 37 °C in the dark. At each time point, a sample 
was centrifuged, and 50 µL of the supernatant was removed. The remaining 10 µL was used for 
fluorescence microscopy.  
 
    BCN-(POE)3-NH2 7 (10 mM in DMSO/H2O 1:9 v/v) was coupled to CNBr-activated Sepharose 
beads (0.1 g freeze-dried beads, GE Healthcare, cat.no.17-0430-01) according to the instructions of 
the manufacturer. Beads were stored in EtOH/H2O 1:4 (v/v) at 4 °C. Beads (100 µL) were incubated 
with azido-ester-coumarin 9 (100 µL of a 1 mM solution in DMSO:H2O 1:99 v/v) for 4 h at rt, 
shaking in the dark at 600 rpm. Fluorescence of the beads was checked with fluorescence microscopy 
(Zeiss Axioskop 20, serial nr. 451487, with an HB050 mercury lamp, using the UV filter).  
    Cleavage of the ester linkage was effected by incubation of 25 µL beads with 100 µL 10 mM 
NaOH at rt. The reaction was followed in time until fluorescence (ex 325 nm, em 452 nm) in solution 
showed saturation (about 3 hours). A standard curve was prepared of 7-hydroxycoumarin in H2O, 
which was followed in time to correct for coumarin degradation by NaOH.   
 
    For all experiments, a protein mixture of 10 µL 1 µg/µL AHA-CalB and 10 µL 1 µg/µL low 
molecular weight marker (LMW, Amersham, 17-0446-01) was used. To the mixture, 10 or 20 µL 
beads of the 10 mM linker concentration was added. This SPAAC mixture was shaken at 600 rpm for 
2 or 18 hours at 4, 20 or 37 °C, centrifuged, and the supernatant was transferred to a new tube and 
stored at 4 °C until loading it on SDS-PAGE. The beads were washed 3 or 5 times with 30 or 200 µL 
PBS with or without 0.5% SDS, possibly followed by 3 washing steps with 200 µL PBS, 2 hours at 
37 °C, shaking at 600 rpm. Cleavage was performed with 100 mM hydrazine for 18 hours at 4 or 37 
°C, shaking at 600 rpm. After cleavage, the samples were centrifuged and the supernatant was 
transferred to a new tube. 15 µL of both the SPAAC and cleavage supernatants, together with 5 µL 4× 
Laemmi sample buffer was used for SDS-PAGE (BioRad mini Protean 3). Markers were made by 
using 1 or 2 µL CalB and/or LMW, adding MQ up to 15 µL and 5 µL 4x sample buffer. To the 
remaining beads, 10 µL 4× sample buffer was added. All samples and markers were boiled at 95 °C 
for 5 minutes before loading them on the gel. Of the bead samples, 10 µL supernatant was loaded on 
gel, the other samples and markers (20 µL) were loaded completely.  
4.6.5 Cleavage of the linker 
4.6.6 Determination of bead loading  
4.6.7 Isolation of CalB from a protein mixture  
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    Optimized conditions: to the protein mixture was added 10 µL beads of the 10 mM linker 
concentration. Subsequently, SPAAC was performed for 18 h at 37 °C. The beads were washed 3 
times with 200 µL PBS and cleavage with 100 mM hydrazine was performed for 18 h at 4 °C.  
    After running, the gels were stained with Coomassie brilliant blue or silver stain (PlusOne/PhastGel 
SDS, fixing solution and silver solution 30 minutes instead of 10 minutes. 
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    In Chapter 4, a hydrazine-sensitive linker was described as a versatile addition to the 
family of cleavable linkers. An attractive feature of the linker involved the presence of a 
strained alkyne, thereby enabling convenient enrichment of azide-containing 
(glyco)proteins from complex biological samples. Nevertheless, treatment of biological 
samples with hydrazine or any other chemical reagent may potentially adversely affect or 
modify the target molecule, as was for example illustrated by the undesired degradation of 
immobilized azidocoumarin (Chapter 4). A particularly mild alternative to chemical 
cleavage is ‘reagent free’ light-induced linker disintegration. In this chapter, two alternative 
approaches to the synthetic preparation and application of such a photosensitive linker are 
described, one based on nitroveratryl, and one on 2-hydroxymethylnaphthol.  
 
     
    Within the field of photolabile protecting groups, presumably the best characterized 
subcategory involves the ortho-nitrobenzyl derivatives
6
 because of their relative 
straightforward accessibility and facile cleavage by light. The latter aspect is further 
illustrated by the fact that ortho-nitrobenzyl-based linkers have been extensively applied in 
combination with solid supports. Based on these observations, the ortho-nitrobenzyl group 
was selected as the first choice of photocleavable linker for enrichment of azide-containing 
molecules.  
    The first application of ortho-nitrobenzyl derivatives as an orthogonal linker for cleavage 
of molecules from solid supports was described in 1973 by Rich et al.
7
 for cleavage of 
peptides from an ortho-nitrobenzyl-functionalized resin (1). Since then, various ortho- 
 
                                                            
5.1 Introduction 
5.2 Photocleavable linkers 
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nitrobenzyl analogs have been developed with tailored chemical properties. For example, 
substitution of the phenyl ring with two methoxy groups increased absorption at higher 
wavelength (350 nm), thereby enabling application to sensitive biological samples. 
    A systematic comparison of photokinetic and cleavage properties of a wide range of 
known and de novo synthesized ortho-nitrobenzyl derivatives was performed by Holmes et 
al.,
9
 as summarized in Figure 5.1. From the comprehensive overview, it was concluded that 
substitution of the phenyl ring by alkoxy groups indeed led to the anticipated bathochromic 
shift in the UV spectra, and the presence of an α-methyl group8 (5, 6 and 7) generally 
resulted in cleavage rate enhancement. Additionally, a longer anchoring tail (structures 6 
and 7) exhibited slower kinetics in aqueous solvents compared to the shorter tail in 5. The 
fastest kinetics of all examined model linkers pertained to amide-releasing linker 7.  
 
 
Figure 5.1. Structures of the photocleavable linkers investigated by Holmes.9 
 
    The amide-containing structure 7, based on its optimal features for cleavage, was 
selected by us for development of a bioorthogonal linker for cleavage of molecules from a 
solid support. In combination with strained alkyne BCN, chosen for its excellent reaction 
kinetics with azides, relatively low lipophilicity and fast synthesis, the overall design is 
depicted in Figure 5.2.  
 
    In 2008, Kulikov et al. reported that photolysis of (3-hydroxy-2-naphthalenyl)methyl-
caged alcohols, phenols and carboxylic acids resulted in efficient release of the substrates 
(Scheme 5.1).
10
 The concomitantly formed 2-naphthoquinone-3-methide (11) subsequently 
underwent rapid hydration to the parent diol 12 or could be trapped with ethyl vinyl ether to 
give Diels-Alder adduct 13. A few years later, the same group described the use of this  
5.2.2 Design of hydroxymethylnaphthol-based photocleavable linker 
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Figure 5.2. The final designs of the nitroveratryl-based (8) and hydroxymethyl naphtol-based (9) photocleavable 
linkers.  
 
  
Scheme 5.1. Irradiation of (3-hydroxy-2-naphthalenyl)methyl-caged alcohols, phenols and carboxylic acids results 
in release of the substrates. 2-Naphthoquinone-3-methide (11) then undergoes rapid hydration or is trapped as 
Diels-Alder adduct 13.  
 
scaffold for light-induced ligation between vinyl ether conjugates and functionalized 
hydroxymethylnaphthol derivatives.
11
 In this case, an attachment handle was incorporated 
in the naphthalene ring via the 1-hydroxy group of 6-(hydroxymethyl)naphthalene-1,7-diol, 
and subsequent irradiation gave full product release in only 20 min. 
    In particular based on the latter observation, we envisioned that the 
hydroxymethylnaphthol scaffold could be an attractive alternative to the nitroveratryl-based 
photocleavable linker, and the final design of this linker is depicted in Figure 5.2.  
 
Synthesis of the nitroveratryl-based photocleavable linker starts with alkylation of  
commercially available acetovanillone 14 with methyl bromoacetate (Scheme 5.2), as 
5.3 Synthesis 
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described by Holmes et al.
9
 Next, treatment of 15 with hydroxylamine leads to oxime 16 in 
quantitative yield without the need of purification, then hydrogenolysis to amine 17, and 
finally acylation with TFAA in dichloromethane to give trifluoroacetate-protected 18 in 
18% yield. In our hands, the use of pyridine as base for the TFAA acylation resulted in 
formation of an inseparable mixture of products. In contrast, acylation of amine 17 in the 
presence of Et3N gave, albeit in low yield, exclusively desired product 18. Subsequent 
nitration of 18 with nitric acid provided 19 in 68% yield, followed by simultaneous removal 
of the trifluoroacetyl group and methyl ester saponification upon treatment with NaOH in 
refluxing CH3OH/H2O to generate free amino acid 20. BCN was then introduced by 
treatment of 20 with commercially available BCN succinimidyl carbonate to give BCN 
derivative 21.   
 
 
Scheme 5.2. Synthesis of building block 21. Reagents and conditions: (a) Methyl bromoacetate, K2CO3, DMF, 60 
°C, 18 h (quant); (b) NH2OH·HCl, pyridine, H2O, rt, 17 h (81%); (c) H2, Pd/C, AcOH, rt, 45 h (63%); (d) (CF3CO)2O, 
Et3N, CH2Cl2, 0 °C, 2 h (18%); (e) HNO3, 0 °C, 3 h (68%); (f) 1 M NaOH in H2O, CH3OH, 65 °C, 18 h (92%); (g) Et3N, 
CH3CN, H2O, BCN succinimidyl carbonate, rt, 10 min (95%). 
 
    In the next step, a spacer was synthesized that provides hydrophilicity to the final BCN-
containing construct 26 (Scheme 5.3). Although direct mono-Fmoc protection of excess 
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diamine 22 with Fmoc-OSu in 1,4-dioxane was not successful, Boc protection gave the 
desired mono-protected product. Subsequent Fmoc protection of the remaining free amine, 
followed by Boc deprotection in dioxane/HCl resulted in desired mono-Fmoc protected 
amine 24, which readily condensed with acid 21 upon treatment with Et3N, EDC and 
HOBt. Finally, deprotection of the Fmoc group resulted in desired amino derivative 26.   
 
 
Scheme 5.3. Synthesis of BCN-conjugated light-cleavable linker 26. Reagents and conditions: (a) Boc2O, dioxane, 
rt, 2 h, then (b) FmocOSu, dioxane/H2O, rt, 1 h (74%, two steps); (c) 2 M HCl in dioxane, 0 °C, 17 h (quant); (d) 
Et3N, CH2Cl2, 18 h, then (e) HOBt, EDC, 21, CH2Cl2, 6 h (73%); (f) 0.1 M NaOH in H2O, dioxane, pH 12, 50 °C, 2 h 
(quant, crude).  
 
    Synthesis of the hydroxymethyl-naphthol-based photocleavable linker started with 
reduction of commercially available 3,5-dihydroxy-2-naphthoic acid 27 (Scheme 5.4), 
followed by conversion into acetonide 29. Direct alkylation of compound 29 with 3-(Fmoc-
amino)propyl bromide resulted in undesired Fmoc deprotection, therefore naphthol 29 was 
first alkylated with 1-bromo-3-chloropropane in 78% yield. The chloride of 30 was 
substituted with sodium azide, followed by reduction to amine 32 and Fmoc protection, to 
give 33 in 54% yield over three steps. Subsequent acetal hydrolysis produced the desired 
diol 34. For selective reaction with substrates of the primary alcohol in compound 34 a 
mono-TBDMS-protected diol derivative was prepared from 34 by a known two-step  
 
5.3.2. Hydroxymethylnaphthol-based photocleavable linker  
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Scheme 5.4. Synthesis of alcohol 36. Reagents and conditions: (a) LiAlH4, THF, 55 °C, 75 min (85%); (b) 2,2-
dimethoxypropane, TsOH, acetone, rt, 22 h (82%); (c) 1-bromo-3-chloropropane, K2CO3, acetone, 65 °C, 19 h 
(78%); (d) NaN3, TBAI, DMF, 75 °C, 18 h, then (e) Pd/C, H2, EtOAc, rt, 18 h, then (f) Fmoc-OSu, 10% NaHCO3, 
dioxane, rt, 19 h (54% over three steps); (g) AcOH:H2O 4:1, 65 °C, 30 min (quant); (h) TBDMSCl, imidazole, DMAP, 
DMF, rt, 18 h (74%); (i) CeCl3, CH3CN, 80 °C, 22 h, then rt, 72 h (85%).  
 
procedure,
12,10
 involving disilylation followed by selective mono-deprotection of the 
primary aliphatic alcohol, to give 36. In the next step, alcohol 36 was acylated with BCN-
derived acid 37 under the influence of EDC and DMAP, thereby affording ester 38 in 74% 
yield (Scheme 5.5). Finally, deprotection of the TBDMS group with simultaneous 
deprotection of the Fmoc group resulted in the desired amino derivative 39.  
 
 
Scheme 5.5. Synthesis of hydroxymethylnaphthol-based cleavable linker 39. Reagents and condtions: (a) EDC, 
DMAP, CH2Cl2, rt, 18 h (71%); (b) TBAF, THF, rt, 10 min (53%). 
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    Having obtained desired amino-derivatives 26 and 39, coupling to a solid support was 
investigated, followed by evaluation of on-resin SPAAC.   
    BCN-containing nitroveratryl amine 26 was coupled to cyanogen bromide-activated 
Sepharose beads, thus affording nitroveratryl-based ‘azido-trap’ beads. To validate on-resin 
SPAAC, the functionalized beads were incubated with fluorescein-derived azide 40. 
Unfunctionalized Sepharose beads were also incubated with 40 as negative control. As 
anticipated, fluorescence microscopy showed clear fluorescent staining of the BCN-
functionalized beads after incubation with azido-FITC 40, whereas the negative control 
beads showed no fluorescence (Figures 5.3A and B), thereby demonstrating specific 
reaction between azido-FITC and BCN-functionalized beads. 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Fluorescence microscopy images of Sepharose beads after incubation with azido-FITC 40. (A) 
Unfunctionalized beads; (B) beads functionalized with nitroveratryl-based cleavable linker 26.  
 
5.4 Immobilization and evaluation of SPAAC   
 
5.4.1 Nitroveratryl-based photocleavable linker 
A. B. 
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    In earlier experiments (Chapter 4), we found that cyanogen bromide-activated Sepharose 
beads combined with the hydrazine-cleavable linker led to aspecific protein binding. 
Therefore we now opted for a resin reported to display low aspecific binding of undesired 
proteins,
13,14
 Thermo Scientific UltraLink Biosupport. The latter resin consists of a 
hydrophilic copolymer of polyacrylamide and azlactone known to react rapidly and 
efficiently with primary amines, resulting in stable amide bonds without the need of pre-
swelling (Scheme 5.6). Thus, amine 39 was coupled to the UltraLink Biosupport resin at 
pH 7.5 at two different concentrations (1 mM and 10 mM).  
 
 
Scheme 5.6. Immobilization chemistry of Thermo Scientific UltraLink Biosupport with primary amines.  
 
    In Chapter 4, we employed the fluorogenic azidocoumarin probe 41 to validate first 
SPAAC on and then cleavage off the beads. Thus, hydroxymethylnaphthol-functionalized 
beads (1 or 10 mM linker concentration) were incubated with azidocoumarin 41 (1 mM) 
overnight and samples were taken for analysis by confocal microscopy. A concentration- 
dependent fluorescence staining of the beads became apparent (Figure 5.4A), which is a 
strong indication that SPAAC between immobilized BCN 26 and azidocoumarin 41 had 
taken place. The highest signal was established with beads charged at 10 mM, so 
forthcoming experiments were performed with 10 mM linker concentration. 
 
 
 
 
 
5.4.2 Hydroxymethylnaphthol-based photocleavable linker 
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Figure 5.4. Light microscope (left) and confocal (right) pictures of hydroxymethyl naphthyl-modified UltraLink 
Biosupport resin. (A) Treatment of hydroxymethylnaphthol-modified resin with fluorogenic substrate 41 
overnight. Top to bottom: 0, 1 and 10 mM linker concentration (26); (B) photocleavage of the linker on the beads 
with 350 nm light. Top to bottom: irradiation time of 0 min, 90 min and 300 min.  
The fluorophore-containing beads also enable straightforward evaluation of the release 
concept by photocleavage of the linker. To this end, azidocoumarin-functionalized beads 
containing the hydroxymethylnaphthol-based linker in PBS buffer were irradiated with 350 
nm light at room temperature, leading to distinct decrease in fluorescence (Figure 5.4B). 
However, a control experiment involving 350 nm irradiation of fluorescent beads obtained 
by SPAAC of azidocoumarin 41 with non-cleavable BCN linker 42 led to the same 
decrease of fluorescence in time (Figure 5.5), indicating that the triazolylcoumarin 
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Figure 5.5. Light microscope (left) and confocal (right) pictures of photostable BCN derivative 42-modified 
UltraLink Biosupport resin after SPAAC with azidocoumarin 41 and photocleavage at 350 nm light. 
 
fluorophore is not photostable at 350 nm light. Therefore, as an alternative strategy, 
photocleavage of linkers 44 and 49 was performed in solution, thereby enabling reaction 
progress monitoring by LC-MS.  
 
    To this end, BCN derivative 26 was subjected to SPAAC with benzyl azide, followed by 
acetylation of the amine (Scheme 5.7). The resulting triazole 44 was dissolved in 
CH3CN:H2O 1:1 and this solution was irradiated at room temperature with 350 nm light (8 
lamps, 4 W each) to give the expected photocleavage products, as indicated by LC-MS.  
     Because photocleavage in solution with LC-MS was successful, LC-MS was next also 
employed for analysis of on-resin photocleavage. Therefore, amine 26 was installed on 
UltraLink Biosupport resin, followed by SPAAC with 1 mM benzyl azide in 0.1 M 3-(N-
morpholino)propanesulfonic acid (MOPS) buffer (pH 7.5):CH3OH 1:1. The resulting beads 
were irradiated at 350 nm, and samples were taken at specific time intervals for analysis 
with LC-MS. Unexpectedly, product formation was too low for detection by LC-MS, also 
after prolonged (2 h) irradiation.  
    Despite failure to detect on-resin photocleavage, we decided to further investigate the 
nitroveratryl linker (vide infra), because cleavage in solution was found to proceed 
successfully.  
  
5.5.1. Nitroveratryl-based photocleavable linker 
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Scheme 5.7. Synthesis of triazole 44 followed by photocleavage at 350 nm. Reagents and conditions: (a) BnN3, 
dioxane, rt, 40 min, then (b) Ac2O, dioxane:0.1 M MOPS buffer pH = 7.5 (quant, 2 steps); (c) H2O:CH3CN 1:1, 350 
nm light. 
 
    To evaluate photocleavage of the hydroxymethylnaphthol-based linker in solution, BCN 
derivative 39 was subjected to SPAAC with benzyl azide, followed by acetylation of the 
amine (Scheme 5.8). Resulting triazole 49 was irradiated with 350 nm light to give 
photocleavage products 50 and 51, as determined by LC-MS analysis. The latter product 50 
is rapidly converted to diol 52 in the presence of water. 
    To evaluate on-resin photocleavage, amine 39 was installed on the beads, followed by 
SPAAC with benzyl azide. The beads were irradiated with 350 nm light, samples were 
taken at specific time points and analyzed with LC-MS. Although product formation after  
5.5.2 Hydroxymethylnaphthol-based photocleavable linker 
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Scheme 5.8. Synthesis of triazole 49 followed by photocleavage at 350 nm. Reagents and conditions: (a) BnN3, 
dioxane, rt, 40 min, then (b) Ac2O, dioxane:0.1 M MOPS buffer pH = 7.5 (81%, 2 steps); (c) H2O:CH3CN 1:1, 350 
nm light.  
 
15 and 30 minutes irradiation was too low to be visualized, LC-MS clearly showed the 
presence of cleavage product 51 after 60 minutes, which reached a maximum after 
approximately 3 hours.  
 
    To test whether ‘azido-trap’ beads 8 and 9 are useful for selective isolation of a specific 
azide-containing protein of interest from a pool of native proteins, we applied the same 
procedure as in Chapter 4, based on enrichment of azidohomoalanine-containing Candida 
antartica lipase B (AHA-CalB).  
 
5.6 Selective enrichment of an azide-modified protein from a 
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    A mixture of proteins, containing AHA-CalB, α-lactalbumin, trypsin inhibitor, carbonic 
anhydrase, ovalbumin, albumin and phosphorylase B, was incubated with 10 or 20 µL 
BCN-derivatized beads containing the nitroveratryl-based photocleavable linker at 20 or 37 
°C for 2 h and the supernatant was resolved on SDS-PAGE (Figure 5.6A). Complete 
disappearance of AHA-CalB was not observed in any of the four experiments, but best 
reaction conditions for scavenging of AHA-CalB involved 20 µL beads at 37 °C for 2 h.  
    Subsequent photocleavage was performed at room temperature for 60 minutes with 350 
nm light and the supernatant of each experiment was loaded on SDS-PAGE gel (Figure 
5.6B). In all lanes a single protein with a mass corresponding to AHA-CalB appeared on 
the gel. Based on the latter results, it can be concluded that SPAAC trapping of protein is 
most efficient with 20 µL bead suspension and incubation at 37 °C for 2 h, corresponding 
nicely to the highest disappearance of AHA-CalB from the supernatant.  
 
 
Figure 5.6. SDS-PAGE gels after enrichment of AHA-CalB from a protein mixture with nitroveratryl-based linker-
coupled beads. CalB (arrows) in a mixture of standard proteins M (from top to bottom phosphorylase B, albumin, 
ovalbumin, carbonic anhydrase, trypsin inhibitor and α-lactalbumin) was used for SPAAC-mediated enrichment. 
(A) Coomassie-stained gel of the supernatant after SPAAC. Lanes 1-4: supernatants after SPAAC, lane 5: AHA-CalB 
in protein mixture M before capture; (B) silver-stained gel of the supernatant after photocleavage. Lanes 1-4: 
supernatant after cleavage, lane 5: AHA-CalB, lane 6: protein mixture M.  
 
   The same SPAAC-release procedure as above was applied to test whether the ‘azido-trap’ 
beads containing the hydroxymethylnaphthol-based photocleavable linker is useful for 
5.6.1. Nitroveratryl-based photocleavable linker         
5.6.2. Hydroxymethylnaphthol-based photocleavable linker 
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enrichment of AHA-CalB. Thus, the same mixture of unfunctionalized proteins combined 
with AHA-CalB was incubated with 10 of 20 µL BCN-derivatized beads containing the 
hydroxymethylnaphthol-based photocleavable linker for 2 or 16 h at 20 or 37 °C. The 
supernatant of the beads after SPAAC was resolved on SDS-PAGE (Figure 5.7A). The 
amount of AHA-CalB is clearly reduced in all experiments except in lane 8 (10 µL beads, 
SPAAC at 37 °C for 16 h). In all cases, incubation with 20 µL bead solution instead of 10 
µL gave more removal of CalB, in particular when combined with SPAAC at 20 °C for 16 
h (lane 5) or at 37 °C for 2 h (lane 7).   
 
 
Figure 5.7. SDS-PAGE gels after enrichment of AHA- CalB from a protein mixture with hydroxymethylnaphthol-
based linker-coupled beads. Arrow: CalB. (A) Coomassie stained gel of the supernatant after SPAAC. Lanes 1-9: 
supernatants after SPAAC, lane 10: AHA-CalB in protein mixture M before capture; (B) silver stained gel of the 
supernatant after photocleavage. Lanes 1-8: supernatant after cleavage, lane 9: AHA-CalB, lane 10: protein 
mixture M.  
 
    Next, photocleavage of all samples was performed at room temperature for 60 minutes 
with 350 nm light and the supernatant of each experiment was loaded on SDS-PAGE gel 
(Figure 5.7B). In nearly all lanes (except lanes 1 and 4) a single protein with a similar mass 
as AHA-CalB appeared on the gel. As becomes clear, the best overall conditions for protein 
recovery involve light-cleavage of 20 µL beads that were obtained by SPAAC at 20 °C for 
2 h or 16 h (lane 2 or 4, respectively) or 37 °C for 16 h (lane 8), or light-cleavage of 10 µL 
beads obtained by SPAAC at 37 °C for 16 h (lane 7). Remarkably, high disappearance of 
AHA-CalB from the supernatant of the SPAAC reaction does not correlate well to high 
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recovery after photocleavage. Additionally, no clear trends in SPAAC reaction conditions 
are visible for recovery after photocleavage, except for a slight tendency of high recovery 
when 20 µL beads are used and/or a longer reaction time.  
 
    As a next step, enrichment of AHA-CalB from a more complex mixture, i.e. a fibroblast 
cell lysate, was investigated. To this end, AHA-CalB was combined with the cell lysate of 
human skin fibroblasts, followed by the addition of 20 µL beads containing linker 26 or 39. 
As negative control, native CalB was also mixed with cell lysate. SPAAC was performed 
for 2 h at rt, after which time beads were washed and subjected to 350 nm light for 60 min 
at room temperature. The supernatant after cleavage was loaded on SDS-PAGE gel (Figure 
5.8). Disappointingly, no CalB could be detected on the gel after enrichment with 
nitroveratryl-based linker 26. However, when the naphthol-based linker 39 was used, a 
protein with the expected mass of AHA-CalB clearly stained on the gel, thereby 
corroborating the usefulness of selective enrichment of an azido-containing protein from a 
complex mixture by means of a SPAAC-release strategy. 
 
 LMW native 
CalB 
lysate AHA 
CalB 
39 26 39 
blanco 
26 
blanco 
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Figure 5.8. SDS-PAGE gel after enrichment of AHA-CalB from cell lysate with bead-coupled 26 and 39. Silver 
stained gel, arrow: CalB. Lane 1: LMW, lane 2: native CalB, lane 3: cell lysate from skin fibroblasts, lane 4: AHA-
CalB, lane 5: supernatant after enrichment of AHA-CalB with linker 39, lane 6: supernatant after enrichment of 
AHA-CalB with linker 26, lane 7: supernatant after enrichment of native CalB with linker 39, lane 8: supernatant 
after enrichment of native CalB with linker 26. 
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     Two ‘azido-trap’ beads were successfully synthesized based on immobilization of a 
nitroveratryl-based and a hydroxymethylnaphthol-based photocleavable linker. We 
demonstrated on-resin SPAAC by fluorescent staining of the beads with azido-FITC (for 
the nitroveratryl-based linker) or azidocoumarin (for the hydroxymethylnaphthol-based 
linker). Cleavage was evaluated first in solution (off-resin) by irradiation with 350 nm light 
after SPAAC with benzyl azide, which resulted in formation of cleavage products for both 
linkers. Subsequent on-resin SPAAC with benzyl azide followed by photocleavage led to 
the desired product release from the hydroxymethylnaphthol-based linker, but not from the  
nitroveratryl-based one. The SPAAC-release concept was successfully applied in selective 
capture of an azide-modified protein (AHA-CalB) from a mixture of five other proteins by 
covalent attachment to either functionalized beads, followed by effective cleavage by 
irradiation with 350 nm light, to give a single product in both cases. Enrichment of AHA-
CalB from a more complex mixture, i.e. cell lysate from human skin fibroblasts, was 
successful only for the hydroxymethylnaphthol-based linker.  
    The combination of the nitroveratryl-based photocleavable linker with a strained alkyne 
was also envisioned by others.
15
 Nonetheless, the combination of the 
hydroxymethylnaphthol-based linker with a solid support or a strained alkyne was never 
reported to our knowledge, and proved to be more prosperous in enrichment of AHA-CalB 
not only from pooled protein but even from cell lysate.  
    Taken together, the successful capture-release of AHA-CalB from a protein mixture with 
two BCN-photolabile linker constructs constitute promising reagent-free alternatives to 
chemical or enzymatical cleavage of a linker. The hydroxymethylnaphthol-based linker in 
particular promises to be useful for enrichment of azide-containing proteins from complex 
biological samples, for example after metabolic incorporation.  
 
    Esra te Brinke and Erik de Heuvel are kindly acknowledged for their work on the 
synthesis of the nitroveratryl-based photocleavable linker. Anne Stultiens is gratefully 
acknowledged for her contribution to the synthesis of the nitroveratryl-based and the 
hydroxymethylnaphthol-based photocleavable linker, and for evaluation of on-resin 
SPAAC with azido-FITC. Dr. Liesbeth Pierson (general instrumentarium) is greatly 
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acknowledged for introduction to the confocal microscope and useful discussions regarding 
confocal microscopy analyses.  
 
    See section 2.9. Proteinase inhibitor was obtained from Roche. UltraLink Biosupport resin was 
obtained from Thermo Scientific. Hydromatrix SD was from Screening Devices, EC5660500. 
Cleavage was done in a mini-Rayonet RMR-600 photochemical reactor equipped with 8 fluorescent 
lamps (4 W each, 350 nm) at ambient temperature. Fluorescence microscopy was done on a Zeiss 
Axio Observer Z1 fitted with Zeiss Colibri LED lamps. Pictures were taken with an Axiocam HRm at 
200× magnification (20× apochromat) and shutter times of 60 ms (brightfield) and 200 ms 
(fluorescence, excitation 470 nm ±30 nm). Confocal microscopy was done on a Leica TCS SP2 
AOBS Confocal Laser Scanning Microscope (excitation: 488 nm).  
 
 
Methyl 2-(4-acetyl-2-methoxyphenoxy)acetate (15) 
Acetovanillone (10.0 g, 60.3 mmol) was dissolved in dry DMF (30 mL) under 
nitrogen atmosphere. Methyl bromoacetate (13.0 g, 85 mmol) and K2CO3 (16.0 g, 
120 mmol) were added, resulting in a yellow slurry. The reaction mixture was 
heated to 60 °C for 18 h. The brown reaction mixture was cooled down to rt and 
the product was extracted from H2O (70 mL) with EtOAc (4 × 160 mL). The 
organic phase was washed with brine (200 mL), dried (Na2SO4) and concentrated in vacuo. Silica gel 
column chromatography (CH2Cl2:CH3OH 99:1) gave keto ester 15 as a yellow solid (14.37 g, 60.3 
mmol, quant.). RF 0.85 (CH2Cl2:CH3OH 9:1). 
1H NMR (400 MHz, CDCl3) δ 7.55-7.51 (m, 2H), 6.78 
(d, J = 8.3 Hz, 1H), 4.77 (s, 2H), 3.94 (s, 3H), 3.80 (s, 3H), 2.56 (s, 3H). 13C NMR (75.5 MHz, 
CDCl3) δ 196.6, 169.7, 151.3, 149.4, 131.7, 122.8, 112.1, 110.9, 65.9, 56.1, 52.4, 26.2. IR (neat, cm
-1) 
ν 2950, 1753, 1671, 1588, 1506, 1411, 1277, 1204, 1152, 1031, 798, 612. GCMS (CI+) m/z calcd for 
C12H15O5 (M+H)
+: 239.0915, found: 239.0911. 
 
Methyl 2-(4-(1-(hydroxyimino)ethyl)-2-methoxyphenoxy)acetate (16) 
Keto ester 15 (14.2 g, 59.4 mmol) was dissolved in pyridine (40 mL) and H2O (20 mL). 
Hydroxylamine hydrochloride (5.38 g, 77 mmol) was added while stirring. After stirring at rt for 17 h, 
the solvent was co-evaporated with toluene (3 × 50 mL). The product was dissolved in CH2Cl2 (150 
5.10 Experimental section  
5.10.1 General methods and procedures 
5.10.2 Synthesis of the nitroveratryl-based photocleavable linker 
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mL), washed with H2O (3 × 130 mL), brine (100 mL), dried over Na2SO4 and 
concentrated in vacuo, yielding oxime 16 (12.26 g, 48.4 mmol, 81%, yellow 
solid). RF  0.56 (EtOAc:heptane 2:1). 
1H NMR (300 MHz, CDCl3) δ 7.27 (d, J = 
2.1 Hz, 1H), 7.10 (dd, J = 8.4, 2.1 Hz, 1H), 6.80 (d, J = 8.4 Hz, 1H), 4.72 (s, 2H), 
3.91 (s, 3H), 3.80 (s, 3H), 2.25 (s, 3H). 13C NMR (75 Hz, CDCl3) δ 169.5, 155.6, 
149.6, 148.4, 131.1, 119.1, 113.5, 109.5, 66.4, 56.1, 52.4, 12.1. IR (neat, cm-1) ν 3400, 2950, 1753, 
1584, 1515, 1277, 1208, 1178, 1148, 1027, 867, 806. HRMS (ESI+) m/z calcd for C12H16NO5 
(M+H)+: 254.1029, found: 254.1031. 
 
Methyl 2-(4-(1-aminoethyl)-2-methoxyphenoxy)acetate (17) 
To a solution of oxime 16 (12.1 g, 48 mmol) in glacial acetic acid (230 mL), 10% 
palladium on charcoal (0.864 g) was added under nitrogen atmosphere. The 
reaction mixture was stirred at rt for 45 h under H2 (1 atm). The mixture was 
filtered over celite and co-evaporated with toluene (4 × 50 mL). Silica gel column 
chromatography (EtOAc:CH3OH:Et3N 84:15:1) gave amine 17 as a brown oil 
(7.23 g, 30 mmol, 63%). RF 0.13 (EtOAc:CH3OH:Et3N 84:15:1). 
1H NMR (400 MHz, CDCl3) δ 7.00- 
6.97 (m, 1H), 6.84 (dd, J = 8.3, 2.0 Hz, 1H), 6.77 (d, J = 8.3 Hz, 1H), 4.18-4.13 (m, 1H), 4.68 (s, 2H), 
3.87 (s, 3H), 3.78 (s, 3H), 1.47 (d, J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 169.4, 149.7, 147.0, 
135.3, 125.1, 118.6, 114.1, 110.5, 66.3, 55.9, 52.2, 50.8, 21.8. IR (neat, cm-1) ν 3370, 2957, 1753, 
1556, 1518, 1408, 1297, 1212, 1147, 1032, 652. HRMS (ESI+) m/z calcd for C12H17NO4Na (M+Na)
+: 
262.1055, found: 262.1067. 
 
Methyl 2-(2-methoxy-4-(1-(2,2,2-trifluoroacetamido)ethyl)phenoxy)acetate (18) 
Amine 17 (6.9 g, 28.6 mmol) was dissolved in dry CH2Cl2 (150 mL) and dry 
Et3N (20 mL). The mixture was cooled to 0 °C and TFAA (6 mL) was added 
dropwise. After stirring for 2 h, the mixture was extracted with CH2Cl2 (120 mL). 
The organic layer was washed with 1 M HCl (70 mL), 1 M NaOH (70 mL) and 
H2O (70 mL), dried over Na2SO4, filtered and concentrated in vacuo. Silica gel 
column chromatography (CH2Cl2:EtOAc 9:1) gave trifluoroacetamide 18 as a 
yellow solid (1.72 g, 5.09 mmol, 18%). RF 0.91 (CH2Cl2:EtOAc:Et3N 89:10:1). 
1H NMR (400 MHz, 
CDCl3) δ 6.85 (s, 1H), 6.82 (dd, J = 8.2, 1.6 Hz, 1H), 6.80-6.78 (m, 1H), 6.57-6.41 (m, 1H), 5.15-5.02 
(m, 1H), 4.69 (s, 2H), 3.88 (s, 3H), 3.79 (s, 3H), 1.57 (d, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ 206.4, 168.7, 149.3, 146.4, 135.3, 117.6, 113.8, 110.2, 65.8, 55.4, 51.7, 48.9, 30.4, 20.3. IR (neat, 
cm-1) ν 3317, 2954, 1757, 1705, 1549, 1515, 1260, 1204, 1148, 1070, 1031, 811. HRMS (ESI+) m/z 
calcd for C14H20F3N2O5 (M+NH4)
+: 353.1324, found: 353.1325. 
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Methyl 2-(2-methoxy-5-nitro-4-(1-(2,2,2-trifluoroacetamido)ethyl)phenoxy)acetate (19) 
Trifluoroacetamide 18 (1.2 g, 3.6 mmol) was slowly added to 70% HNO3 (30 
mL) at 0 °C. The mixture was stirred in the dark at 0 °C for 3 h. The reaction was 
quenched by pouring the mixture into H2O (270 mL). The slurry was cooled to 0 
°C for 2 h and filtered to give a light yellow solid. The solid was washed with 
H2O and recrystallized from CH3OH:H2O to afford 19 as a light yellow solid 
(0.930 g, 2.4 mmol, 68%). 1H NMR (400 MHz, CDCl3) δ 7.55 (s, 1H), 7.40-7.30 
(m, 1H), 6.92 (s, 1H), 5.59-5.46 (m, 1H), 4.76 (s, 2H), 3.98 (s, 3H), 3.83 (s, 3H), 1.62 (d, J = 7.1 Hz, 
3H). 13C NMR (75 MHz, CD3CN) δ 169.6, 146.9, 141.4, 134.3, 110.7, 110.6, 66.6, 57.1, 52.8, 46.9, 
21.1.IR (neat, cm-1) ν 3313, 1735, 1701, 1519, 1329, 1269, 1178, 884, 733, 642. HRMS (ESI+) m/z 
calcd for C14H15F3N2O7Na (M+Na)
+: 403.0733, found: 403.0729. 
 
2-(4-(1-Aminoethyl)-2-methoxy-5-nitrophenoxy)acetic acid (20) 
Acetamide 19 (1.01 g, 2.66 mmol) was dissolved in warm CH3OH (20 mL). 1 M 
NaOH (8 mL, 8 mmol) was added and the solution was heated to reflux in the dark 
overnight. The mixture was cooled to rt, neutralized with 1 M HCl and 
concentrated in vacuo. Ion exchange column chromatography was performed on a 
2 M NaOH column (Amberlite IRA 410 resin). The column was first flushed with 
H2O (8 bed volumes, pH was neutral). The crude product was applied as a 5% w/w solution in H2O at 
pH 9. The column was first flushed with H2O (8 bed volumes, until pH was neutral) and then with 2 
M AcOH (4 bed volumes). The acetic acid fractions that contained product were concentrated in 
vacuo, yielding amine 20 (658 mg, 2.43 mmol, 92%, light yellow solid). RF 0.56 (CHCl3:CH3OH:NH3 
60:45:20) . 
1H NMR (400 MHz, D2O) δ 7.58 (s, 1H), 7.26 (s, 1H), 5.17 (q, J = 6.8 Hz, 1H), 4.59 (s, 
1H), 4.03 (s, 1H), 1.74 (d, J = 6.8 Hz, 1H). 13C NMR (75 MHz, D2O) δ 174.8, 153.0, 146.5, 140.4, 
127.4, 109.4, 109.2, 66.9, 56.0, 45.7, 18.0. IR (neat, cm-1) ν 3390, 2958, 2846, 1601, 1524, 1411, 
1337, 1273, 1212, 1096, 1057, 819, 793. HRMS (ESI+) m/z calcd for C11H15N2O6 (M+H)
+: 271.0930, 
found: 271.0929. 
 
2-(4-(1-((((1R,8S,9s)-Bicyclo[6.1.0]non-4-yn-9-ylmethoxy)carbonylamino)ethyl)-2-methoxy-5-
nitrophenoxy)acetic acid (21) 
BCN succinimidyl carbonate (51 mg, 0.17 mmol) was dissolved in 1 mL CH3CN. Amine 20 (56 mg, 
0.21 mmol), H2O (0.25 mL) and Et3N (120 μL, 0.86 mmol) were added. The mixture was stirred in 
the dark for 10 min, H2O (2 mL) was added, CH3CN was evaporated and the pH of the aqueous 
solution was lowered to 1 with 1 M HCl. The mixture was extracted with CH2Cl2 (3 × 3 mL). The 
organic layers were dried over Na2SO4 and concentrated in vacuo. Silica gel column chromatography 
(CH2Cl2:CH3OH:AcOH 94:5:1) gave desired compound 21 (70 mg, 0.16 mmol, 91%). RF 0.45 
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(CH2Cl2:CH3OH:AcOH 66:33:1). 
1H NMR (400 MHz, CD3OD) δ 7.55 (s, 
1H), 7.19 (s, 1H), 5.42-5.28 (m, 1H), 4.74 (s, 2H), 4.09 (d, J = 8.0 Hz, 
2H), 3.95 (s, 3H), 2.28-2.07 (m, 6H), 1.63-1.51 (m, 2H), 1.48 (d, J = 6.9 
Hz, 3H), 1.37 (d, J = 6.6 Hz, 1H), 1.15 (d, J = 6.2 Hz, 1H), 1.00-0.84 (m, 
2H). 13C NMR (75 MHz, CD3OD) δ 175.7, 172.2, 158.2, 155.4, 147.1, 
141.4, 138.1, 111.3, 110.5, 67.0, 99.7, 64.5, 64.0, 57.0, 49.0, 30.0, 22.2, 
21.8, 20.9, 21.2, 18.8. IR (neat, cm-1) ν 3360, 2976, 2924, 2526, 1705, 
1580, 1515, 1450, 1376, 1450, 1377, 1333, 1273, 1212, 1178, 1074, 1009. HRMS (ESI+) m/z calcd 
for C22H26N2O8Na (M+Na)
+: 469.1587, found: 469.1586. 
 
(9H-Fluoren-9-yl)methyl tert-butyl ((ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))dicarbamate 
(23) 
1,8-diamino-3,6-dioxaoctane 22 (4.93 mL, 33.7 mmol) was 
dissolved in 1,4-dioxane (25 mL). Boc anhydride (1.43 g, 6.58 
mmol) was dissolved in 1,4-dioxane (8 mL) and added dropwise. 
The mixture was stirred for 2 h and concentrated in vacuo. H2O (40 mL) was added and the mixture 
was extracted with CH2Cl2 (3 × 15 mL). The combined organic layers were washed with brine (3 × 
10 mL), dried over Na2SO4 and concentrated in vacuo, giving the mono-boc protected product as a 
colourless oil (1.42 g). The crude product (1.20 g) was dissolved in 1,4-dioxane (17 mL) and H2O (15 
mL) was added. The pH was lowered to 8.6 with 1 M HCl. Fmoc-OSu (2.544 g, 7.92 mmol) was 
dissolved in 1,4-dioxane (13 mL) and added to the reaction mixture. The pH dropped to 6.5 and was 
adjusted to 8 by use of 1 M NaOH. The reaction mixture was stirred for 1 h at rt and H2O (32 mL) 
was added, resulting in the formation of a white precipitate. The solvent was evaporated and the 
product was extracted with CH2Cl2 (3 × 40 mL). The organic layers were washed with brine (40 mL) 
and dried over Na2SO4. Silica gel column chromatography (EtOAc:heptane 1:2 to 3:1) gave 23 as a 
colourless oil (1.98 g, 4.20 mmol, 74% over two steps). RF 0.21 (EtOAc:heptane 1:1) . 
1H NMR (400 
MHz, CDCl3) δ 7.82-7.72 (m, 2H), 7.60 (d, J = 7.3 Hz, 2H), 7.43-7.35 (m, 2H), 7.31 (td, J = 7.5, 1.2 
Hz, 2H), 5.35 (s, 1H), 5.00 (s, 1H), 4.41 (d, J = 6.5 Hz, 2H), 4.22 (t, J = 6.9 Hz, 1H), 3.65-3.59 (m, 
4H), 3.53 (t, J = 5.2 Hz, 4H), 3.44-3.38 (m, 2H), 3.35-3.27 (m, 2H), 1.47-1.40 (m, 9H). 13C NMR (75 
MHz, CDCl3) δ 156.5, 156.0, 144.0, 141.3, 127.7, 127.1, 125.1, 112.0, 79.3, 70.3, 66.6, 53.5, 47.3, 
41.0, 40.4, 28.4. IR (neat, cm-1) ν 3352, 2976, 2868, 1697, 1515, 1442, 1364, 1247, 1165, 1100, 754, 
733. HRMS (ESI+) m/z calcd for C26H34N2O6Na (M+Na)
+: 493.2315, found: 493.2315. 
 
BCN α-methyl-6-nitroveratryl ethylene glycol linker (25) 
Linker 23 (500 mg, 1.1 mmol) was dissolved in 2 M HCl-dioxane (4 mL) at 0 °C and stirred for 17 h 
under nitrogen. The solvent was removed in vacuo (470 mg). The crude product (54 mg, 0.133 mmol) 
Chapter 5 
 
- 126 - 
 
was dissolved in CH2Cl2 (1 mL) and Et3N (19 μL, 0.136 mmol) 
was added. The mixture was stirred for 1.5 h at rt. BCN α-
methyl-6-nitroveratryl acid 21 (33 mg, 0.074 mmol), n-
hydroxybenzotriazole (0.5 mg, 3.7 µmol) and EDC (20 mg, 
0.0126 mmol) were added, resulting in a yellow suspension. The 
reaction mixture was stirred for 16 h and directly loaded onto a 
silica column. Silica gel column chromatography 
(CH2Cl2:CH3OH 100:0→99:1→97.5:2.5→9:1) gave the desired 
product as a yellow solid (43 mg, 0.054 mmol, 73%). RF  0.75 (CH2Cl2:CH3OH 4:1).  
1H NMR (400 
MHz, CDCl3) δ 7.74 (d, J = 7.4 Hz, 2H). 7.57 (d, J = 7.3 Hz, 2H), 7.38 (s, 2H), 7.34 (dt, J = 15.0, 7.0 
Hz, 2H), 4.62-4.46 (m, 1H), 4.46-4.33 (m, 1H), 4.25-4.15 (m, 1H), 4.14-3.99 (m, 1H), 3.92 (s, 2H), 
3.74-3.25 (m, 8H), 2.40-2.04 (m, 6H), 1.83-1.70 (m, 2H), 1.62-1.41 (m, 3H), 1.01-0.76 (m, 2H). 13C 
NMR (75 MHz, CDCl3) δ 167.6. 156.6, 155.8, 154.1, 145.6, 144.0, 141.4, 140.6, 127.8, 127.1, 125.1, 
98.9, 120.1, 77.2, 70.4, 69.9, 69.3, 66.7, 63.3, 56.4, 47.4, 41.0, 39.0, 29.1, 21.5, 20.2, 17.7. IR (neat, 
cm-1) ν 3404, 2924, 2859, 1705, 1645, 1519, 1442, 1273, 1122. HRMS (ESI+) m/z calcd for 
C43H51N4O16 (M+H)
+: 799.3554, found: 799.3551.  
 
((5aR,6S,6aS)-1-Benzyl-1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d][1,2,3]triazol-
6-yl)methyl (1-(4-((2,13-dioxo-6,9-dioxa-3,12-diazatetradecyl)oxy)-5-methoxy-2-nitrophenyl) 
ethyl)carbamate (44) 
Fmoc protected linker 25 (31 mg, 0.039 mmol) was dissolved 
in 1,4-dioxane (1.5 mL). 0.1 M NaOH was added (4.5 mL). 
The reaction mixture was stirred for 2 h rt and 1 h at 50 °C. 
TLC indicated incomplete deprotection, so 1.0 M NaOH (0.5 
mL) was added and the reaction mixture was stirred for 1.5 h 
at 50 °C. 1 M HCl was added dropwise to neutralize the 
solution to pH 7 and the solvent was removed in vacuo to give 
crude amine 43. The crude product (11 mg, 0.020 mmol) was 
suspended in 1,4-dioxane (600 µL) and benzyl azide (7 mg, 6.5 µL, 0.052 mmol) was added. The 
reaction mixture was stirred at rt for 40 min, until LC-MS indicated complete conversion to the 
product. 0.1 M MOPS buffer pH 7.5 (600 µL) and acetic anhydride (2 mg, 2 µL, 0.021 mmol) were 
added and the reaction mixture was stirred at rt for 30 min. The mixture was poured into H2O (2 mL) 
and aqueous saturated NH4Cl solution (0.8 mL) and the product was extracted with CH2Cl2 (3 × 3 
mL). The combined organic phases were washed with brine (6 mL), dried (Na2SO4), filtered and 
evaporated in vacuo. Purification by silica gel column chromatography (CH2Cl2:CH3OH 
100:0→99:1→9:1) gave the desired product as a yellow oil (9 mg, 0.012 mmol, 62% over 2 steps). RF  
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0.49 (CH2Cl2:CH3OH 4:1)  
1H NMR (400 MHz, CDCl3) δ 7.77-7.01 (m, 8H), 5.52-5.35 (m, 4H), 4.55 
(s, 2H), 4.29-3.99 (m, 2H), 3.96 (s, 3H), 3.60-3.36 (m, 12H), 3.15-3.02 (m, 1H), 2.97-2.83 (m, 1H), 
2.80-2.67 (m, 1H), 2.58-2.45 (m, 1H), 2.30-2.00 (m, 2H), 1.96 (s, 3H), 1.68-0.81 (m, 7H). 13C NMR 
(75 MHz, CDCl3) 170.5, 167.7, 155.8, 154.1, 145.6, 145.2, 140.6, 135.4, 133.1, 129.1, 128.3, 127.0, 
112.4, 110.2, 70.4, 70.0, 69.9, 69.4, 63.1, 56.5, 53.6, 52.1, 48.5, 39.4, 39.1, 31.9, 31.7, 29.8, 29.5, 
29.4, 29.3, 29.2, 29.1, 26.4, 26.1, 23.3, 22.8, 22.7, 22.5, 22.4, 22.3, 21.6, 19.7, 19.6, 19.4, 19.3, 17.5, 
14.2.  IR (neat, cm-1) ν 3292, 2926, 1659, 1519, 1270, 1073, 760. HRMS (ESI+) m/z calcd for 
C37H50N7O10 (M+H)
+: 752.3619, found: 752.3594. 
 
5.10.3 Synthesis of the hydroxymethylnaphthol-based photocleavable linker 
     
6-(Hydroxymethyl)naphthalene-1,7-diol (28) 
A brown solution of 3,5-dihydroxy-2-naphthoic acid 27 (2.061 g, 10.1 mmol) in 
anhydrous THF (16 mL), was added dropwise to a stirred grey suspension of 
LiAlH4 (0.773 g, 20.4 mmol) in anhydrous THF (20 mL) at 0 °C and under 
nitrogen atmosphere. The reaction mixture was heated to 55 °C for 75 min. The 
reaction was quenched with 5% HCl until the pH was 3. The product was extracted using EtOAc (3 × 
100 mL). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
The product was absorbed on silica. Silica gel column chromatography (EtOAc:heptane 
1:9→1:4→2:3→1:1), gave desired diol 28 as a yellow solid (1.626 g, 8.55 mmol, 85%). RF 0.66 
(EtOAc:heptane 4:1, 1% acetic acid) . 
1H NMR (300 MHz, CD3OD) δ 9.41-9.38 (m, 1H), 7.69 (s, 
19H), 7.46 (s, 17H), 7.23 (d, J = 8.3 Hz, 20H), 7.04 (dd, J = 8.2, 7.5 Hz, 19H), 6.72 (dd, J = 7.4, 1.0 
Hz, 19H), 4.80 (d, J = 0.8 Hz, 93H), 4.07 (q, J = 7.1 Hz, 1H), 1.99 (s, 2H), 1.21 (t, J = 7.1 Hz, 2H). 
13C NMR (75 MHz, CD3OD) δ 153.8, 152.9, 131.4, 131.2, 127.4, 126.9, 124.1, 120.0, 108.8, 104.6, 
61.44. IR (neat, cm-1) ν 3309, 1640, 1606, 1528, 1459, 1390, 1273, 1187, 1139, 1022, 979, 858, 784. 
GCMS (EI+) m/z calcd for C11H8O2 (M-H2O): 172.0524, found: 172.0532. 
 
2,2-Dimethyl-4H-naphtho[2,3-d][1,3]dioxin-9-ol (29) 
2,2-dimethoxypropane (0.97 mL, 7.9 mmol) and p-toluenesulfonic acid (24 mg, 
0.13 mmol)  were added to a yellow solution of diol 28 (0.503 g, 2.64 mmol) in 
acetone (25 mL). The reaction was stirred for 22 h at rt and the reaction mixture 
was neutralized using saturated aqueous NaHCO3 solution, resulting in a white 
precipitate. The solvent was removed in vacuo and H2O (15 mL) was added. The product was 
extracted with EtOAc (3 × 25 mL). The combined organic layers were dried over MgSO
4
 and 
concentrated in vacuo, resulting in a brown oil. Silica gel column chromatography (EtOAc:heptane 
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1:9→1:4→2:1) gave desired acetonide 29 as a light orange solid (0.500 g, 2.17 mmol, 82%). RF 0.72 
(EtOAc:heptane 1:1). 1H NMR (400 MHz, acetone-d6) δ 8.95 (s, 1H). 7.60 (s, 1H), 7.46 (s, 1H), 7.26 
(d, J = 8.3 Hz, 1H), 7.17-7.12 (m, 1H), 6.86 (dd, J = 7.4, 0.9 Hz, 1H), 5.02 (d, J = 1.3 Hz, 2H), 1.55 
(s, 7H). 13C NMR (75 MHz, acetone-d6) δ 206.4, 152.9, 150.1, 130.9, 126.3, 124.8, 124.2, 122.6, 
119.5, 108.4, 107.2, 100.4, 61.6, 29.8, 25.2. IR (neat, cm-1) ν 3360, 2980, 1610, 1515, 1463, 1372, 
1333, 1264, 1182, 1130, 1009, 958, 867, 836, 780, 746, 633. GCMS (EI+) m/z calcd for C14H14O3: 
230.0937, found: 230.0943. 
 
9-(3-Chloropropoxy)-2,2-dimethyl-4H-naphtho[2,3-d][1,3]dioxine (30) 
K2CO3 (4 mg, 0.68 mmol) was added to an orange solution of acetonide 29 (51 
mg, 0.22 mmol) in acetone (3.5 mL). 1-Bromo-3-chloropropane (28 μL, 0.28 
mmol) was diluted in acetone (0.5 mL) and the solution was added dropwise to the 
reaction mixture, which was refluxed for 19 h. The mixture was cooled to rt, 
filtered and concentrated in vacuo. Silica gel column chromatography (EtOAc:heptane 1:99) gave 
chloride 30 as a colourless oil (53 mg, 0.17 mmol, 78%). RF 0.86 (CH2Cl2). 
1H NMR (300 MHz, 
CDCl3) δ 7.63 (s, 1H), 7.43 (s, 1H), 7.32 (d, J = 8.3 Hz, 1H), 7.29-7.18 (m, 1H), 6.75 (d, J = 7.5 Hz, 
1H), 5.07 (s, 2H), 4.26 (t, J = 5.7 Hz, 2H), 3.85 (t, J = 6.4 Hz, 2H), 2.44-2.23 (m, 2H), 1.62 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ 153.5, 149.6, 129.6, 126.2, 123.9, 123.3, 121.6, 120.0, 106.9, 104.5, 
100.0, 77.2, 64.5, 61.3, 41.9, 32.6, 25.1. IR (neat, cm-1) ν 2989, 2868, 1645, 1606, 1571, 1506, 1450, 
1385, 1227, 1260, 1225, 1200, 1130, 1053, 958, 893, 836, 784, 737, 603. GCMS (EI+) m/z calcd for 
C17H19ClO3: 306.1023, found: 306.1021. 
 
9-(3-Azidopropoxy)-2,2-dimethyl-4H-naphtho[2,3-d][1,3]dioxine (33)  
NaN3 (83 mg, 1.3 mmol) and TBAI (68 mg, 0. 19 mmol) were added to a 
solution of 30 (249 mg, 0.81 mmol) in DMF (10 mL) and stirred overnight at 75 
°C. The solvent was removed in vacuo, diethyl ether (50 mL) was added and the 
solution was washed with brine (3 × 50 mL), dried over MgSO4 and 
concentrated in vacuo, giving the crude azide (234 mg, 0.75 mmol, 92%). To a solution of crude 
product (125 mg, 0.40 mmol) in EtOAc (2.5 mL) was added 10% (w/w) Pd/C (13 mg) under nitrogen 
atmosphere. The mixture was stirred at rt for 18 h under H2 (1 atm). The mixture was filtered over 
celite and the filtrate was concentrated in vacuo to afford crude amine 32, which was suspended in a 
mixture of 10% aqueous Na2CO3 solution (1 mL) and 1,4-dioxane (0.5 mL). Fmoc-OSu (59 mg, 0.18 
mmol) was dissolved in 1,4-dioxane (1 mL) by gentle heating and the solution was added dropwise 
with vigorous stirring. The reaction mixture was stirred at rt for 19 h. H2O (20 mL) was added and the 
product was extracted with CH2Cl2 (3 × 20 mL). The organic layers were washed with brine (50 mL), 
dried over MgSO4 and concentrated in vacuo. The product was absorbed onto Hydromatrix SD. Silica 
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gel column chromatography (EtOAc:hepane 1:9→2:3) gave desired compound 33 (119 mg, 0.23 
mmol, 54% over three steps). RF 0.04 (EtOAc:heptane 1:9). 
1H NMR (400 MHz, CDCl3) δ 7.76 (d, J 
= 7.6 Hz, 2H), 7.65 (s, 1H), 7.59 (d, J = 6.7 Hz, 2H), 7.43 (s, 1H), 7.42-7.19 (m, 6H), 5.18 – 5.09 (m, 
1H), 5.04 (s, 2H), 4.41 (d, J = 7.0 Hz, 2H), 4.24 (t, J = 6.9 Hz, 1H), 4.18 (t, J = 5.5 Hz, 2H), 3.59-3.45 
(m, 2H), 2.19-2.10 (m, 2H), 1.54 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 156.6, 153.6, 149.7, 144.1, 
141.4, 129.6, 127.8, 127.2, 126.2, 125.2, 123.8, 123.4, 121.7, 120.1, 106.9, 104.5, 100.0, 66.8, 61.3, 
65.9, 47.4, 38.9, 29.6, 25.0. IR (neat, cm-1) ν 3326, 3062, 2941, 1714, 1601, 1511, 1446, 1381, 1260, 
1200, 1130, 1091, 1053, 893, 836, 741. HRMS (ESI+) m/z calcd for C32H31NO5Na (M+Na)
+: 
532.2112, found: 532.2091. 
 
(9H-Fluoren-9-yl)methyl 3-(7-hydroxy-6-(hydroxymethyl)naphthalen-1-yloxy)propylcarbamate 
(34) 
Acetonide 33 (633 mg, 1.240 mmol) was suspended in glacial acetic acid (50 
mL) and H2O (12.5 mL). The solution was heated to 60 °C for 2 h followed by 
70 °C for 10 min. Lyophilization gave desired diol 34 as an off-white solid (565 
mg, 1.24 mmol, quant). RF 0.29 (EtOAc:heptane 1:1). 
1H NMR (400 MHz, 
CD3OD) δ 7.75 (d, J = 7.5 Hz, 2H). 7.72 (s, 1H), 7.60 (d, J = 7.5 Hz, 2H), 7.40-7.05 (m, 6H), 7.52 (s, 
1H), 6.76 (d, J = 7.6 Hz, 1H), 4.79 (s, 3H), 4.34 (d, J = 6.8 Hz, 3H), 4.25-3.96 (m, 3H), 3.49-3.35 (m, 
2H), 2.16-2.01 (m, 2H), 1.99 (s, 2H). 13C NMR (75 MHz, CDCl3) δ 156.8, 153.7, 153.4, 144.0,141.4, 
129.6, 127.8, 127.2, 125.2, 123.6, 120.5, 120.1, 105.6, 105.5, 66.9, 66.0, 64.2, 47.4, 38.8, 29.6. IR 
(neat, cm-1) ν 3335,1698, 1524, 1451, 1264, 1078, 866, 740.  
 
(9H-Fluoren-9-yl)methyl (3-((7-((tert-butyldimethylsilyl)oxy)methyl)naphthalen-1-yl)oxy) 
propyl)carbamate (35) 
Diol 34 (100 mg, 0.220 mmol) was dissolved in dry DMF (2 mL) and 
imidazole (90 mg, 1.32 mmol), DMAP (2.7 mg, 0.022 mmol) and TBDMSCl 
(99 mg, 0.660 mmol) were added. The mixture was stirred for 16 h at rt and 
the reacion mixture was poured into 1 M HCl (20 mL). The product was 
extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (15 mL), 
dried over Na2SO4 and filtered, and the solvent was removed in vacuo. Purification by silica gel 
column chromatrography gave 35 (112 mg, 0.160 mmol, 73%) as a wite solid. RF 0.73 
(EtOAc:heptane 1:1). 1H NMR (400 MHz, CDCl3) δ 7.86 (s, 1H), 7.75 (d, J = 7.6 Hz, 2H), 7.56 (d, J 
= 7.5 Hz, 2H), 7.51 (s, 1H), 7.42-7.36 (m, 3H), 7.29-7.22 (m, 3H), 6.76 (d, J = 7.6 Hz, 1H), 4.99 (bs, 
1H), 4.89 (s, 2H), 4.41 (d, J = 6.9 Hz, 2H), 4.22-4.17 (M, 3H), 3.51 (q, J = 6.3 Hz, 2H), 2.15 (qn, J = 
6.0 Hz, 2H), 1.04 (s, 9H), 1.00 (s, 9H), 0.29 (s, 6H), 0.15 (s, 6H). ). 13C NMR (75 MHz, CDCl3) δ 
156.6, 153.4, 150.8, 144.1, 141.5, 134.3, 130.3, 127.8, 127.2, 125.4, 125.2, 123.6, 120.5, 120.1, 
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107.3, 104.7, 66.7, 65.5, 61.3, 47.5, 38.5, 29.6, 26.2, 25.9, 18.7, 18.5, -4.1, -5.2. IR (neat, cm-1) ν 
2954, 2929, 2857, 1705, 1448, 1250, 1095, 908, 836, 729. HRMS (EI+) m/z calcd for C41H55NO5Si2 
(M+●): 697.3619, found: 697.3645. 
 
9H-Fluoren-9-yl)methyl (3-((7-((tert-butyldimethylsilyl)oxy)-6-(hydroxymethyl)naphthalen-1-yl) 
oxy)propyl)carbamate (36) 
Compound 35 (900 mg, 1.290 mmol) was dissolved in 5% (v/v) H2O in CH3CN 
(45 mL) and cerium trichloride heptahydrade (192 mg, 5.160 mmol) was added. 
The reaction mixture was stirred at 80 °C for 22 h followed by 72 h at rt to give 
a clear, brown solution. H2O (200 mL) was added and the product was extracted 
with EtOAc (3 × 150 mL). The combined organic layers were washed with brine (400  mL), dried 
over Na2SO4, filtered and evaporated in vacuo. The product was dissolved in CH2Cl2 and absorbed on 
hydromatrix. The product was purified by silica gel column chromatrography (EtOAc: heptane 
5:1→3:1→2:1) to give the desired product as a white solid (640 mg, 1.096 mmol, 85%). RF  0.62 
(EtOAc:heptane 1:1). 1H NMR (400 MHz, CDCl3) δ 7.76-7.74 (m, 3H), 7.59 (s, 1H), 7.57 (d, J = 7.5 
Hz, 2H), 7.41 (s, 1H), 7.38 (d, J = 7.4 Hz), 7.30-7.32 (m, 3H), 6.77 (d, J = 7.6 Hz, 2H), 5.04 (bs, 1H), 
4.83 (d, J = 6.3 Hz, 2H), 4.43, (2, J = 6.8 Hz, 2H), 4.22-4.14 (m, 3H), 3.51 (q, J = 6.4 Hz, 2H), 2.14 
(qn, J = 6.4 Hz, 2H), 1.06 (s, 9H), 0.34 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 156.6. 153.3, 151.7, 
144.0, 141.4, 133.3, 130.1, 127.8, 127.1, 126.0, 125.1, 124.0, 120.3, 120.1, 108.0, 105.1, 66.7, 65.4, 
62.4, 47.4, 38.4, 29.6, 25.9, 18.4, -4.1. IR (neat, cm-1) ν 2930, 2858, 1703, 1449, 1250, 1079, 907, 
838, 728. 
 
(5-(3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)propoxy)-3-((tert-butyldimethylsilyl)oxy) 
naphthalen-2-yl)methyl 1-((1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-yl)-3,14-dioxo-2,7,10-trioxa-4,13-
diazaoctadecan-18-oate (38)  
BCN-3,14-dioxo-2,7,10-trioxa-4,13-diazo-
octadecan-18-oic acid 37 (144 mg, 0.328 
mmol) was dissolved in CH2Cl2 (6 mL) and 
compound 36 (160 mg, 0.274 mmol), EDC 
(79 mg, 0.411 mmol) and DMAP (3.3 mg, 0.027 mmol) were added. The reaction mixture was stirred 
at rt for 18 h, CH2Cl2 (15 mL) was added and washed with brine (15 mL). The organic layer was 
dried (Na2SO4), filtered and evaporated in vacuo. Purification by silica gel column chromatorgraphy 
(CH2Cl2:CH3OH 1:0→99:1→97.5:2.5) to give desired product 38 as a colourless oil (196 mg, 0.195 
mmol, 71%). RF 0.75 (CH2Cl2:CH3OH 4:1). 
1H NMR (400 MHz, CDCl3) δ 7.75-7.73 (m, 3H), 7.58 
(s, 1H), 7.56 (d, J = 7.6 Hz, 2H), 7.39-7.36 (m, 3H), 7.29-7.22 (m, 3H), 6.77 (d, J = 6.8 Hz, 1H), 6.06 
(bs, 1H), 5.27 (s, 2H), 5.06 (bs, 1H), 4.41 (d, J = 6.8 Hz, 2H), 4.21-4.12 (m, 5H), 3.57 (s, 4H), 3.52-
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3.34 (m, 10H), 2.45 (t, J = 7.2 Hz, 2H), 2.30-2.11 (m, 8H), 2.00 (qn, J = 7.3, 2H), 1.59-1.50 (m, 2H), 
1.37-1.28 (m, 1H), 1.03 (s, 9H), 0.94-0.89 (m, 2H), 0.31 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 173.1, 
172.3, 156.9, 156.5, 153.3, 151.6, 144.0, 141.4, 129.8, 128.8, 128.4, 127.7, 127.1, 126.4, 125.1, 
124.0, 120.3, 120.0, 108.0, 105.3, 98.9, 70.3, 70.1, 69.9, 66.6, 65.4, 62.9, 62.5, 47.4, 40.8, 39.3, 38.3, 
35.5, 33.4, 29.6, 29.1, 25.9, 21.5, 21.0, 20.2, 18.4, 17.8, -4.1. IR (neat, cm-1) ν 2931, 2858, 1708, 
1519, 1451, 1253, 1143, 1082, 906, 840, 726, 647. HRMS (ESI+) m/z calcd for C57H74N3O11Si1 
(M+H)+: 1004.5093, found: 1004.5105.  
 
(5-(3-Aminopropoxy)-3-hydroxynaphthalen-2-yl)methyl 1-((1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-
yl)-3,14-dioxo-2,7,10-trioxa-4,13-diazaoctadecan-18-oate (39) 
Compound 38 (65 mg, 0.065 mmol) was 
dissolved in dry THF (2 mL) and TBAF (1 
M in THF, 388 µL, 0.388 mmol) was added 
dropwise. The reaction mixture was stirred 
at rt for 10 min and poured into H2O (5 mL). 
The product was extracted with EtOAc (3 × 5 mL). The combined organic layers were wahed with 
brine (10 mL), dried over Na2SO4 and filtered and the solvents were removed in vacuo. Purification 
by silica gel column chromatography (CH2Cl2:CH3OH 1:0→9:1→4:1→2:1) gave the desired product 
as a yellow oil (23 mg, 0.034 mmol, 53%). RF 0.26 (CH2Cl2:CH3OH 4:1). 
1H NMR (400 MHz, 
CDCl3) δ 7.67 (s, 1H), 7.52 (s, 1H), 7.22 (d, J = 8.4 Hz, 1H), 7.02 (t, J = 7.9 Hz, 1H), 6.54 (bs, 1H), 
6.41 (d, J = 7.7 Hz, 1H), 5.38 (bs, 1H), 5.15 (s, 2H), 4.08 (d, J = 7.7 Hz, 2H), 3.91 (bs, 2H), 3.51 (s, 
4H), 3.39-3.25 (m, 10H), 2.36-2.13 (m, 14 H), 1.90 (qn, J = 7.0 Hz, 2H), 1.54-1.45 (m, 2H), 1.30-1.23 
(m, 1H), 0.90-0.84 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 173.4, 173.0, 157.1, 153.3, 152.7, 129.3, 
129.0, 126.5, 125.3, 123.3, 120.7, 105.5, 104.4, 98.9, 70.2, 69.9, 65.8, 63.0, 62.5, 40.9, 39.4, 38.8, 
35.3, 33.5, 29.1, 28.5, 21.5, 21.2, 20.2, 17.9. IR (neat, cm-1) ν 3402, 2929, 2874, 1699, 1640, 1530, 
1455, 1264, 1143, 1082, 734. HRMS (ESI+) m/z calcd for C36H50N3O9 (M+H)
+: 668.3547, found: 
668.3527.   
 
(5-(3-Acetamidopropoxy)-3-hydroxynaphthalen-2-yl)methyl 1-((5aR,6S,6aS)-1-benzyl-1,4,5,5a, 
6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d][1,2,3]triazol-6-yl)-3,14-dioxo-2,7,10-trioxa-4, 
13-diazaoctadecan-18-oate (49) 
Amine 39 (5 mg, 7.5 µmol) was suspended in 1,4-dioxane (0.2 mL) and benzyl azide (3 mg, 2.8 µL, 
22.5 µmol) was added. The reaction mixture was stirred at rt for 40 min and 0.1M MOPS buffer pH 
7.5 (0.2 mL) was added. Acetic anhydride (0.76 mg, 0.7 µL, 7.5 µmol in 5 µL 1,4-dioxane) was 
added and the reaction mixture was stirred for 20 h at rt. The reaction mixture was poured into H2O (1 
mL) and aqueous saturated NH4Cl solution (0.4 mL). The product was extracted with CH2Cl2 (3 × 1.5 
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mL) and the combined organic layers 
were washed with brine (1 × 3 mL), 
dried (Na2SO4), filtered and 
evaporated in vacuo to give the 
desired compound in 81% yield (5 mg, 
6.1 µmol). 1H NMR (400 MHz, 
CDCl3) δ 7.73 (s, 1H), 7.68 (s, 1H), 
7.41-7.28 (m, 4H), 7.20-7.16 (m, 1H), 7.09 (d, J = 8.0 Hz, 1H), 6.46 (bs, 1H), 6.32 (bs, 1H), 5.46 (s, 
2H), 5.30 (s, 2H), 4.16 (t,  J = 5.7 Hz, 2H), 4.08-3.93 (m, 2H), 3.70 (s, 4H), 3.69-3.29 (m, 14H), 3.09-
3.02 (m, 1H), 2.90-2.82 (m, 1H), 2.73-2.66 (m, 1H), 2.50-2.45 (m, 1H), 2.40 (t, J = 6.7 Hz, 2H), 2.18 
(t, J = 7.1 Hz, 2H), 2.11 (qn, J = 6.1 Hz, 2H), 1.98 (s, 3H), 1.99-1.95 (m, 2H), 1.80-158 (m, 4H), 
1.46-1.33 (m, 1H), 0.89-0.86 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 173.7, 172.6, 170.9, 166.8, 
157.0, 153.2, 145.2, 130.7, 129.4, 129.1, 128.3, 127.0, 125.1, 123.6, 120.5, 105.9, 105.3, 70.3, 67.3, 
66.1, 63.2, 62.8, 61.7, 52.2, 40.9, 39.3, 37.3, 35.4, 33.5, 32.0, 31.7, 29.8, 29.4, 29.1, 26.4, 26.0, 23.4, 
23.2, 22.8, 22.5, 22.3, 21.6, 19.6, 19.3, 17.5, 14.2. IR (neat, cm-1) ν 3306, 2925, 2856, 1712, 1654, 
1546, 1454, 1263, 1142, 1081, 734. HRMS (ESI+) m/z calcd for C45H59N6O10 (M+H)
+: 843.4293, 
found: 843.4295. 
 
  
Nitroveratryl-based photocleavable linker    
Immobilizaton on Sepharose beads: CNBr-activated SepharoseTM 4B beads (GE Healthcare, 33 mg) 
were washed by addition of 1 mM HCl (0.5 mL), centrifugation for 2 min at 3000 rpm and careful 
removal of the supernatant. This process was repeated 10 times. Coupling buffer (0.5 mL, 0.1 M 
NaHCO3 pH 8.3, containing 0.5 M NaCl) was added and the sample was centrifuged for 2 min at 
3000 rpm, after which the supernatant was removed carefully. An 8.5 mM solution of amine 26 in 
50% CH3OH was added to the beads (0 μL for the negative control, 12 μL for the experiment) and 
coupling buffer was added to a total amount of 120 μL. Samples where incubated for 1 h at rt while 
rotating end-over-end, centrifuged for 5 min at 3000 rpm and the supernatant was removed. Coupling 
buffer (500 μL) was added, the sample was mixed, centrifuged for 5 min and the supernatant was 
removed. 0.1 M Tris-HCl buffer pH 8 containing 0.5 M NaCl (500 μL) was added, the sample was 
incubated for 1.5 h while rotating end-over-end, centrifuged for 5 min at 3000 rpm and the 
supernatant was removed. The sample was washed by addition of 0.1 M acetate buffer pH 4.0 
containing 0.5 M NaCl (500 μL), centrifugation for 2 min. The supernatant was removed and 0.1 M 
Tris-HCl pH 8 containing 0.5 M NaCl (500 μL) was added, the sample was centrifuged for 2 min and 
5.10.4 Immobilization and evaluation of SPAAC  
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the supernatant was removed. This cycle was repeated 3 times. The functionalized beads were stored 
in 20% ethanol in H2O (500 μL) at 4 °C.  
SPAAC with azido-FITC 40 and fluorescence microscopy: Azido-FITC derivative 40 (5 mg, 8.5 
μmol) was dissolved in 20% CH3CN in H2O (0.5 mL), CH3CN (275 μL) and PBS buffer (25 μL), 
yielding a 10 mM solution of the fluorophore. The solution was diluted 10 times in PBS buffer and 50 
μL of the 1 mM solution was added to 50 μL beads (either functionalized with linker 26 or negative 
control). After incubation for 15 min, 5 µL of the beads were taken and washed with MilliQ (5 × 10 
μL). The supernatant was removed and 2 μL of the beads were combined with 10 μL MilliQ on a 
glass slide for fluorescence microscopy.  
 
General protocol for immobilization of both linkers on UltraLink Biosupport resin 
Compound 26 and 39 were attached to Thermo Scientific UltraLink Biosupport according to the 
instructions of the manufacturer. Briefly, 0.2 (39) or 2 mg (26 and 39) linker was dissolved in 0.1 M 
MOPS buffer pH 7.5:1,4-dioxane 1:1 (300 µL) and added to the dry beads (10 mg). After brief 
vortexing, the mixture was shaken at rt for 1 h. The sample was centrifuged at 2000 × g for 5 min to 
pellet beads and the supernatant was removed. Unreacted sites were quenched with 1.0 M TRIS 
buffer pH 8 (800 µL) for 2.5 h. After centrifugation the supernatant was removed and the beads were 
washed 15 min at rt with successively PBS buffer (1 × 800 µL), 1.0 M NaCl solution (1 × 800 µL) 
and PBS buffer (2 × 800 µL). The supernatant was removed and BCN functionalized beads were used 
for SPAAC immediately after preparation.  
 
SPAAC of 7-hydroxyazidocoumarin with hydroxymethylnaphthol-based linker coupled beads 
To the entire amount (10 mg dry weight) of hydroxymethylnaphthol-based linker coupled beads 
(coupling with 0.2 and 2 mg linker) was added a 1 mM solution of 7-hydroxyazidocoumarin 41 in 
CH3OH:0.1 M MOPS buffer pH 7.5 1:1 (300 µL) and the mixture was shaken on at rt. After 
centrifugation the supernatant was removed and the beads were washed with PBS buffer (2 × 800 µL) 
for 15 min at rt. PBS buffer (800 µL) was added and 10 µL of both resulting suspensions was used for 
confocal microscopy.  
 
 
Nitroveratryl-based photocleavable linker 
Photocleavage of linker 44 in solution: Triazole 44 (1 mg, 1.3 µmol) was dissolved in CH3CN:H2O 
1:1 (1 mL) and placed in a quartz tube. The reaction mixture was irradiated at 350 nm at rt, samples 
(30 µL) were taken and analyzed by LC-MS (Figure 5.9). 
5.10.5 Photocleavage  
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Figure 5.9. LC-MS spectra of the reaction mixture after photocleavage of linker 44. From top to bottom: total 
scan PDA after 40 min irradiation; total scan PDA after 90 min irradiation; ESI mass spectrum of peak 1 in total 
PDA scan (MW ketone photocleavage product 46 = 425.2 Da); ESI mass spectrum of peak 2 in total PDA scan 
(MW triazole photocleavage product 45 = 326.4 Da); ESI mass spectrum of peak 3 in total PDA scan (MW starting 
material 44 = 751.8 Da).  
 
Photocleavage of linker-coupled beads: to the linker-coupled beads (see section 5.9.4) was added 800 
µL PBS buffer and the suspension was divided in 2. One part was placed in a quartz tube and 
irradiated at 350 nm at rt and samples (50 µL) were taken after 15, 30, 60, 90 and 120 min. Samples 
were centrifuged before the supernatant was analyzed by LC-MS.  
Time 
1. 
2. 
3. 
1. 
2. 
3. 
1. 2. 
3. 
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Hydroxymethylnaphthol-based photocleavable linker 
Photocleavage of azidocoumarin-functionalized beads: The bead solution obtained after reaction with 
7-hydroxyazidocoumarin was placed in a quartz tube in a Rayonet mini reactor and irradiated with 
350 nm light at rt. Bead samples (75 µL) were taken every 30 min, centrifuged for 5 min, washed 
with PBS (2 × 75 µL) for 15 min at rt and 10 µL was analyzed by confocal microscopy.  
Coupling and photocleavage of photostable BCN-derivative 42: BCN-amine 42 (1.4 mg, 4.3 µmol) 
and 7-hydroxyazidocoumarin 41 (1.0 mg, 4.8 µmol) were dissolved in 1,4-dioxane:0.1 M MOPS 
buffer pH 7.5 1:1 (350 µL) and stirred at rt for 50 min until LC-MS showed complete disappearance 
of amine 42. 300 µL of this solution (corresponding to 2 mg final product) was added to 10 mg 
Thermo Scientific UltraLink Biosupport and coupled according to the protocol used for the 
photocleavable linkers. Photocleavage of the resulting 7-hydroxyazidocoumarin-coupled beads was 
also performed at rt with 350 nm light and samples (75 µL) were taken every 60 min. Bead samples 
were washed with PBS (2 × 75 µL) for 15 min at rt and 10 µL was analyzed by confocal microscopy.  
Photocleavage of linker 49 in solution: triazole 49 (1 mg, 1.2 µmol) was dissolved in CH3CN:H2O 
1:1 (1 mL) and placed in a quartz tube. The reaction mixture was irradiated at 350 nm at rt, samples 
(30 µL) were taken after 20 and 80 min and analyzed by LC-MS (Figure 5.10). 
Photocleavage of linker-coupled beads: to the linker-coupled beads (see section 5.9.4) was added 800 
µL PBS buffer and the suspension was divided in 2. One part was placed in a quartz tube and 
irradiated at 350 nm at rt and samples (50 µL) were taken after 15, 30, 60, 90, 150, 210 and 270 min. 
Samples were centrifuged before supernatant was analyzed by LC-MS (Figure 5.11).  
 
 
General procedure for both photocleavable linkers 
To the linker-coupled beads (see section 5.7.4) was added 400 µL PBS buffer. For all experiments, 10 
µL AHA-CalB (1 µg/µL) and 10 µL low molecular weight marker (LMW, 1 µg/µL) were combined. 
To this mixture, 10 or 20 µL beads of the 10 mM linker concentration was added. This SPAAC 
mixture was shaken for 2 or 16 h at 20 or 37 °C. The mixture was centrifuged and the supernatant was 
transferred to a new tube and stored at 4 °C until it was loaded on SDS-PAGE gel. The beads were 
washed for 15 min at rt with PBS (3 × 100 µL) and PBS buffer (20 µL) was added. Cleavage was 
performed for 1 h with 350 nm light at rt. The samples after cleavage were centrifuged and 20 µL of 
the supernatant was combined with 5 µL 5× Laemmi sample buffer. 20 µL of the supernatant after 
SPAAC was combined with 5 µL 5× Laemmi sample buffer. Markers were prepared with 2.5 µL 
AHA-CalB solution (2 µg/µL), 5 µL LMW solution (1 µg/µL), 12.5 µL PBS buffer and 5 µL 5× 
Laemmi sample buffer. Alternatively, marker solutions for AHA-CalB and LMW were applied  
5.10.6 Selective enrichment of AHA-CalB from a protein mixture 
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Figure 5.10. LC-MS spectra of the reaction mixture after photocleavage of linker 49. From top to bottom: total 
scan PDA after 25 min irradiation; total scan PDA after 85 min irradiation; ESI mass spectrum of peak 1 in total 
PDA scan (2 × MW diol cleavage product 52 = 578.6 Da, MW naphthoquinone methide product 50 = 271.3 Da); 
ESI mass spectrum of peak 2 in total PDA scan (MW BCN photocleavage product 51 = 571.7 Da); ESI mass 
spectrum of peak 3 in total PDA scan (MW starting material 49 = 843.0 Da).  
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Figure 5.11. LC-MS spectra of the reaction mixture after photocleavage of on-resin 39. From top to bottom: total 
scan PDA after 60 min irradiation; total scan PDA after 210 min irradiation; ESI mass spectrum of peak 1 in total 
scan PDA (MW photocleavage product 51 = 571.7 Da). 
 
separately:  5 µL LMW solution (1 µg/µL) combined with 15 µL PBS buffer and 5 µL 5× sample 
buffer, and 2.5 µL AHA-CalB solution (2 µg/µL) combined with 17.5 µL PBS buffer and 5 µL 5× 
sample buffer. All samples and markers were boiled at 95 °C for 5 min before loading them 
completely on a 12% SDS-PAGE gel. After running, gels were stained with Coomassie brilliant blue 
or silver stain.  
 
 
General procedure for both photocleavable linkers 
Cell lysate was prepared from the pellet of human skin fibroblasts combined with 0.5 mL 
homogenization buffer (30 mM TRIS, 3 mM EDTA, 150 mM NaCl, 1% Triton X-100, pH 7.4) and 
10 µL proteinase inhibitor. The resulting suspension was sonicated 3 × 10 sec and centrifuged at 
13000 g at 4 °C for 12 min. The supernatant was concentrated to 60 µL using a Milipore amicon ultra 
centrifugal filter (3 kDa cut off) and an additional 5 µL proteinase inhibitor solution was added. To 10 
µL of the resulting mixture was added 5 µL AHA-CalB or native CalB (both 2 µg/µL) and 5 µL PBS 
buffer. To the linker-coupled beads (see section 5.7.4) was added 300 µL PBS buffer and 20 µL of the 
resulting suspension was added to the CalB-cell lysate mixture. The samples were shaken at 900 rpm 
for 2 h at 20 °C, centrifuged and washed 15 min with PBS at rt (4 × 100 µL). The supernatant was 
5.10.7 Selective enrichment of AHA-CalB from cell lysate  
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removed, and 20 µL PBS buffer was added. The beads were placed in a quartz tube and irradiated 
(350 nm) for 60 min at rt. After centrifugation, 20 µL of the supernatant after cleavage was combined 
with 5 µL 5× sample buffer. LMW and CalB markers were prepared as described earlier (see section 
5.7.6) and the cell lysate marker was prepared with 2.5 µL cell lysate, 17.5 µL PBS buffer and 5 µL 
5× sample buffer. All samples and markers were boiled at 95 °C for 5 min before loading them on a 
12% SDS-PAGE gel.    
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    The binding of glycans to proteins is an essential step in the mediation of numerous 
biological processes, such as cell-cell adhesion, intercellular communication, pathogen 
recognition, cell trafficking and even in tumor metastasis.
1
 Through the years, a large 
number of particular glycan structures have been discovered, and much has become known 
about their interaction with particular binding proteins (lectins). At the same time, the 
complexity of glycan structures and the low natural abundance, in combination with the 
cumbersome isolation or synthesis of a particular glycan structure, have been bottlenecks to 
obtain detailed insight in glycan-mediated biological processes. One approach to study 
glycan-protein interactions in a high-throughput manner involves microarray technology, 
for the first time applied to glycans in 2002.
2
 An important consideration when designing a 
glycan microarray is the immobilization strategy of the glycans onto the desired solid 
support, as interactions between glycans and glycan binding elements are strongly 
dependent on linker length and immobilization concentration.
3
 Several methods for 
immobilization have been developed which can broadly be classified into four categories:
3
 
(a) non-covalent, aspecific attachment of glycans; (b) non-covalent, site-specific attachment 
of glycans; (c) covalent, aspecific attachment of glycans and (d) covalent, site-specific 
attachment of glycans. In the ideal situation, glycans are covalently and site-specifically 
attached to a solid surface via the reducing sugar, the natural attachment point of glycans to 
other biomolecules. One of the first examples of this type of immobilization method relied 
on well-established thiol-maleimide conjugation. In this strategy, maleimide-functionalized 
carbohydrates were attached to thiol-derivatized glass slides,
4
 or inversely, thiol-
functionalized sugars were attached to a maleimide-derivatized surface.
5
 Other ligation 
reactions that have been used to establish the connection between glycans and a solid 
surface include disulfide bond formation between thiosulfonate-conjugated sugars and a 
thiol-coated surface,
6
 Diels-Alder reaction between cyclopentadiene-modified sugars and a 
benzoquinone-coated surface,
7
 reaction between an amine-linked glycan and a cyanuric 
chloride-coated surface
8
 and a N-hydroxysuccinimide ester-functionalized surface,
9
 
reaction between hydrazide-linked glycans and an epoxide-coated surface,
10
 Staudinger 
ligation between azide-functionalized sugars and a phosphane-coated surface
11
 and CuAAc 
between azide-linked glycans on an alkyne-derivatized surface
12
 or the inverse strategy.
13
 
Without exception, these immobilization strategies require the reaction of a functionalized 
6.1 Introduction 
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solid support (Y) with a reactive group X on a saccharide (Scheme 6.1A). The installation 
of X on a glycan is typically established during (multistep) synthesis of an oligosaccharide, 
thereby limiting the application of any of these strategies to synthetically accessible, 
relatively simple glycans. To overcome these issues, Shin et al. reported a strategy for site-
specific and covalent immobilization of free carbohydrates irrespective of their nature and 
size.
14
 The essential strategic difference involved the functionalization of a glass slide with 
 
Scheme 6.1. Strategies for site-specific, covalent modification of glycans to a solid support. (A) Reaction of a 
functionalized glycan with a complementary reaction partner-coated surface; (B) oxime or hydrazone ligation of 
native glycans with a hydrizide- or aminooxy-coated surface; (C) reductive amination of native glycans with a 2,6-
dimethylpyridine-coated surface; (D) reaction of native sugars with an N-methylhydroxylamine-coated surface.  
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aminooxy or hydrazide for oxime or hydrazone ligation, respectively, with the aldehyde 
form of native mono-, di- or oligosaccharides (Scheme 6.1B). Similar approaches for 
covalent attachment of native saccharides via imine-type bond formation involve reductive 
amination with 2,6-diaminopyridine (Scheme 6.1C)
15
 or reaction with N-methylaminoether-
containing linkers (Scheme 6.1D),
16
 to yield acyclic or cyclic adducts, respectively.  
     A field of research where immobilization of glycans on a surface also plays a pivotal 
role is the synthesis of stable isosteres of glycopeptides and -proteins. Similar reactions as 
delineated above are used to prepare substantial amounts of homogeneous glycoproteins for 
investigations regarding structure-activity relationships
17
 or therapeutic applications.
18
 For 
example, Van Kasteren et al. reported a combination of CuAAC and disulfide bond 
formation for the site-specific introduction of both a sialyl-Lewis X tetrasaccharide and a 
sulfated tyrosine mimic onto a reporter protein for the in vivo visualization of inflammatory 
brain lesions in a malarial disease model.
19
 As was the case for microarray fabrication, 
introduction of a reactive group to saccharides is limited to relatively simple glycans, 
because this is usually established during multistep synthesis of the glycans. Also in this 
research area, a strategy was reported that involves functionalization of a peptide with 
aminooxy groups followed by conjugation with the open form of native glycans.
20
 
Additionally, the reductive amination protocol with 2,6-diaminopyridine and sodium 
cyanoborohydride was used for the preparation of neoglycoconjugates.
15
 
    In 2009, Tanaka et al. developed a method for the one-step conversion of unprotected 
sugars to glycosyl azides in water and applied this method for the conversion of mono-, di-, 
tri-, tetra- and even decasaccharides.
21
 The strategy follows pKa-based selective activation 
of the anomeric hydroxy group over the other hydroxy groups by 1,3-dimethyl-2-
chloroimidazolinium chloride (DMC, Scheme 6.2). A reaction mechanism was proposed 
involving 1,2-anhydrosugar intermediates, resulting in α-glycosyl or β-glycosyl azides for 
saccharides containing an axial or equatorial OH at the 2-position, respectively.  
    We envisioned that this method for anomeric azide modification of sugars could be 
readily applied for the immobilization of sugars to the surface of a microarray or protein by 
strain-promoted alkyne–azide cycloaddition. In particular, such an approach would 
combine the advantage of the oxime/hydrazone ligation or reductive amination, i.e. the use 
of native oligosaccharides, with the advantages of late-stage introduction of a stable yet 
reactive handle to the glycan. An additional benefit of the use of glycosyl azides is the 
retention of the reducing sugar in the cyclic form, thereby warranting minimal 
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conformational deviation from the natural glycan. In this chapter, the preparation and 
attachment of azidoglycans to either an alkyne-functionalized solid support or an alkyne-
functionalized protein is explored. In agreement with previous chapters, BCN was chosen 
as the strained alkyne for its excellent reaction kinetics with azides, its relatively low 
lipophilicity and fast synthesis. 
 
 
Scheme 6.2.  The one-step conversion of unprotected sugars to glycosyl azides in water by activation with DMC 
described by Tanaka et al.21 
 
 
6.2.1 Microtiter plates    
    A straightforward approach to evaluate the usefulness of SPAAC for the immobilization 
of glycans to a solid support involved the preparation of BCN-functionalized microtiter 
plates, followed by glycan immobilization and functional read-out. Thus, an amino-
derivative of BCN (1) was reacted with Corning DNA-BIND NHS-modified polystyrene 
96-well plates, by incubation of the plate with a 10 μM solution of 1 for two hours at room 
temperature. To validate in-well SPAAC of a model azide with immobilized BCN, 100 μM 
azido-biotin 2 was added to the plate and incubated overnight at room temperature prior to 
addition of streptavidin-conjugated horse radish peroxidase (HRP), rinsing and finally 
addition of hydrogen peroxide and 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 
(ABTS, 3). Upon addition of ABTS, a time-dependent increase in absorbance became 
apparent (Figure 6.1), whereas absorbance in solutions where one of the components was 
omitted increased only marginally, thereby clearly corroborating the potential of SPAAC 
for the specific immobilization of biological ligands.   
6.2 Glycan immobilization on a solid support 
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Figure 6.1. Absorbance at 408 nm of solutions in BCN-functionalized wells after addition of azido-biotin 2, 
streptavidin-HRP, ABTS and hydrogen peroxide. 
 
    Having established in-well SPAAC with azido-biotin 2, SPAAC was performed with 
200 μM lactosyl azide 4 or 6′-sialyllactosyl azide 5 for 3 hours at room temperature. To the 
lactosyl azide-functionalized wells was then added HRP-functionalized peanut agglutinin 
(PNA), a lectin known to bind specifically to terminal, non-reducing β-D-galactose residues 
(as in lactose). To the sialyllactosyl azide-functionalized wells was added HRP-
functionalized Sambucus nigra agglutinin (SNA), a lectin selective for Neu5Ac-(α2-6)-Gal 
sequences as present in 6′-sialyllactose.22 After addition of hydrogen peroxide and ABTS, a 
time-dependent increase in absorbance of the solutions became apparent for both lactosyl 
and sialyllactosyl azide-functionalized plates (Figures 6.2A and B, blue lines). However, 
nearly all control experiments also gave an increased signal (other lines except yellow), in  
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one case even higher than that of the parent experiment. Additionally, cross reactivity tests 
showed aspecific binding of SNA and PNA to the surface of the microtiter plates (yellow 
lines), indicating that the selective detection of glycan-binding proteins (lectins) with the 
Corning 98-wells plates was not achievable. 
 
 
Figure 6.2. Absorbance at 408 nm of solutions in BCN-functionalized wells. (A) After addition of β-D-lactosyl azide 
(4), HRP-PNA, ABTS and hydrogen peroxide; (B) after addition of β-D-6′-sialyllactosyl azide (5), HRP-SNA, ABTS 
and hydrogen peroxide. 
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6.2.2. UltraLink Biosupport resin 
    In earlier experiments (Chapter 5) with UltraLink Biosupport resin, a hydrophilic 
copolymer of polyacrylamide and azlactone, no aspecific binding of a range of proteins was 
detected. Therefore the same resin was selected for further experiments to examine the 
immobilization of glycans to a solid support via intermediate conversion into anomeric 
azide. On-resin SPAAC of BCN-functionalized amine 1 with a fluorogenic azidocoumarin 
probe was already established, so BCN-functionalized beads were subjected to SPAAC 
with glycosyl azides. To this end, the crude reaction mixture of either lactosyl azide (4) or 
6′-sialyllactosyl azide (5), prepared from the respective native sugars by treatment with 
DMC, sodium azide, and DIPEA in water, was added to BCN-functionalized beads, 
followed by incubation with fluorescein isothiocyanate (FITC)-functionalized SNA or 
 
Figure 6.3. Light microscope (left) and confocal microscopy (right) images of BCN-amine 1 functionalized beads 
after SPAAC with lactosyl azide (4) and incubation with FITC-functionalized SNA. (A) Parent experiment; (B)-(D) 
control experiments; (E) cross-experiment with SNA.  
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PNA. Confocal microscopy images of these experiments, depicted in Figures 6.3 and 6.4, 
showed a clear fluorescent staining of the BCN-functionalized beads after SPAAC with 
lactosyl azide (4) or 6′-sialyllactosyl azide (5) and incubation with respectively PNA or 
SNA (Figures 6.3A and 6.4A). Negative control experiments with omission of BCN-
derivative 1 (Figures 6.3B and 6.4B) or the lectin (Figures 6.3D and 6.4D), showed no 
fluorescence, as expected. Some fluorescence was detectable in control experiments lacking 
the saccharide (Figures 6.3C and 6.4C), but significantly less intense than in the parent 
experiment, thereby demonstrating successful immobilization of crude lactosyl azide and 
6′-sialyllactosyl azide to the Biosupport resin. Cross experiments, where SNA was added to 
lactosyl azide- functionalized beads and PNA to 6′-sialyllactosyl azide-functionalized beads 
(Figures 6.3E and 6.4E), also showed some fluorescent staining, indicating some aspecific  
 
Figure 6.4. Light microscopy (left) and confocal microscopy (right) images of BCN-functionalized beads after 
SPAAC with sialyllactosyl azide (5) and incubation with FITC-functionalized SNA. (A) Parent experiment; (B)-(D) 
control experiments; (E) cross-experiment with PNA.  
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binding of the lectins to the saccharides. A mixture of lactose and 6′-sialyllactose was also 
converted to the corresponding azides, loaded on BCN-functionalized beads and incubated 
with PNA or SNA. Confocal microscopy showed fluorescent staining for both PNA (Figure 
6.5A) and SNA (Figure 6.5E), whereas negative control beads showed no fluorescence  
Figure 6.5. Light microscopy (left) and confocal microscopy (right) images of BCN-functionalized beads after 
SPAAC with a mixture of lactosyl azide (4) and 6′-sialyllactosyl azide (5) and incubation with FITC-functionalized 
PNA (A-D) or SNA (E-H). (A) and (E) Parent experiment; (B)-(D) and (F)-(H) control experiments.  
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(Figures 6.5B, D, F and H). As was observed before, lactosyl azide-functionalized beads 
incubated with SNA and 6′-sialyllactosyl azide-functionalized beads incubated with PNA 
showed faint fluorescence, indicating partial aspecific binding of the lectins (Figures 6.5C 
and G). 
    It is known that in some cases the reducing end of glycans in glycoconjugates may be an 
important site of protein interaction, such as in the binding of certain antibodies to sialyl-
Lewis
x
 (SLex).
23
 The selective antibody detection of SLex was therefore considered a 
relevant test-case to validate the above described approach, because conversion into 
anomeric azide retains the cyclic form of the reducing sugar, in contrast to most of the other 
technologies. Hence, SLex was converted to the corresponding azide 6 and the reaction 
mixture was loaded on BCN-functionalized Biosupport resin, followed by incubation with a 
commercially available anti-SLex antibody (CHO131), then Alexa488 labeled goat anti-
mouse IgM. Confocal images of these experiments are depicted in Figure 6.6. To our 
disappointment, beads incubated with SLex azide (6) and consecutively with either 
antibody showed only faint fluorescence (Figure 6.6A). Worse than that, fluorescence in the 
negative control experiment involving omission of SLex azide (Figure 6.6C) was even 
slightly more intense than the parent experiment. No suitable explanation for these 
unsatisfactory results could be found at this stage, but later experiments gave a clear insight 
in the inability to detect of SLex (vide infra).  
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Figure 6.6. Light microscopy (left) and confocal microscopy (right) images of BCN-amine 1 functionalized beads 
after SPAAC with SLex  azide (6) and incubation with anti-SLex antibody (CHO131), then Alexa488 labeled goat 
anti-mouse IgM. (A) Parent experiment; (B)-(D) control experiments. 
 
    In 2012 we reported on a method for the introduction of BCN to green fluorescent 
protein (GFP) by genetic encoding of a BCN-containing amino acid in the presence of a 
heterologous suppressor tRNA/aminoacyl tRNA synthetase pair with altered specificity.
24,25
 
We realized that the presence of a single BCN in a protein provides a convenient chemical 
handle for the synthesis of glycoprotein isosteres (neoglycoproteins) upon copper-free 
cycloaddition with azide-modified glycans. Thus, to a 200 μM solution of BCN-GFP in 
PBS was added lactosyl azide (4) or SLex azide (6) to give a final glycan concentration of 2 
mM. After overnight incubation at room temperature, mass spectrometric analysis (Figure 
6.7) showed in both cases the presence of a single product together with a small amount of 
starting protein. For lactosyl azide, the product mass corresponds nicely to the expected 
mass (29221 Da). However, SPAAC of BCN-GFP with SLex-azide (6) gave a mass of 
28895, only 44 Da higher than the starting material. Clearly, the SLex glycan is not present, 
although a reaction of BCN-GFP did take place. A plausible explanation for the unexpected 
formation of the product with a mass of +44 involves a disconnection of the SPAAC 
product between the reducing end of the sugar and the anticipated triazole ring (Scheme 
6.3), which would predict a MW of 28897 Da for GFP-BCN-triazole-H. Apparently, the  
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Figure 6.7. Mass spectra (bottom) and deconvoluted mass spectra (top) of GFP-BCN. (A) Native GFP-BCN (MW = 
28854 Da); (B) GFP-BCN after SPAAC with lactosyl azide 4 (MW = 29221 Da); (C) GFP-BCN after SPAAC with SLex-
azide 6 (MW product = 29700 Da; MW after SPAAC - SLex = 28897 Da).  
 
latter triazole displacement from the anomeric position takes place only in 2-N-acetyl 
sugars such as present in SLex, presumably with concomitant formation of sugar oxazoline 
(Scheme 3) but not in 2-OH sugars such as present in lactose.   
  
A. 
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    The in situ conversion of native saccharides to azides based on the protocol originally 
developed by Tanaka et al. was successfully applied for the immobilization of 2-OH sugars  
lactose and 6′-sialyllactose on Biosupport resin, by addition of the crude reaction mixture 
after azide conversion to BCN-functionalized beads. The same method can also be used for 
conjugation of these sugars to a BCN-functionalized protein, as was shown for lactosyl 
azide. However, when the Tanaka-method was applied to 2-N-acetyl-containing glycan 
SLex and the reaction mixture was added to BCN-functionalized beads, a lack of specific 
signal was found. Additionally, when SLex azide was added to a BCN-functionalized 
protein, it was established that only an unsubstituted triazole derivative was formed. A 
likely explanation involves an intramolecular nucleophilic substitution with concomitant 
formation of an oxazoline after SPAAC, with the triazole ring acting as a leaving group. 
Verification of this hypothesis can be accomplished by isolation and structural elucidation 
of the reaction products after SPAAC between a small 2-N-acetyl sugar azide and a simple 
BCN-derivative.  
   Taken together, a simple alternative for the immobilization of native 2-OH sugars with a 
closed reductive end sugar was developed, which can be advantageously applied for the 
preparation of microarrays and neoglycoproteins.  
 
Scheme 6.3. Oxazoline formation after SPAAC. 
 
6.4 Conclusions & outlook  
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6.6.1 General methods and procedures   
     See section 2.9. Polystyrene DNA-BIND NHS-modified 96-well microtiter plates were obtained 
from Corning (USA). UltraLink Biosupport resin was obtained from Thermo scientific (USA) 6′-
Sialyllactose sodium salt and 3′-sialyl lewis X (SLex) were obtained from CarboSynth (UK), human 
PSGL-1/CD162 MAb (Clone CHO131), mouse IgM antibody to SLex was obtained from R&D 
Systems (USA), Alexa Fluor® 488 Goat Anti-Mouse IgM (µ chain) was obtained from Life 
Technologies (USA), Sambucus nigra Lectin (SNA), HRP conjugate was obtained from EY 
Laboratories (USA), Peanut Agglutin lectin (PNA), HRP conjugate and FITC conjugate, were 
obtained from Sigma Aldrich (USA), BCN derivataves where obtained from Synaffix B.V. (NL), 
Sambucus Nigra Lectin (SNA, EBL), FITC conjugate and Carbo-Free Blocking Solution (10× 
concentrate) were obtained from Vector Laboratories (USA).  Confocal microscopy was done on a 
Leica TCS SP2 AOBS Confocal Laser Scanning Microscope (excitation: 488 nm for FITC-
conjugated lectins and Alexa Fluor-488-conjugated antibody). Absorbance at 408 nm was measured 
on a Tecan Infinite 200 plate reader. 
 
6.6.2 Synthesis of glycosyl azides 4, 5 and 6 
 
β-D-Lactosyl azide (4) 
2-Chloro-1,3-dimethylimidazolinium chloride (471 mg, 2.79 mmol) was 
added to a mixture of β-D-lactose monohydrate (202 mg, 560 µmol), N,N-
diisopropylethylamine (1.45 mL, 8.32 mmol) and sodium azide (909 mg, 
14.0 mmol) in D2O (5 mL). The reaction mixture was stirred at room 
temperature for 23 h. The reaction mixture was concentrated in vacuo, the 
crude product was redissolved in ethanol and the solid was removed by vacuum filtration. 
Approximately 50% of the filtrate was adsorbed on hydromatrix and purified by silica column 
chromatography (CH3CN:H2O 6:1→4:1→3:1) and concentrated in vacuo to give the title compound 
6.5 Acknowledgements 
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as a yellow oil (69 mg, 33%). RF = 0.24 (CH3CN:H2O 3:1). 
1H NMR (400 MHz, D2O) δ 4.76 (d, J = 
8.8 Hz, 1H), 4.44 (d, J = 7.8 Hz, 1H), 4.03-3.89 (m, 2H), 3.88-3.60 (m, 8H), 3.57-3.48 (m, 1H), 3.34-
3.24 (m, 1H). 13C NMR (75 MHz, D2O) δ 102.4, 89.4, 77.2, 76.2, 74.9, 73.9, 72.0, 70.4, 68.1, 60.5, 
59.4. FT-IR νmax (cm
-1) = 3338, 2875, 2116, 2036, 1678, 1519, 1404, 1249, 1075, 762. 
 
β-D-6′-Sialyllactosyl azide (5) 
2-Chloro-1,3-dimethylimidazolinium chloride (16 mg, 95 
µmol) was added to a mixture of 6′-sialyllactose sodium salt 
(12.5 mg, 19 µmol), N,N-diisopropylethylamine (51 µL, 290 
µmol) and sodium azide (61 mg, 950 µmol) in D2O (1 mL). 
The reaction mixture was stirred at room temperature for 19 
h. The reaction mixture was concentrated in vacuo, the 
crude product was redissolved in ethanol and the solid was removed by vacuum filtration. The filtrate 
was concentrated in vacuo and purified by RP-HPLC (5-100% MeCN in H2O, flow rate 4 mL/min, 
UV 215/254 nm) and concentrated in vacuo to give the title compound as a colorless oil (3 mg, 24%). 
RF = 0.27 (CH3CN:H2O:AcOH 74.5:24.5:1). 
1H NMR (400 MHz, D2O) δ 4.75 (d, J = 8.9 Hz, 1H), 
4.41 (d, J = 7.8 Hz, 1H), 4.03-3.74 (m, 8H), 3.74-3.46 (m, 11H), 3.33 (s, 1H), 2.69 (dd, J = 12.4, 4.7 
Hz, 1H), 2.01 (s, 3H), 1.72 (t, J = 12.2 Hz, 1H). 13C NMR (126 MHz, D2O) δ 174.9, 173.5, 103.2, 
89.8, 79.0, 76.6, 74.6, 73.7, 72.5, 72.5, 72.4, 71.8, 70.8, 68.5, 68.4, 63.6, 62.7, 60.0, 51.8, 40.1, 22.1. 
FT-IR νmax (cm
-1) 3307, 1679, 1445, 1207, 1138, 845, 803, 725. HRMS (ESI-) m/z calcd for 
C23H37N4O18 (M-H)
-: 657.2103, found: 657.2094. 
 
β-D-3′-Sialyl Lewis X azide (6) 
Sodium azide (2.88 mg, 44.3 µmol) was added to a 
mixture of 3′-sialyl Lewis X (NeuNAc-α(2-3)-Gal-β(1-
4)-[Fuc-α(1-3)]-GlcNAc) (1.45 mg, 1.77 µmol), N,N-
diisopropylethylamine (4.62 µL, 26.5 µmol) and 2-
chloro-1,3-dimethylimidazolinium chloride (1.50 mg, 
8.85 µmol, 5 eq) in H2O (30.8 µL). The reaction 
mixture was stirred at room temperature for 54 h. After 25 h an additional 10 equivalents of DMC in 
H2O and 25 equivalents of sodium azide were added and the reaction mixture was stirred until LC-
MS indicated complete conversion to the product (25 h). The reaction mixture was used without 
further purification. HRMS (ESI+) m/z calcd for C31H51N5O22Na (M+Na)
+: 868.2923, found: 
868.2951. 
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6.6.3 Glycan immobilization on microtiter plates  
 
Immobilization of BCN-amine 1, SPAAC with biotin-azide 2, then streptavidin-HRP 
A solution of BCN-(POE)3-NH2 (1, 0.32 µg, 1 nmol) in coupling buffer (50 mM phosphate buffer, 1 
mM ethylenediaminetetraacetic acid (EDTA), pH 8.3) (10 µM,  100 µL) was added to each well of  
Corning polystyrene DNA-BIND NHS-modified 96-well microtiter plates and incubated at rt for 2 h. 
The wells were washed with PBS containing 0.1% (w/w) Tween-20 (3 × 200 µL). PBS containing 2% 
(w/w) BSA (200 µL) was added to block non-reacted sites and incubated at rt for 55 min. The 
blocking solution was removed without rinsing. A solution of biotin-(POE)4-azide in 25 mM 
phosphate buffer, pH 7.0 (100 µM, 100 µL) was added and incubated at rt for 17 h. The wells were 
washed with Carbo-Free blocking solution (6 × 200 µL). A solution of HRP-streptavidin in Carbo-
Free blocking solution (0.65 µM, 100 µL) was added and incubated at rt for 1 h. The wells were 
washed with PBS (4 × 200 µL). PBS (145.7 µL), a solution of H2O2 (116 nmol) in PBS (27 mM, 4.3 
µL) and a solution of 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt 
(ABTS; 10 nmol) in PBS (200 µM, 50 µL) were subsequently added to each well and absorbance at 
408 nm was immediately measured for 10 h with 45 sec interval at 31-33 °C.  
 
Immobilization of BCN-amine 1, SPAAC with glycosyl azides, then lectin-HRP 
A 20 μM solution of BCN-(POE)3-NH2 (1, 1 nmol) in coupling buffer (50 μL) was added to each well 
and incubated at rt for 1.5 h. The wells were washed with PBS containing 0.1% (w/w) Tween-20 (3 × 
200 µL). Carbo-Free blocking solution (200 μL) was added to block non-reacted sites and incubated 
at rt for 50 minutes. The blocking solution was removed, a solution of lactosyl azide (4) or 6ʹ-
sialyllacosyl azide (5) in 25 mM phosphate buffer, pH 7.0 (200 μM, 50 μL) was added and incubated 
at rt for 3 h. The wells were washed with Carbo-Free blocking solution (6 × 200 µL). A solution of 
PNA-HRP or SNA-HRP in Carbo-Free blocking solution (1 μM, 50 μL) was added to lactosyl azide- 
or 6′-sialyllactosyl azide-functionalized wells, respectively, and incubated at rt for 3 h. The wells 
were washed with 1% BSA (w/w) in PBS (2 × 200 µL, 5 minutes) and PBS (2 × 200 µL). PBS (121 
µL), H2O2 in PBS (5 mM, 29 µL) and ABTS in PBS (1 mM, 50 µL) were subsequently added to each 
well and absorbance at 408 nm was measured immediately with 45 sec interval at 30-33 °C. For 
control experiments, the corresponding component was omitted. For cross experiments, PNA-HRP 
was added to 6′-sialyllactosyl azide-functionalized wells and SNA-HRP was added to lactosyl azide-
functionalized wells.  
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6.6.4 Glycan immobilization on Biosupport resin 
 
Immobilization of BCN-amine 1, SPAAC with lactosyl azide 4 or 6′-sialyllactosyl azide 6, then 
PNA- or SNA-FITC 
A solution of BCN-POE3-NH2 (1, 485 µg, 1.5 µmol) in 0.1 M 3-(N-morpholino)propanesulfonic acid 
(MOPS) buffer, pH 7.5 (150 µL, 10 mM), was added to UltraLink Biosupport resin (5 mg). Samples 
were vortexed briefly to suspend beads and shaken at rt for 1 h. Samples were centrifuged at 4000 
rpm at rt for 5 min to pellet beads and the supernatant was removed. A solution of 
tris(hydroxymethyl)aminomethane (TRIS) in H2O, pH 8.0 (1.0 M, 400 µL) was added to the beads to 
block non-reacted sites.  Samples were vortexed briefly to suspend beads and shaken at rt for 2.5 h. 
Samples were centrifuged at 4000 rpm at rt for 5 min to pellet beads and the supernatant was 
removed. The beads were washed with PBS (3 × 400 µL). For each washing step, 400 µL wash 
solution was added, samples were vortexed briefly to suspend beads and shaken at rt for 15 min. 
Samples were centrifuged at 4000 rpm at rt for 5 min to pellet beads and the supernatant was 
removed. A solution of crude β-D-lactosylazide (4, 0.06 mg, 0.15 µmol) in 25 mM phosphate buffer 
pH 7.0 (1 mM, 150 µL), crude 6′-sialyllactosyl azide (5, 0.20 mg, 0.15 µmol, 1 mM) in 25 mM 
phosphate buffer pH 7.0 (1 mM, 150 µL) or a mixture of crude β-D-lactosylazide (4, 0.06 mg, 0.15 
µmol) in 25 mM phosphate buffer pH 7.0 (1 mM, 150 µL) and crude 6′-sialyllactosyl azide (5, 0.20 
mg, 0.15 µmol, 1 mM) in 25 mM phosphate buffer pH 7.0 (1 mM, 150 µL) was added. Samples were 
vortexed briefly to suspend beads and shaken at rt for 16 h. Samples were centrifuged at 4000 rpm at 
rt for 5 min to pellet beads and the supernatant was removed. The beads were washed with Carbo-
Free blocking solution (4 × 400 µL, 15 min) and a solution of PNA-FITC (lactosyl azide 
functionalized beads) or SNA-FITC (6′-sialyllactosyl azide-functionalized beads) in Carbo-Free 
blocking solution (1 µM, 100 µL) was added to the beads. Samples were vortexed briefly to suspend 
beads and shaken at rt for 1 h. Samples were centrifuged at 4000 rpm at rt for 5 min to pellet beads 
and the supernatant was removed. The beads were washed with PBS containing 1% BSA (w/w) (1 × 
400 µL, 15 min) and with PBS (2 × 400 µL, 15 min). The beads were resuspended in PBS (150 µL) 
and analyzed with confocal microscopy. For control experiments, the corresponding component was 
omitted. For cross experiments, PNA-FITC was added to 6′-sialyllactosyl azide-functionalized beads 
and SNA-FITC was added to lactosyl azide-functionalized beads.  
 
Immobilization of BCN-amine 1, SPAAC with SLex azide, then CHO131 and goat anti-mouse 
IgM 
A solution of BCN-POE3-NH2 (1, 526 µg, 1.62 µmol) in 0.1 M MOPS buffer, pH 7.5 (10 mM, 162 
µL) was added to UltraLink Biosupport resin (5.4 mg). Samples were vortexed briefly to suspend 
beads and shaken at rt for 1 h. Samples were centrifuged at 4000 rpm at rt for 5 min to pellet beads 
Fast and simple protocol for conjugation of native glycans to microarrays and proteins 
- 159 - 
 
and the supernatant was removed. A solution of 1.0 M TRIS in H2O, pH 8.0 (1.0 M, 432 µL) was 
added to the beads to block non-reacted sites. Samples were vortexed briefly to suspend beads and 
shaken at rt for 165 min. Samples were centrifuged at 4000 rpm at rt for 5 min to pellet beads and the 
supernatant was removed. The beads were washed with PBS (3 × 432 µL). In each washing step, the 
wash solution was added, samples were vortexed briefly to suspend beads and shaken at rt for 15 min. 
Samples were centrifuged at 4000 rpm at rt for 5 min to pellet beads and the supernatant was 
removed. A solution of crude SLex azide 6 (178 µmol, 0.21 µmol) in 25 mM phosphate buffer, pH 
7.0 (1.3 mM, 162 µL) was added. Samples were vortexed briefly to suspend beads and shaken at rt 
for 17 h. Samples were centrifuged at 4000 rpm at rt for 5 min to pellet beads and the supernatant was 
removed. The beads were washed with Carbo-Free blocking solution (2 × 432 µL, 15 min) and TSM 
buffer (20 mM Tris HCl, 150 mM NaCl, 0.2 mM CaCl2, 0.2 mM MgCl2, pH 7.4) (1 × 432 µL, 15 
min). A solution of Human PSGL-1/CD162 MAb (Clone CHO131) in TSM buffer containing 0.1% 
BSA (w/w) (0.5 mg/mL, 162 µL) was added to the beads. Samples were vortexed briefly to suspend 
beads and shaken at rt for 1 h. Samples were centrifuged at 4000 rpm at rt for 5 min to pellet beads 
and the supernatant was removed. The beads were washed with PBS (2 × 432 µL, 15 min) and TSM 
buffer (1 × 432 µL, 15 min). A solution of Alexa Fluor 488 goat anti-mouse IgM (µ chain) in TSM 
buffer containing 0.1% BSA (w/w) (5 µg/mL, 162 µL) was added to the beads. Samples were 
vortexed briefly to suspend beads and shaken at rt for 1 h. Samples were centrifuged at 4000 rpm at rt 
for 5 min to pellet beads and the supernatant was removed. The beads were washed with PBS (3 × 
432 µL, 15 min). The beads were resuspended in PBS (162 µL) and analyzed with confocal 
microscopy. For control experiments, the corresponding component was omitted. 
 
6.6.5 Neoglycoprotein synthesis 
Conjugation of lactosyl azide and SLex azide to GFP-BCN 
β-D-Lactosyl azide (4, 7.3 µg, 20 nmol) or SLex azide (6, 16.9 µg, 20 nmol) was added to GFP-
BCN24 (57.7 µg, 2 nmol) in PBS (10 μL) and the reaction was incubated at rt for 24 h. The crude 
reaction mixture was used for mass spectrometry measurements. ESI-TOF: calculated 29221 Da, 
found 29219 Da (lactose conjugation); calculated 29700 Da, found 28895 Da (SLex conjugation). 
 
1 M. M. Fuster, J. D. Esko, Nat. Rev. Cancer 2005, 5, 526-542. 
2 D. Wang, S. Liu, B. J. Trummer, C. Deng, A. Wang, Nat. Biotechnol. 2002, 20, 
275-281. 
3 I. Shin, S. Park, M. Lee, Chem. Eur. J. 2005, 11, 2894-2901. 
4 S. Park, I. Shin, Angew. Chem. Int. Ed. 2002, 41, 3180-3182. 
5 B. T. Houseman, E. S. Gawalt, M. Mrksich, Langmuir 2002, 19, 1522-1531. 
6.7 References  
Chapter 6 
- 160 - 
 
6 L. G. Harris, W. C. E. Schofield, K. J. Doores, B. G. Davis, J. P. S. Badyal, J. Am. 
Chem. Soc. 2009, 131, 7755-7761. 
7 B. T. Houseman, M. Mrksich, Chem. Biol. 2002, 9, 443-454. 
8 M. Schwarz, L. Spector, A. Gargir, A. Shtevi, M. Gortler, R. T. Altstock, A. A. 
Dukler, N. Dotan, Glycobiology 2003, 13, 749-754. 
9 O. Blixt, S. Head, T. Mondala, C. Scanlan, M. E. Huflejt, R. Alvarez, M. C. 
Bryan, F. Fazio, D. Calarese, J. Stevens, N. Razi, D. J. Stevens, J. J. Skehel, I. van 
Die, D. R. Burton, I. A. Wilson, R. Cummings, N. Bovin, C.-H. Wong, J. C. 
Paulson, Proc. Natl. Acad. Sci. 2004, 101, 17033-17038. 
10 M. Lee, I. Shin, Angew. Chem. Int. Ed. 2005, 44, 2881-2884. 
11 M. Köhn, R. Wacker, C. Peters, H. Schröder, L. Soulère, R. Breinbauer, C. M. 
Niemeyer, H. Waldmann, Angew. Chem. Int. Ed. 2003, 42, 5830-5834. 
12 X.-L. Sun, C. L. Stabler, C. S. Cazalis, E. L. Chaikof, Bioconj. Chem. 2005, 17, 
52-57. 
13 O. Michel, B. J. Ravoo, Langmuir 2008, 24, 12116-12118. 
14 M. Lee, I. Shin, Org. Lett. 2005, 7, 4269-4272. 
15 B. Xia, Z. S. Kawar, T. Ju, R. A. Alvarez, G. P. Sachdev, R. D. Cummings, Nat. 
Methods 2005, 2, 845-850. 
16 O. Bohorov, H. Andersson-Sand, J. Hoffmann, O. Blixt, Glycobiology 2006, 16, 
21C-27C. 
17 D. P. Gamblin, E. M. Scanlan, B. G. Davis, Chem. Rev. 2008, 109, 131-163. 
18 K. J. Doores, D. P. Gamblin, B. G. Davis, Chem. Eur. J. 2006, 12, 656-665. 
19 S. I. van Kasteren, H. B. Kramer, H. H. Jensen, S. J. Campbell, J. Kirkpatrick, N. 
J. Oldham, D. C. Anthony, B. G. Davis, Nature 2007, 446, 1105-1109. 
20 S. E. Cervigni, P. Dumy, M. Mutter, Angew. Chem. Int. Ed. 1996, 35, 1230-1232. 
21 T. Tanaka, H. Nagai, M. Noguchi, A. Kobayashi, S. Shoda, Chem. Commun. 2009, 
3378-3379. 
22 N. Shibuya, I. J. Goldstein, W. F. Broekaert, M. Nsimba-Lubaki, B. Peeters, W. J. 
Peumans, J. Biol. Chem. 1987, 262, 1596-1601. 
23 X. Song, Y. Lasanajak, B. Xia, D. F. Smith, R. D. Cummings, Chem. Biol. 2009, 
4, 741-750. 
24 A. Borrmann, S. Milles, T. Plass, J. Dommerholt, J. M. M. Verkade, M. Wießler, 
C. Schultz, J. C. M. van Hest, F. L. van Delft, E. A. Lemke, ChemBioChem 2012, 
13, 2094-2099. 
25 K. Lang, L. Davis, S. Wallace, M. Mahesh, D. J. Cox, M. L. Blackman, J. M. Fox, 
J. W. Chin, J. Am. Chem. Soc. 2012, 134, 10317-10320. 
 
 
 
 
 
 
 
Fast and simple protocol for conjugation of native glycans to microarrays and proteins 
- 161 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
Chapter 7 
 
- 164 - 
 
    The research described in this Thesis was aimed at the development of new 
biocompatible and/or bioorthogonal conjugation tools in order to support research towards 
glycosylation biosynthetic pathways and functions. The first addition to the current 
chemical toolbox was the development of a reaction involving nitrone functionality in a 
strain-promoted cycloaddition. An important advantage of this so-called SPANC reaction is 
the much faster kinetics (up to 200 times) than the more traditionally applied SPAAC. 
Unfortunately, metabolic labelling of Jurkat cells with nitrone derivatives of D-
mannosamine, sialic acid or D-galactose followed by SPANC with DIBO-biotin and 
staining with avidin-FITC did not lead to detectable cell-surface fluorescence labeling.
2
 
One possible explanation is that the biosynthetic glycosylation machinery, executed by 
highly evolved enzymes, does not accept nitrone modifications of the normal substrate, or 
alternatively nitrones may undergo intracellular hydrolysis prior to metabolic incorporation. 
To overcome this issue, metabolic labelling could potentially be achieved with ketone
3
 or 
aldehyde-functionalized sugars, followed by the addition of  N-methylhydroxylamine and a 
strained alkyne. The latter approach might at the same time annihilate intracellular 
background staining because the (hydrophilic) hydroxylamine is unlikely to pass the cell 
membrane.  
    The SPANC reaction also enabled site-selective introduction of two functional groups in 
a one-pot procedure. However, prolonged reaction time and increased stoichiometry of the 
reagents were in this case needed, probably due to increased steric hindrance compared to 
introduction of only one functional group. An alternative approach was also presented, 
utilizing a BCN-conjugated functional group and N-propargylhydroxylamine in a SPANC 
reaction followed by CuAAC with a second, azide-conjugated functional group. The 
applicability and utility of both approaches in for example multimodality imaging remains 
to be investigated.  
    The next addition to the bioconjugation toolbox was the development of a reactive probe 
for enrichment of azide-functionalized biomolecules by a capture-release strategy. Based on 
a hydrazine-cleavable Lev linker and BCN, we succeeded in selective pull-down of the 
azidoprotein AHA-CalB from a mixture of proteins. However, treatment of biological 
samples with hydrazine or any other chemical reagent may potentially adversely affect or 
modify the target molecule. To improve upon this, two ‘reagent-free’ light-induced 
cleavable linkers were developed, one based on nitroveratryl, and one on 2-
hydroxymethylnaphthol. Both linkers were successfully applied in selective pull-down of 
AHA-CalB from a mixture of proteins followed by effective cleavage by irradiation with 
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350 nm light. Enrichment of AHA-CalB from a more complex mixture, i.e. cell lysate from 
human skin fibroblasts, was successful only for the hydroxymethylnaphthol-based linker. 
Ultimately, the hydroxymethylnaphthol-based photocleavable linker promises to be 
particularly useful for enrichment of azide-containing biomolecules from complex samples, 
for example after metabolic incorporation of azidosugars. The latter approach would 
subsequently allow structural analysis of the isolated glycans. In order to assess the 
usefulness of the photocleavable linker for this purpose, it is necessary to determine the 
efficiency of the described capture-release protocol. On the basis of this result, it can be 
determined if SPAAC and photocleavage conditions might require further optimization.  
    The last addition to the toolbox for applications in chemical biology was the convenient, 
one-pot introduction of an azide to the reducing end of native saccharides in water,
4
 
followed by site-specific, covalent functionalization of a solid support or a BCN-
functionalized protein. The approach was found to be successful for the immobilization of 
2-hydroxysugars, without the need for purification after introduction of the azide. 
Unfortunately, SPAAC with azides derived from 2-N-acetyl-glycans resulted in 
disconnection of the glycan from the triazole. This limits application of this method to 
saccharides containing a 2-OH glycan at the reducing end, a group of glycans that is not so 
abundant in Nature because for example all glycoproteins contain a 2-N-acetyl sugar at the 
reducing end.  
    Altogether, the described research further expands the bioconjugation toolbox for 
application in glycobiology research. Use of these chemistry tools in research towards 
glycosylation, but possibly also in other biological research areas, might in the future 
provide answers to questions regarding for example structure-function relationship of 
glycans or diagnosis of patients with defects in their glycosylation machinery.  
 
    The essential role of glycans in states of health and disease, such as infection, 
inflammation and cancer metastasis is now widely recognized. Mechanistic insights in 
glycosylation processes might serve as an inspiration for the design of new medical 
diagnostics or even therapeutics. The increasing application of chemical approaches for 
research to elucidate the fundamental basis of such processes is a promising development in 
this respect. At the same time, the challenge remains to image glycans in their native 
habitat, because glycan composition and size is strongly dependent on the presence and 
activity of various enzymes.
5
 It is therefore essential that chemists and biologists operate 
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shoulder-to-shoulder to develop and optimize experimental conditions. Additionally, 
glycosylation research (and many other research areas) would benefit greatly from the 
possibility of doing chemistry in living organisms, especially humans. However, 
performing chemistry in living organisms, so-called bioorthogonal chemistry, is a highly 
challenging task. Especially the concentration at which a reaction needs to take place is 
hampering the applicability of chemical reactions in living organisms. It is therefore 
necessary to develop even faster reactions between completely abiotic groups.  
    The sensitivity of metabolic oligosaccharide engineering can also be improved from 
another point of view. The introduced artificial sugar analogs have a lower affinity to 
metabolic enzymes compared to endogenous sugars, and therefore only a small amount of 
the incorporated sugars bears the reactive group.
6
 Inhibition of the endogenous synthesis of 
sugars is for example a strategy to increase incorporation of sugar analogs relative to 
endogenous sugars.
7
 In this case, however, it is doubtful that the measured amount of sugar 
fully reflects the in vivo glycan distribution. From my point of view, it is therefore 
worthwhile to put more effort in the development of glycan analogs that are better accepted 
by the relevant metabolic enzymes, potentially aided by computational docking studies.  
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    Synthesis of a peptide or protein on the rough endoplasmatic reticulum (ER) is often 
followed by attachment and processing of carbohydrates in the ER and Golgi, a process 
called glycosylation. With as many as 50% of the human proteins glycosylated, this 
modification is of tremendous importance. In addition, only minor mistakes in the DNA 
encoding of the glycosylation machinery have a dramatic effect on the functioning of an 
entire organism. Nevertheless, glycobiology research progresses slowly compared to the 
DNA and protein fields. One of the reasons of the lagging state of glycobiology research is 
that the biosynthesis of glycans is not template-driven and this leads to micro- and 
macroheterogeneity in glycan structures. Additionally, researchers have suffered from a 
shortage of advanced tools to explore the complex glycosylation process. A relatively new 
approach for the elucidation and manipulation of the functional roles of glycans in 
biological processes lies in the field of chemical biology. Currently, the chemical biology 
toolbox is only poorly filled and relies on only a handful of chemical reactions, mainly 
based on the azide functional group. Therefore, the research described in the preceding 
chapters was aimed at the development of new biocompatible and/or bioorthogonal 
conjugation tools in order to shed more light on glycosylation biosynthetic pathways and 
functions.      
    Chapter 1 provides an overview of the current state of the chemical toolbox for 
glycoprotein research, such as the available biocompatible and bioorthogonal reactions 
(Figure 1) and their application in glycobiology research.  
 
 
Figure 1. Biocompatible reactions are inert for functional groups present in biomolecules such as proteins, 
nucleotides and glycans, and are suitable for bioconjugation. Bioorthogonal reactions can even be used in live 
cells or entire organisms. 
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    Our first addition to the chemical toolbox is described in Chapter 2, the development of 
a novel biocompatible reaction pair based on strain-promoted alkyne–nitrone cycloaddition 
(SPANC, Figure 2). This reaction leads to N-alkylated isoxazolines and proceeds with 
much faster kinetics than similar reactions with azide. Additionally, this new methodology 
was used in a one-pot three-step protocol for site-specific modification of peptides and 
proteins.  
 
Figure 2. The strain-promoted alkyne–nitrone cycloaddtion.  
 
    Chapter 3 demonstrates the dual functionalization of peptides and proteins (Figure 3) 
and optimization of the SPANC procedure for this purpose. The usefulness of the dual 
labeling protocol was exemplified by the simultaneous introduction of two endosomal 
escape-improving functional groups onto the cell-penetrating peptide hLF (human 
lactoferrin). Further optimization of the SPANC protocol for proteins led to conditions 
highly suitable for introduction of N-propargylhydroxylamine and BCN-biotin to the 
protein S-eGFP within a few hours. The terminal alkyne then served as a convenient anchor 
point for a CuAAC reaction with azide-functionalized fluorescein, thereby demonstrating 
the potential of combined SPANC and CuAAC for the dual functionalization of proteins.  
 
 
Figure 3. Dual functionalization of S-eGFP with SPANC. 
 
    Chapter 4 describes the next addition to the chemical toolbox, a novel, readily 
accessible and reactive probe for enrichment of azide-functionalized biomolecules. This 
‘azido-trap’ was based on a combination of Sepharose beads, a hydrazine-sensitive linker, 
and the strained alkyne BCN. We demonstrated the concept by fluorogenic staining of the 
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beads with azidocoumarin. Next, we succeeded in selective pull-down of the azide-
modified protein AHA-CalB from a mixture of proteins by covalent attachment to the 
beads. Finally, both the coumarin derivative and the protein were effectively cleaved from 
the beads by treatment with hydrazine (Figure 4).  
 
 
Figure 4. Enrichment protocol for azide-functionalized proteins with ‘azido-trap’ beads. 
 
    This capture-release concept is further expanded in Chapter 5, which presents two 
alternative cleavable linkers. Two ‘azido-trap’ beads were successfully synthesized based 
on immobilization of a nitroveratrylamine-based and a hydroxymehtylnaphthol-based 
photocleavable linker. On-resin SPAAC was demonstrated by fluorescent staining of the 
beads. Cleavage was demonstrated first off-resin for both linkers by irradiation with 350 
nm light after SPAAC with benzyl azide, and then on-resin for the hydroxymethylnaphthol-
based linker. The SPAAC-release concept was successfully applied in selective capture of 
AHA-CalB from a mixture of proteins with both photocleavable linkers, followed by 
effective cleavage by irradiation with 350 nm light. Enrichment of AHA-CalB from a cell 
lysate from human skin fibroblasts was successful only for the hydroxymethylnaphthol-
based linker.  
    In Chapter 6, the preparation and attachment of azidoglycans to a BCN-functionalized 
solid support and a BCN-functionalized protein are explored (Figure 5). The in situ 
conversion of native saccharides to azides was successfully applied for the immobilization 
of 2-OH sugars to BCN-functionalized beads and the protein GFP-BCN. However, a lack 
of specific signal was observed when a 2-N-acetyl-containing azidoglycan was immobilized 
on BCN-functionalized beads. Later experiments involving conjugation of the same 2-N-
acetyl-containing glycan to GFP-BCN indicated that triazole formation with this type of 
glycans leads to an intramolecular nucleophilic substitution with oxazoline formation after 
SPAAC, with the triazole ring acting as a leaving group.  
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    Chapter 7 concludes this thesis with some final remarks on the presented work and an 
outlook for possible future work. 
 
 
 
Figure 5. Immobilization of azidoglycans to a BCN-functionalized solid support or protein.  
 
    .  
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    De synthese van een eiwit in het ruw endoplasmatisch reticulum (ER) wordt vaak 
gevolgd door de koppeling van koolhydraten aan het eiwit, een proces dat we glycosylering 
noemen. Ongeveer 50% van de menselijke eiwitten is geglycosyleerd en deze modificatie is 
van groot belang voor ons functioneren. Daarnaast heeft slechts een klein defect in het 
DNA dat codeert voor de glycosyleringsmachinerie een grote invloed op het functioneren 
van het hele organisme. Ondanks het grote belang van eiwitglycosylering is de vooruitgang 
in het onderzoek op dit gebied nog niet zo groot vergeleken met het onderzoek naar DNA 
en eiwitten. Eén van de redenen waarom onderzoek naar glycosylering zo veel langzamer 
vooruit gaat, is dat de biosynthese van glycanen, de koolhydraten die aan het eiwit 
gekoppeld worden, niet vastgelegd ligt in ons DNA zoals bij eiwitten. In de plaats daarvan 
wordt de samenstelling bepaald door de aanwezigheid en activiteit van de glycaan 
verwerkende enzymen, wat leidt tot micro- en macroheterogeniteit in de glycanen die 
aanwezig zijn op eiwitten. Daarnaast is er een tekort aan geavanceerd chemisch 
gereedschap om het complexe proces van eiwitglycosylering te onderzoeken. Een relatief 
nieuwe benadering om de structuren, eigenschappen en functies van glycanen te 
onderzoeken verloopt met behulp van chemische reacties. Echter, de gereedschapskist met 
geschikte chemische reacties is nog niet zo ver gevuld en bovendien gebaseerd op slechts 
een handjevol chemische reacties, voornamelijk met het azide als functionele groep. Het in 
dit proefschrift beschreven onderzoek is daarom bedoeld om nieuw chemisch gereedschap 
te ontwikkelen dat kan bijdragen aan de opheldering van de functies, structuren en 
eigenschappen van glycanen. 
    Hoofdstuk 1 geeft een overzicht van de huidige status van de chemische 
gereedschapskist voor het onderzoek naar glycanen, zoals de bestaande biocompatibele en 
bio-ortogonale reacties (Figuur 1) en de toepassing daarvan.  
 
 
Figuur 1. Biocompatibele reacties kunnen plaatsvinden in aanwezigheid van de vele functionele groepen in 
biomoleculen, zoals eiwitten, nucleotiden en glycanen en zijn dus geschikt voor bioconjugatie. Bio-ortogonale 
reacties kunnen zelfs gebruikt worden in levende cellen en complete organismen.  
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    Onze eerste aanvulling op de chemische gereedschapskist wordt beschreven in 
Hoofdstuk 2 met de ontwikkeling van een nieuw biocompatibel reactiepaar gebaseerd op 
de strain-promoted cycloadditie van een alkyn en een nitron (Figuur 2), een reactie die we 
‘SPANC’ noemen. De SPANC-reactie resulteert in N-gealkyleerde isoxazolinen en 
verloopt aanzienlijk sneller dan vergelijkbare reacties met een azide. Daarnaast hebben we 
aangetoond dat de SPANC-reactie gebruikt kan worden in een één-pot-drie-staps-protocol 
voor de plaatsspecifieke introductie van een functioneel label (zoals een glycaan) aan 
peptiden en eiwitten.  
 
 
Figuur 2. De strain-promoted cycloadditie van een alkyn en een nitron. 
 
    Hoofdstuk 3 laat vervolgens zien dat we dezelfde reactie kunnen gebruiken om in één 
klap twee functionele labels te introduceren aan een peptide of eiwit (Figuur 3) en daarnaast 
is de SPANC reactie geoptimaliseerd. Het nut van het tegelijkertijd introduceren van twee 
labels is geïllustreerd met de introductie van twee functionele groepen die de endosomale 
ontsnapping stimuleren van het cel-penetrerende peptide hLF (humaan lactoferrine). 
Verdere optimalisatie van de SPANC procedure leidde tot condities die uitermate geschikt 
zijn voor het introduceren van N-propargylhydroxylamine en BCN-biotine aan het eiwit S-
eGFP in slechts een paar uur. Het eindstandige alkyn kon vervolgens heel gemakkelijk 
gebruikt worden in een CuAAC-reactie met azide-gefunctionaliseerd fluoresceine, waarbij 
de vele mogelijkheden van de gecombineerde SPANC- en CuAAC-reactie zijn aangetoond. 
 
 
Figuur 3. De introductie van twee functionele labels aan het eiwit S-eGFP met behulp van de SPANC reactie. 
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    Hoofdstuk 4 beschrijft de volgende aanvulling van de chemische gereedschapskist, een 
nieuw, synthetisch goed toegankelijk en reactief molecuul voor de verrijking van azide-
gefunctionaliseerde biomoleculen. Deze ‘azide-hengel’ is gebaseerd op de combinatie van 
Sepharosebolletjes, een linker die geknipt wordt in de aanwezigheid van hydrazine en het 
gespannen alkyn BCN. De toepasbaarheid van deze methode is aangetoond met behulp van 
fluorogene kleuring van de bolletjes met azidocoumarine en de selectieve verrijking van het 
azide-gemodificeerde eiwit AHA-CalB uit een mengsel van eiwitten via covalente binding 
aan de bolletjes. Vervolgens konden zowel het coumarine-derivaat als het eiwit losgeknipt 
worden van de bolletjes met behulp van hydrazine (Figuur 4).  
 
 
Figuur 4. Procedure voor de verrijking van een azide-gefunctionaliseerd eiwit met behulp van een ‘azide-hengel’.  
 
    Dit concept met de ‘azide-hengel’ is vervolgens verbeterd in Hoofdstuk 5, waarin twee 
alternatieve linkers gepresenteerd zijn die geknipt worden in de aanwezigheid van licht met 
een golflengte van 350 nm. Deze twee alternatieve linkers, de één gebaseerd op 
nitroveratrylamine en de ander op hydroxymethylnaftol, zijn met succes gesynthetiseerd en 
vervolgens aan de bolletjes gekoppeld. SPAAC op de bolletjes is aangetoond door middel 
van fluorescente kleuring van de bolletjes. Knippen met behulp van 350 nm licht is eerst 
voor beide linkers aangetoond in oplossing na SPAAC met benzylazide en daarna op de 
bolletjes voor de linker gebaseerd op hydroxymethylnaftol. De toepasbaarheid van beide 
linkers is vervolgens getest door het afvangen van AHA-CalB uit een mengsel van eiwitten, 
gevolgd door het losknippen van de bolletjes met 350 nm licht. Verrijking van AHA-CalB 
uit een cellysaat van humane huidfibroblasten was alleen succesvol voor de linker 
gebaseerd op hydroxymethylnaftol.  
    In Hoofdstuk 6 is de synthese en de koppeling van azidoglycanen aan BCN-
gefunctionaliseerde bolletjes en eiwitten onderzocht (Figuur 5). De in situ omzetting van 
natuurlijke glycanen in het overeenkomstige azide is met succes gedaan, gevolgd door de 
immobilisatie van 2-OH suikers op BCN-gefunctionaliseerde bolletjes en het eiwit GFP-
Samenvatting 
 
- 175 - 
 
BCN. Helaas was echter geen signaal te zien na immobilisatie van 2-N-acetyl-bevattende 
azidoglycanen op BCN-gefunctionaliseerde bolletjes. Vervolgexperimenten waarin 
hetzelfde 2-N-acetyl-bevattende glycaan werd gekoppeld aan GFP-BCN toonden aan dat 
triazoolvorming met dit type glycanen leidt tot een intramoleculaire nucleofiele substitutie 
met oxazolinevorming na SPAAC, waarbij het triazool als vertrekkende groep optreedt. Dit 
beperkt deze methode tot de immobilisatie van 2-OH suikers, een groep suikers die in de 
natuur beperkt voorkomt in geïmmobiliseerde vorm. 
 
 
Figuur 5. De immobilizatie van azidosuikers op een BCN-gefunctionaliseerd bolletje of eiwit.  
 
    Ten slotte staat in Hoofdstuk 7 nog een aantal aanvullende opmerkingen en conclusies 
over het gepresenteerde onderzoek en ideeën voor toekomstig onderzoek op het gebied van 
glycosylering.  
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    Onderzoek doe je nooit alleen en daarom wil ik de mensen bedanken die bijgedragen 
hebben aan het tot stand brengen van dit proefschrift. Ik heb lang uitgekeken naar het 
moment waarop ik dit stukje tekst mocht gaan schrijven, want dat betekent dat mijn 
proefschrift toch echt helemaal af is. Daarnaast leek het me op het eerste gezicht vrij 
eenvoudig vergeleken met de rest van de inhoud. Nu blijkt echter dat het toch niet zo 
gemakkelijk is, want er zijn heel veel mensen die in meer of mindere mate hebben 
bijgedragen, soms zelfs zonder dat zij zich er zelf bewust van waren. Ik heb erg mijn best 
gedaan allen te vernoemen, mocht ik mensen vergeten zijn, daarvoor mijn 
verontschuldiging en bij dezen: hartelijk bedankt! 
    Allereerst wil ik mijn promotor en co-promotor Floris Rutjes en Floris van Delft 
bedanken. Jullie hebben het in de eerste plaats mogelijk gemaakt dat ik dit onderzoek kon 
doen en ik heb veel van jullie geleerd. Floris van Delft, als mijn directe begeleider heb je 
vele leuke ideeën geopperd, suggesties aan de hand gedaan als ik het even niet meer wist en 
ten slotte je kritische blik over elk hoofdstuk in dit proefschrift laten gaan. Ik waardeer je 
enthousiasme en persoonlijke interesse, en wil je heel veel succes wensen met jullie bedrijf 
SynAffix! Floris Rutjes, ik bewonder je enorme organisch chemische kennis en wil je 
bedanken voor alle suggesties betreffende het onderzoek en mijn manuscript. Daarnaast wil 
ik de manuscriptcommissie bedanken voor het lezen van mijn manuscript, hun suggesties 
en het plaatsnemen in mijn promotiecommissie: prof. Jan van Hest, dr. Dirk Lefeber en 
dr. Maarten Merkx.  
    Verschillende analysemethoden zijn toegepast om gesynthetiseerde verbindingen, 
eiwitten, beads, etc. te karakteriseren en daarbij heb ik hulp gekregen van Peter van Galen, 
Ad Swolfs, Paul Schlebos, Helene Amatdjais en Liesbeth Pierson (GI), waarvoor dank! 
Hulp op allerlei andere vlakken heb ik gehad van Jan Dommerholt (suggesties voor 
synthese, het doen van bestellingen, enz.), Jacky Versteeg (o.a. het plannen van 
afspraken), Peter van Dijk (bestellingen, allerlei glaswerk en andere attributen en 
natuurlijk altijd een gezellig praatje!), Desirée van der Wey, Marieke Egbertsen, Hans 
Adams (synthese van SKYRAG) en René Aben (hulp bij het maken van de rotavaps etc.). 
Allemaal hartelijk bedankt daarvoor.  
    Tijdens mijn promotieonderzoek heb ik zes studenten begeleid, te beginnen met Erik en 
Lisanne, twee bachelorstudenten. Bedankt voor jullie bijdrage! Daarnaast zijn er ook nog 
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masterstudenten geweest, waarvan Esra de eerste was. Een groot gedeelte van jouw 
onderzoek mede onder begeleiding van Monique staat beschreven in Hoofdstuk 4 en 
daarnaast heb jij een begin gemaakt met de synthese die beschreven staat in Hoofdstuk 5. 
Hopelijk heb je net zo veel mooie resultaten tijdens je eigen promotieonderzoek, succes 
daarmee! Loek, jij was de volgende masterstudent, ook jou wil ik veel succes wensen met 
je promotieonderzoek. Hartelijk dank voor jouw bijdrage aan Hoofdstuk 3, ik waardeer het 
doorzettingsvermogen dat je hebt getoond met de functionalisatie van hLF. Anne, jouw 
werk vormt de basis van hoofdstuk 5. Hoewel de synthese soms moeizaam ging (al lag dat 
niet aan jou of aan je inzet!), heb je doorgezet en hebben we een kei gezellige tijd gehad op 
het lab. Succes bij Phenomenex! Als laatste masterstudent wil ik Dorine bedanken. 
Ondanks dat je zelf baalde van de tegenvallende resultaten, heeft jouw werk toch geleid tot 
Hoofdstuk 6. Wat mij betreft een waardevolle bijdrage, waar je trots op kan zijn!  
    Ik heb veel geleerd van verschillende samenwerkingsverbanden, zoals de samenwerking 
met prof. Otto Boerman, dr. Peter Laverman en Gerben Franssen van de afdeling 
nucleaire geneeskunde. Uiteindelijk heeft ons gezamenlijke project helaas niet opgeleverd 
waar we op hoopten, maar het was het proberen waard! Daarnaast wil ik prof. dr. Roland 
Brock en dr. Wouter Verdurmen (NCMLS) bedanken voor de samenwerking. Een andere 
zeer nuttige en prettige samenwerking was die met dr. Dirk Lefeber en dr. Monique van 
Scherpenzeel van de afdeling Genetische, Endocriene en Metabole Ziekten. Hartelijk 
bedankt voor jullie suggesties, ideeën en alle gezamenlijke projecten! Ik heb veel van jullie 
geleerd over glycosylering, ik heb echt bewondering voor jullie uitgebreide kennis 
daarover. Ook de andere deelnemers aan de glycobiologie meeting, zoals Liz en Samuel 
wil ik hartelijk danken voor hun input.  
    In relatie hiermee kan ook Thomas niet ontbreken. Ook jouw kennis over glycosylering 
en daarnaast over synthese is echt indrukwekkend, bedankt voor al je adviezen en 
suggesties op die gebieden! Heel veel succes met je academische carrière, het kan niet 
anders dan dat je het ver gaat schoppen. Natuurlijk ook erg bedankt voor de gezellige tijd 
op het lab en daarbuiten. Ook de anderen van lab 03.112 bedankt voor alle gezelligheid, ik 
heb het er erg naar mijn zin gehad met jullie!  
    De mensen die ook echt niet mogen ontbreken in dit dankwoord zijn de andere oud-
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